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RHODIUM(III)-CATALYZED AMIDE-DIRECTED C-H ACTIVATION AND  
[4+2] CYCLOADDITION FOR MODULAR ASSEMBLY OF NITROGEN HETEROCYCLES 
This dissertation describes the ligand and reaction developments by amide-directed 
rhodium(III)-catalyzed C(sp2)-H bond activation followed by amidoannulation with alkenes to 
form nitrogen-containing heterocycles. Chapter 1 details the ligand development for 
stereoselective synthesis of [4.1.0] dihydroisoquinolones through benzamidation of cyclopropenes 
mediated by Rh(III) catalysis. Quantum chemical calculations revealed the important role of 
heptamethylindenyl (Ind*) ligand and O-substituted ester of benzhydroxamate for achieving high 
diastereoselectivity in cyclopropene insertion. Efforts toward stereoselective synthesis of [4.1.0] 
dihydroisoquinolones have been also studied by streptavidin-based artificial metalloenzyme. 
Chapter 2 presents the stereoselective synthesis of [4.2.0] dihydroisoquinolones via the 
benzamidation of cyclobutenes. The transformation proved to have a broad substrate scope and 
functional group tolerance that generates the cyclobutane-fused azacycles with excellent 
diastereoselectivity. The artificial metalloenzymes can render this reaction asymmetric furnishing 
the dihydroisoquinolone products in moderate enantioselectivity. 
Chapter 3 communicates Rh(III)-catalyzed C-H activation and [4+2] annulation reaction 
of N-pivaloyloxy acrylamides with alkenes for an efficient synthesis of α,β-unsaturated--lactams. 
This process offers a platform for the rapid assembly of a diverse set of -lactams from simple and 
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 In recent years, transition metal-catalyzed C–H bond activation has attracted attention for 
streamlining organic synthesis by increasing step and atom economy.2 Since C–H bonds are 
abundant in organic molecules, the transformation of specific C–H bond to a desired functional 
group is challenging. Traditionally, a C–H bond is converted to a carbon-halogen bond. The 
well-known cross-coupling reactions can then be used to transform the C-X bond providing the 
desired functional group (Figure 1a).3 An ideal strategy would directly transform a C–H bond to 
the functional group in a single step (Figure 1b). A significant challenge in achieving this goal is 
controlling the chemo-, regio- and enantio- selectivity of the C–H activation as well as 
overcoming issues of reactivity and functional group tolerance. A strategy frequently employed 
to control chemoselectivity is the use of a directing group. Use of a coordinating functional 
                                                                
1 The portion of this work was published, see: Semakul, N.; Jackson, K. E.; Paton, R. S.; Rovis, T. Chem. Sci. 2017, 
8, 1015-1020.  
2 Reviews, see: (a) Daugulis, O.; Do, H. Q.; Shabashov, D. Acc. Chem. Res. 2009, 42, 1074-1086. (b) Colby, D. A.; 
Bergman, R. G.; Ellman, J. A. Chem. Rev. 2010, 110, 624-655. (c) Lyons, T. W.; Sanford, M. S. Chem. Rev. 2010, 
110, 1147-1169. (d) McMurray, L.; O'Hara, F.; Gaunt, M. J. Chem. Soc. Rev. 2011, 40, 1885-1898. (e) Yeung, C. S.; 
Dong, V. M. Chem. Rev. 2011, 111, 1215-1292. (f) Ackermann, L. Chem. Rev. 2011, 111, 1315-1345. (g) 
Yamaguchi, J.; Yamaguchi, A. D.; Itami, K. Angew. Chem. Int. Ed. 2012, 51, 8960-9009. (h) Arockiam, P. B.; 
Bruneau, C.; Dixneuf, P. H. Chem. Rev. 2012, 112, 5879-5918 (i) Satoh, T.; Miura, M. Chem. Eur. J. 2010, 16, 
11212-11222. 
3 (a) Seechurn, C.; Kitching, M. O.; Colacot, T. J.; Snieckus, V. Angew. Chem. Int. Ed. 2012, 51, 5062-5085. (b) 
Meijere, A. d.; Diederich, F. Metal-Catalyzed Cross-Coupling Reactions. Wiley-VCH: 2004; Vol. 2. 
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group in the organic molecule can serve as a ligand for metal catalyst and direct the C–H 
activation and functionalization in a highly selective fashion (Figure 1c). Numerous directing 
groups have been reported for such transformations including carboxylic acids, amides, alcohols, 
amines, ketones, aldehydes, imines, oximes, and pyridines to overcome the selectivity issues. 
However, the removal of such directing groups are required after the desired transformation was 
achieved. 
 
Figure 1.1  
 The Miura and Satoh laboratory reported the seminal work in which rhodium/copper 
catalyst system efficiently mediates a coupling between benzoic acids and internal alkynes to 
afford isocoumarins (Scheme 1.1, eq 1). 4  In this way, the heteroatom directing group also 
                                                                
4 Ueura, K.; Satoh, T.; Miura, M. Org. Lett. 2007, 9, 1407-1409. 
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incorporates and providing synthetically useful heterocycles. The reaction is understood to 
proceed by the coordination of benzoate ligand to Rh(III) and ortho C-H activation to form a 
five-membered rhodacycle intermediate. Subsequent alkyne coordination, migratory insertion, 
and reductive elimination generate isocoumarin product and Rh(I) species. The copper cocatalyst 
then oxidizes Rh(I) to complete a catalytic turnover. The same group also illustrated the C-H 
activation/C-N bond formation by using phenylazoles with alkynes to produce the 
imidazoisoquinoline products (eq 2). 5  Concurrently, Fagnou group reported that the C-H 
activation of anilides with alkynes to deliver indoles (eq 3).6 In the same year, Jones also studied 
the Rh(III)-mediated stoichiometric transformation by using pyridine or imine as directing 
groups to couple with alkynes affording quinolinium salts (eq 4).7 Along these lines, these works 
demonstrated that the heteroatom-directed and metal-catalyzed (or mediated) C-H activation, C-
C/C-heteroatoms bond formation is an efficient tool to synthesize heterocycles from simple and 
readily available precursors without substrate preactivations. 
                                                                
5 Umeda, N.; Tsurugi, H.; Satoh, T.; Miura, M. Angew. Chem. Int. Ed. 2008, 47, 4019-4022. 
6 Stuart, D. R.; Bertrand-Laperle, M.; Burgess, K. M. N.; Fagnou, K. J. Am. Chem. Soc. 2008, 130, 16474-16475. 





 The Rovis lab has long been interested in N-heterocycle synthesis.8 The amide is a 
common functional group in organic chemistry. Hence, this directing group can serve as the 
nitrogen source for the synthesis of N-heterocycles via C–H/N–H bond cleavages and C–C/C–N 
bond formation.9 Our group and others utilized the amide as a directing group for Rh(III)-
catalyzed [4+2] formal cycloaddition of benzamides with alkynes to generate isoquinolones 
(Scheme 1.2 eqs 5 and 6).10 However, a stoichiometric oxidant is needed to achieve a catalyst 
turnover (eq 2). Unfortunately, superstoichiometric amounts of oxidant and its waste limits the 
                                                                
8 Reviews, see: (a) Johnson, J. B.; Rovis, T. Acc. Chem. Res. 2008, 41, 327-338. (b) Perreault, S.; Rovis, T. Chem. 
Soc. Rev. 2009, 38, 3149-3159. 
9 (a) Zhu, C.; Wang, R.; Falck, J. R. Chem. Asian J. 2012, 7, 1502-1514. (b) Gulías, M.; Mascareñas, J. L. Angew. 
Chem. Int. Ed. 2016, 55, 11000-11019. 
10 (a) Mochida, S.; Umeda, N.; Hirano, K.; Satoh, T.; Miura, M. Chem. Lett. 2010, 39, 744-746. (b) Hyster, T. K.; 
Rovis, T. J. Am. Chem. Soc. 2010, 132, 10565-10569. (b) Song, G. Y.; Chen, D.; Pan, C. L.; Crabtree, R. H.; Li, X. 
W. J. Org. Chem. 2010, 75, 7487-7490. 
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substrate scope and gives undesired side products. Fagnou11 and Glorius12 independently 
investigated Rh(III)-catalyzed annulation of O-substituted benzhydroxamic acids with alkene 
coupling partners. They observed two distinct mechanisms from different directing groups. 
While -C(O)NHOMe was employed, an olefinated product was observed (eq 7). The 
transformation delivers dihydroisoquinolone when -C(O)NHOPiv was used as the internal 
oxidant (eq 8). The application of directing groups that contain an internal oxidant provides mild 
reaction conditions that do not require metallic oxidants while expanding the variety of 
components tolerated as a coupling partner. 
 
Scheme 1.2 
                                                                
11 (a) Guimond, N.; Gouliaras, C.; Fagnou, K. J. Am. Chem. Soc.  2010, 132, 6908. (b) Guimond, N.; Gorelsky, S. I.; 
Fagnou, K. J. Am. Chem. Soc. 2011, 133, 6449-6457. 
12 Rakshit, S.; Grohmann, C.; Besset, T.; Glorius, F. J. Am. Chem. Soc.  2011, 133, 2350-2353. 
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 Proposed reaction mechanism for this transformation is outlined in Figure 1.2. The amide 
functional group directs ortho C–H bond activation to afford rhodacycle I via concerted 
metallation-deprotonation (CMD) mechanism. TSI shows the transition state for CMD 
mechanism in which acetate on rhodium(III) deprotonates a C–H bond and rhodium(III) inserts 
to the C–H bond simultaneously. Consequently, the oxidation state of Rh(III) does not change 
during this process. Rhodacycle I can then undergo alkene or alkyne coordination followed by 
migratory insertion to afford rhodacycle II. Upon reductive elimination of II to form 
dihydroisoquinolone, reductive cleavage of the N–O bond can oxidize Rh(I) to Rh(III) 
completing a catalyst turnover. In contrast, -hydride elimination may occur when -





 Rhodium(III) is a particularly effective catalyst in performing the annulation of aromatic 
and vinylic C-H bond bearing an amide directing group. Several coupling partners, for example, 
alkynes, carbon monoxide, alkenes (including cyclopropenes), and donor-acceptor diazo 
compound have been shown to incorporate to yield N-heterocycles via C–H activation. The 
recent development of rhodium(III) catalyzed C–H activation to access N-heterocycles by our 
group is summarized in Figure 1.3.13 In some case, the reaction generates stereocenter(s) in 
which the chiral catalyst potentially render the reaction asymmetric. 
 
Figure 1.3 Examples of heterocyclic structures accessed using Rh(III) catalyzed C-H activation 
annulations in the Rovis group  
                                                                
13 The use of amide as a direct group, see: (a) Hyster, T. K.; Rovis, T. Chem. Sci. 2011, 2, 1606-1610. (b) Du, Y.; 
Hyster, T. K.; Rovis, T. Chem. Comm. 2011, 47, 12074-12076. (c) Hyster, T. K.; Ruhl, K. E.; Rovis, T. J. Am. 
Chem. Soc. 2013, 135, 5364-5367. (d) Davis, T. A.; Hyster, T. K.; Rovis, T. Angew. Chem. Int. Ed. 2013, 52, 
14181-14185. (e) Hyster, T. K.; Dalton, D. M.; Rovis, T. Chem. Sci. 2015, 6, 254-258. Review, see: Zhu, R. Y.; 
Farmer, M. E.; Chen, Y. Q.; Yu, J. Q., Angew. Chem. Int. Ed. 2016, 55, 10578-10599.  
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 The ability to render rhodium(III)-catalyzed C–H activation reaction asymmetric is an 
ongoing challenge in the field. Figure 1.4 depicts the structure of Cp*Rh(III) three-legged piano-
stool complex (or half-sandwich complex). Indeed, the introduction of exogenous chiral ligand is 
non-productive since three coordinating sites are required for ligand attachment (two X-type 
ligands and one L-type ligand) during a catalytic cycle. The engineering of chiral ligand-metal 
complexes has been demonstrated by Cramer,14 You,15 Antonchick, and Waldmann16 to render 
the reaction asymmetric. However, several limitations for example, multistep synthesis, 
structural variability and electronic properties of those chiral Cp ligands, remain unsolved. 
 
Figure 1.4 a) Cp*Rh(III) piano-stool complex b)  the requirement of three coordinating sites 
during the catalytic cycles 
 An alternative approach to rendering an asymmetric transformation is to anchor the 
catalyst to a supramolecular scaffold. An enzyme catalysis is a powerful tool since nature can use 
proteins to create molecules in a highly asymmetric fashion. The marriage of transition metal 
catalysis with an enzyme or a so-called "artificial metalloenzyme" will provide useful tools for 
organic synthesis.17 In addition, biology tools such as site-directed mutagenesis and directed 
evolution can tailor the amino acid residues in the enzyme pocket to achieve higher reactivity 
                                                                
14 For review, see: (a) Ye, B. H.; Cramer, N. Acc. Chem. Res. 2015, 48, 1308-1318. (b) Newton, C. G.; Kossler, D.; 
Cramer, N. J. Am. Chem. Soc. 2016, 138, 3935-3941. 
15 Zheng, J.; Cui, W. J.; Zheng, C.; You, S. L., J. Am. Chem. Soc. 2016, 138, 5242-5245. 
16 Jia, Z. J.; Merten, C.; Gontla, R.; Daniliuc, C. G.; Antonchick, A. P.; Waldmann, H., Angew. Chem. Int. Ed. 2017, 
56, 2429-2434. 
17 Heinisch, T.; Ward, T. R., Acc. Chem. Res. 2016, 49, 1711-1721. 
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and selectivity. In this vein, Rovis, Ward and coworkers explored an artificial metalloenzyme 
based on biotinylated rhodium(III) ligated streptavidin as a tool for asymmetric C–H activation. 
The introduction of a biotin-tethered pentamethylcyclopentadienyl (Cp*) ligand to the 
streptavidin (SAV) resulted in a high concentration of the metal in the enzyme. In this way, the 
biotinylated [RhCp*Cl2]2 complex was anchored to streptavidin and catalyzed the coupling of O-
pivaloylbenzhydroxamic acid 1a with alkene 2a to furnish the dihydroisoquinolone 3aa.18 With 
the best mutant S112Y-K121E, dihydroisoquinolone 3aa could be accessed in high yield, high 
regioselectivity, and good enantioselectivity (eq 9). An engineered streptavidin with a 
carboxylate amino acid residue allows for greater rate of carboxylate-assisted C–H bond 
cleavage which is the turnover-limiting step and accelerating the reaction.  
 
 Hyster and Rovis also found that O-pivaloyl benzhydroxamic acid 1a could be coupled to 
3,3-disubstituted cyclopropene 4a, generating [4.1.0] dihydroisoquinolone 5aa in 95% yield 
(1.4:1 dr, Table 1.1, entry 1).19 However, the low diastereoselectivity is thought to result from a 
lack of facial selectivity during cyclopropene migratory insertion. Hyster also explored this 
reaction using SAV-based artificial metalloenzymes. In this study, the N118K-K121E SAV 
mutant provided the [4.1.0] dihydroisoquinolone product (5aa) in 80% yield (1.4:1 dr, 89:11 er, 
                                                                
18 Hyster, T. K.; Knorr, L.; Ward, T. R.; Rovis, T. Science 2012, 338, 500-503. 
19 Hyster, T. K.; Rovis, T. Synlett 2013, 24, 1842-1844. 
10 
 
entry 2).20 Additionally, the S112Y-K121E mutant gave 5aa in 60% yield (1.4:1 dr, 83:17 er, 
entry 3). Ongoing efforts are directed towards developing a stereoselective coupling between O-
pivaloyl benzhydroxamic acids with cyclopropenes. 
Table 1.1 
 
1.1.2 Ligand Development in Rh(III) Catalysis 
 Rh(III)-catalyzed C-H bond functionalization strategies have emerged as a powerful 
synthetic tool.21 The methodology allows for the functionalization of simple organic molecules 
and expedient synthesis of N-heterocycles from readily available precursors. Cyclopropenes 
constitute a class of building blocks with a special reactivity due to their high ring strain energy 
(54 kcal/mol). In this context, a handful of reactions utilizing transition metals has been 
developed for the stereoselective functionalization of cyclopropenes.22 Under the aegis of Rh(III) 
                                                                
20 Hyster, T. K. (2013) Ligand and reaction development in the rhodium(III)-catalyzed C-H activation-mediated 
synthesis of N-heterocycles (Doctoral dissertation). 
21 For the review of Rh(III)-catalyzed C-H activation, see: (a) Colby, D. A.; Bergman, R. G.; Ellman, J. A., Chem. 
Rev. 2010, 110, 624-655. (b) Satoh, T.; Miura, M. Chem. Eur. J. 2010, 16, 11212-11222. (c) Patureau, F. W.; 
Wencel-Delord, J.; Glorius, F. Aldrichimica Acta 2012, 45, 31. (d) Song, G. Y.; Wang, F.; Li, X. W. Chem. Soc. 
Rev. 2012, 41, 3651-3678. (e) Zhu, C.; Wang, R.; Falck, J. R. Chem. Asian. J. 2012, 7, 1502-1514 (f) Song, G. Y.; 
Li, X. W. Acc. Chem. Res. 2015, 48, 1007-1020.  
22 For the review for the functionalization of cyclopropene, see: Rubin, M.; Rubina, M.; Gevorgyan, V. Chem. Rev. 
2007, 107, 3117-3179. Selected examples: (a) Rubina, M.; Rubin, M.; Gevorgyan, V. J. Am. Chem. Soc. 2002, 124, 
11 
 
catalysis, Wang and coworkers have shown that cyclopropenes 7 participate in a Rh(III) 
catalyzed reaction with N-phenoxyacetamide 6 to give 2H-chromenes 8 (eq 2).23 
 
 Our group reported the Rh(III)-mediated coupling of O-pivaloyl benzhydroxamate 1a 
with 3,3-diester substituted cyclopropene 4b to afford 4-substituted isoquinolone 9 after ring 
opening of the three-membered ring (Scheme 1.3, eq 11).  During this study, when using the less 
activated methyl 1-phenylcycloprop-2-ene-1-carboxylate 4a as a substrate, the Cp*Rh(III) 
catalyst gives the [4.1.0] bicyclic product 5aa in low diastereoselectivity (Scheme 1.3, 1.4:1 dr, 
eq 12). We believe the lack of diastereoselectivity stems from the poor facial selectivity during 
coordination of the cyclopropene and the migratory insertion step of cyclopropene unit. We 
reasoned that creating anisotropy around the cyclopentadienyl ligand of the rhodium metal center 
could solve this selectivity issue.  
                                                                                                                                                                                                               
11566-11567. (b) Rubina, M.; Rubin, M.; Gevorgyan, V. J. Am. Chem. Soc. 2003, 125, 7198-7199. (c) Rubina, M.; 
Rubin, M.; Gevorgyan, V. J. Am. Chem. Soc. 2004, 126, 3688-3689. (d) Phan, D. H. T.; Kou, K. G. M.; Dong, V. 
M. J. Am. Chem. Soc. 2010, 132, 16354-16355. (e) Tian, B.; Liu, Q.; Tong, X. F.; Tian, P.; Lin, G. Q. Org. Chem. 
Front. 2014, 1, 1116-1122. (f) Parra, A.; Amenos, L.; Guisan-Ceinos, M.; Lopez, A.; Ruano, J. L. G.; Tortosa, M. J. 
Am. Chem. Soc. 2014, 136, 15833-15836. (g) Muller, D. S.; Marek, I. J. Am. Chem. Soc. 2015, 137, 15414-15417. 
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 Our group24 and others25 have developed several Rh(III)-catalyzed transformations where 
the nature of the Cp ligand drastically impacts the reactivity and selectivity of the reaction. For 
                                                                
24 Electron deficient Cp*CF3, see: (a) Neely, J. M.; Rovis, T. J. Am. Chem. Soc. 2014, 136, 2735-2738. (b) Romanov-
Michailidis, F.; Sedillo, K. F.; Neely, J. M.; Rovis, T. J. Am. Chem. Soc. 2015, 137, 8892-8895. Cp*bisCF3Ar, see: (c) 
Davis, T. A.; Wang, C. Q.; Rovis, T. Synlett 2015, 26, 1520-1524. 
13 
 
example, the sterically bulky di-tert-butylcyclopentadienyl (Cpt) ligand26  has been shown to 
improve the regiochemistry of alkyne (11a and 11b) and alkene (12b) insertion events in the 
synthesis of pyridones (12aa, eq 13), pyridines (14ab and 14ab', eq 14) and 
dihydroisoquinolones (3ab, eq 15). 
 Recently, our group disclosed a cyclopropanation reaction with the coupling of N-
enoxyphthalimides 15 and electron-deficient alkenes (2c and 2d). 
Monoisopropylcyclopentadienyl (CpiPr) ligand 27  outperforms the more common Cp* ligand, 
furnishing the trans-cyclopropane (16ac) in high diastereoselectivity (eq 11). Alternatively, a 
divergent carboamination path was identified when using a hindered tert-
buyltetramethylcyclopentadienyl (Cp*t-Bu) ligand delivering the acyclic adduct (16ad) with high 
chemoselectivity (eq 12).28 
                                                                                                                                                                                                               
25 (a) Shibata, Y.; Tanaka, K. Angew. Chem. Int. Ed. 2011, 50, 10917-10921. (b) Fukui, M.; Hoshino, Y.; Satoh, T.; 
Miura, M.; Tanaka, K. Adv. Synth. Catal. 2014, 356, 1638-1644. (c) Hoshino, Y.; Shibata, Y.; Tanaka, K. Adv. 
Synth. Catal. 2014, 356, 1577-1585. 
26 (a) Hyster, T. K.; Rovis, T. Chem. Sci. 2011, 2, 1606-1610. (b) Hyster, T. K.; Rovis, T. Chem. Commun. 2011, 47, 
11846-11848. (c) Hyster, T. K.; Dalton, D. M.; Rovis, T. Chem. Sci. 2015, 6, 254-258. 
27 Piou, T.; Rovis, T. J. Am. Chem. Soc. 2014, 136, 11292–11295. 





 Motivated by these results, we believed ligand design could provide a solution to the 
inherent selectivity issues encountered for the coupling of benzamide 1 and 3,3-disubstituted 
cyclopropenes 4 (eq 13). 
 
1.2 Results and Discussion 
1.2.1 Efforts Towards Stereoselective Benzamidation of Cyclopropenes 
Initially, the project goal was to identify the SAV mutant needed to improve the 
diastereoselectivity and enantioselectivity of this transformation. Several streptavidin mutants, 
provided by Professor Thomas Ward (University of Basel), were screened under optimal 
conditions. Our main goal was to find a SAV mutant that would lead to increased 
diastereoselection. Coupling between O-pivaloyl benzhydroxamic acid 1a and cyclopropene 4a 
were used as the model system. A variety of SAV mutants at the S112 position were examined as 
15 
 
summarized in Table 1.2. We found that the S112F SAV mutant gave the desired product in 36% 
yield and 1.4:1 dr (entry 1). However, other mutants at the S112 position did not provide the 
corresponding product (entries 2-8). Utilizing the methyl acrylate as the coupling partner in the 
presence of metalloenzyme gave the same results as previously reported, confirming the integrity 
of the SAV mutant.  
Table 1.2 
 
Next, mutations at the K121 position were examined (Table 1.3). We found that the 
desired product 5aa was afforded in modest yields when K121A, K121E, and K121F SAV 
mutants were employed (44-69% yield, entries 1-3). The K121N SAV mutant provided the 
product in low yield (entry 4). No reactivity was obtained from the K121C, K121H, and K121M 
SAV mutants (entries 5-7). This is likely due to the coordinating ability of the cysteine, 
16 
 
methionine, and histidine residues to the Rh(III) active site. Double mutants such as 
N118K/K121D SAV gave the desired product 5aa in 39% yield (91:9 and 92:8 er) despite low 
level of diastereoselection (entry 8). Higher reactivity was obtained when S112Y/K121E SAV 
was employed (entry 9). Overall, no notable improvements in diastereoselection were observed 
with these mutants. 
Table 1.3 
 
 We hypothesized that steric bulk of substituents on cyclopropene may assist in 
differentiating facial selectivity during cyclopropene insertion. To test this hypothesis, 
cyclopropenes 4c-4e were prepared (Table 1.4). To our delight, we observed that increasing 
steric on the ester moeity (4c and 4d) substantially improves the diastereoselectivity of 
17 
 
cyclopropene insertion with [Cp*RhCl2]2 (ranging from 2:1 to >10:1 dr). However, cyclopropene 
4c gave the product 5ac with the same level of diastereoselectivity when the S112Y-K121E SAV 
mutant was employed as the catalyst (entry 1, 1.5:1 dr). Cyclopropene 4d was found to be 
ineffective under the metalloenzyme conditions, presumably due to the steric and solubility 
factors and the ability of the substrate to enter into the catalytic pocket (entry 2). However, 






 We also found that the O-acyloxy substituent of the benzhydroxamate precursor slightly 
influences the diastereoselectivity of cyclopropene insertion (Table 1.5). Benzhydroxamate ester 
precursors 1b and 1c were found to improve the diastereoselectivity up to 5:1 dr of the product 
5aa by using [Cp*RhCl2]2 precatalyst. However, O-Boc substrate 1b was hydrolyzed under 
metalloenzyme conditions to give a benzhydroxamic acid (entry 1). Substrate 1c, which has 
steric properties analogous to O-Boc, was examined. Precursor 1c delivered the corresponding 
product (5) in good yield (1.6:1 dr) and slightly improved enantioselectivity (93:7 er) under 
metalloenzyme conditions (entry 2). 
Table 1.5 a,b 
  
Although promising levels of enantioselection were observed, we did not see an 
improvement of diastereoselectivity under metalloenzyme conditions. We questioned whether 
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steric and electronic modulations of cyclopentadienyl ligands on rhodium(III) might have a 
beneficial effect on the diastereoselectivity of cyclopropene insertion. 
1.2.2 Ligand Development for Diastereoselective Benzanulation of Cyclopropene 
 We began our investigation by employing O-pivaloyl benzhydroxamate ester 1a and 
cyclopropene 4e as model substrates for the optimization of the catalytic process (Table 1.6). 
[Cp*RhCl2]2 provides the desired product in a moderate yield and diastereoselectivity (entry 1, 
5.8:1 dr). The relative stereochemistry of the major diastereoisomer of 5ae was confirmed by 
NOESY. By modulating the steric and electronic properties of the Cp ligand, we have shown that 
the diastereoselectivity of the reaction is considerably affected. Sterically hindered di-tert-
butylcyclopentadienyl (Cpt) and the electron-poor trifluoromethyl tetramethylcyclopentadienyl 
(Cp*CF3) ligands give only modest diastereoselectivity (entries 2, 3). The 
monoisopropylcyclopentadienyl ligand (CpiPr) gave the desired product in a good yield albeit 
with no diastereocontrol (entry 4). 3,5-(Bistrifluoromethyl)aryltetramethylcyclopentadienyl 
(Cp*bisCF3Ar) provides the desired product in  good yield with slightly improved 
diastereoselectivity (7.0:1 dr, entry 5). Good level of diastereocontrol (8.8:1 dr) is achieved when 
tert-butyl tetramethylcyclopentadienyl (Cp*tBu) ligand was employed (entry 6). Gratifyingly, 
heptamethylindenyl ligand29 (Ind*) provides high reactivity and diastereoselectivity with 90% 
yield and 15.2:1 dr (entry 7). To demonstrate the scalability of the transformation, the reaction 
was performed on 2 mmol scale of substrate 1a, which gives the expected product with 
comparable yield and selectivity. The catalyst loading can be lowered to 0.5 mol% [Ind*RhCl2]2 
without affecting the reactivity.  
                                                                
29 Kakkar, A. K.; Stringer, G.; Taylor, N. J.; Marder, T. B. Can. J. Chem. 1995, 73, 981-988. 
20 
 
 We then examined the nature of the directing group. It was found that using O-Boc 
benzhydroxamate ester 1b as a substrate gave excellent diastereoselectivity (>20:1 dr) but with 
slightly lower yield (Scheme 1.6, eq 14), presumably due to a competitive Lossen rearrangement 
under the basic conditions (Scheme 1.6).30 
Table 1.6 Ligand Optimizationa,b,c 
 
 
                                                                





1.2.3 Substrate Scope 
 Both benzamide directing groups, O-Piv (condition A) and O-Boc (condition B), were 
used for studying the scope of the transformation (Table 1.7). Substituents at the para position of 
the benzamide are tolerated in the reaction (1d-1h). The O-Piv directing group with an electron 
rich para-methoxy substituent (OMe) gave excellent diastereoselectivity (>20:1 dr, product 5ee) 
compared to electron deficient substituents (~10:1 dr, products 5fe, 5ge and 5he). The electron-
rich benzamide derived from gallic acid furnishes the desired product with good yield and 
excellent diastereoselectivity (>20:1 dr, product 5je). The O-Boc directing group gives the 
products in good to excellent diastereoselectivity (5de-5ge). Of interest are halogen substituents 
at the para positions (Cl and Br) which provide a functional group handle for further chemical 
modification. The ortho-methyl arylbenzhydroxamate substrate retards the transformation 
presumably due to steric hindrance. Substituents at the meta position on the arylhydroxamates 
can potentially deliver two regioisomeric products arising from the selectivity of C-H activation. 
Meta-trifluoromethyl arylhydroxamate exclusively provides the 6-substituted product (5je) in 
good yield and diastereoselectivity. Tetrahydronaphthalene-derived arylhydroxamate underwent 
the transformation with good regioselective at the less hindered position (8.6:1 ratio) to give the 
desired product (5ke) in good yield and high diastereoselectivity. However, meta-methyl 
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arylhydroxamate gave ~3.6:1 regioisomeric ratio of C-H activation in good yield and 
diastereoselectivity (5le). meta-Methoxy arylhydroxamate provided 1:1 mixture of regioisomeric 
products (5me and 5me') in good diastereocontrol, presumably a consequence of a combination 
of steric effects and kinetic acidity issues. In addition, X-ray structure of 5me unambiguously 









































A 90% (>20:1 dr)








A 89% (>20:1 dr)








A 77% (10.2:1 dr)








A 73% (8.5:1 dr)
B 63% (>20:1 dr)
A 83% (11.2:1 dr)
condition A: R = Piv












































































a Conditions: OPiv for condition A or OBoc for condition B (0.1 mmol), 4e (0.11 
mmol), Rh catalyst (1 mol %), CsOPiv (25 mol%) in MeOH (0.1 M) at 23 °C for 
18 h. 
b Isolated yield of the major diastereomer after silica gel column 
chromatography. 







 Variations of the cyclopropene coupling partner were explored for the transformation 
using the O-Boc benzhydroxamate 1b (Table 1.8). Cyclopropenes bearing substituents at the 
para position gave the desired products in moderate yields and excellent diastereoselectivity 
regardless of the electronic nature of substituents (5bf, 5bg and 5bh). Cyclopropene with a meta-
methoxy group 4i undergoes the transformation with slightly lower diastereoselectivity relative 
to the para-methoxy group (4g). A naphthalene-substituted cyclopropene 4j and a spiro-tetralin 
containing substrate 4k each furnish the desired products 5bj and 5bk in good yield and 
excellent diastereoselectivity. In our previous studies, we found that methyl 1-phenylcycloprop-
2-ene-1-carboxylate 4a reacts with benzamide 1a and gives the desired product 5aa with low 
diastereoselectivity (1.4:1 dr) using [Cp*RhCl2]2 as the precatalyst. With the [Ind*RhCl2]2 
ligand, we were pleased to find that cyclopropene 4a affords the dihydroisoquinolone 5aa with 
improved diastereoselectivity (8.7:1 dr). The relative stereochemistry of the major diastereomer 
of 5aa was confirmed by NOESY. The observed major diastereomer can be rationalized by the 
size of the substituents on the cyclopropane ring. Thus, the phenyl group is larger than the 
carboxylate ester (A-values for Ph- and –CO2Me are 3.0 and 1.3, respectively) leading to higher 
diastereoselectivity observed in these reactions.  The amidoarylation with benzyl substituted 
cyclopropene 4l affords the desired product 5bl in good yield but with lower diastereoselectivity. 
This observation can be explained by the steric differences of phenyl vs benzyl groups (A-values 
for Ph and Bn are 3.0 and 1.75, respectively). 2,3,3-Trisubstituted cyclopropenes did not 











1.2.4 Mechanistic Studies 
 We then investigated the mechanism of the transformation (Scheme 1.7). The 
reversibility of C-H activation was first examined. Trace deuterium incorporation (<5%) was 
observed when the reaction was run in CD3OD, suggesting the C-H activation is largely 
irreversible (eq 15). The competitive reaction between p-bromobenzamide (1h) and 
unsubstituted benzamide (1a) was conducted to probe the electronic preference of reaction (eq 
16). The product formation favors an electron deficient substrate in a 3:1 ratio. Kinetic isotope 
studies revealed KIE values of 6.7 and 5.7 for the parallel and competition experiments, 
respectively (eq 17). These studies together suggest that the C-H activation occurs via concerted 
metallation-deprotonation (CMD) mechanism and is the rate-determining step, as seen in several 
previous examples of C-H activation with Rh(III). To determine if epimerization of the product 
occurs under the reaction conditions, we independently prepared product 5ae (1:1 dr) and 
resubjected it to the reaction conditions of benzamide 1f' and cyclopropene 4e. After full 
conversion to 5fe (70% yield, 17:1 dr), we did not observe any change of the dr of 5ae, 




Scheme 1.7 Mechanistic experiments 
Based on literature precedent 31  and our mechanistic studies, the mechanism of the 
transformation is proposed in Figure 1.5. The Ind*Rh(OPiv)2 species is generated in situ by an 
anion exchange of [Ind*RhCl2]2 and CsOPiv. The amide directed C-H activation occurs via a 
CMD mechanism to give the five-membered rhodacycle intermediate I, which then coordinates 
                                                                
31 Concerted metallation deprotonation (CMD) mechanism in Rh(III) catalyzed C-H activation, see: (a) Lapointe, 




the cyclopropene giving intermediate II. Migratory insertion of cyclopropene gives intermediate 
III. Reductive elimination (C-N bond formation) occurs to generate a Rh(I) species. The 
saturated coordination of acyl directing group to Rh(III) of intermediate III is important for the 
reductive elimination step since O-methyl benzhydroxamate is not reactive for the 
transformation. Finally, the Rh(I) is oxidized by insertion into the N-O bond to regenerate the 
active Rh(III) catalyst species and liberate the dihydroisoquinolone product. The Rh(V)-nitrenoid 
intermediate, after the migration of O-Boc to Rh, was invoked from several computational 
studies. Finally, reductive elimination (C-N bond formation) occurs to generate Rh(III) species 
































































We performed density functional theory (DFT) calculations in collaboration with Kelvin 
Jackson and Professor Robert Paton (University of Oxford) to understand diastereoselectivity 
and the effect of the Ind* ligand for this transformation. 32  We hypothesized that the 
diastereoselectivity arises from the facial selectivity during the coordination and migratory 
insertion of the cyclopropene. The calculations indicate that the migratory insertion step is 
largely irreversible step, hence this step determines the diastereoselectivity of the transformation. 
The coordination and the insertion step of the cyclopropene can occur through four possible 
transition states i.e. trans-endo, trans-exo, cis-endo and cis-exo TSs as depicted in Figure 1.6. It 
should be noted that trans- and cis- nomenclature was adopted from the trans- and cis- products 
that observed experimentally. In addition, two conformers exist in which the cyclopropene 
oriented towards (endo) or away (exo) from the benzamide moiety. The observed trans-product 
agrees with the calculation in which trans-exo TS is the most favorable. In this transition state, 
the methyl group oriented towards the Ind* ligand. However, trans-endo is less favorable due to 
the H---H clash (2.16Å) about the incipient C-C bond. In contrast, the cis-diastereomer results 
from the unfavorable steric interaction resulting by the phenyl group pointed towards the Ind* 
ligand (cis-exo TS) or towards the benzamide and directing group (cis-endo TS). These 
calculations also confirmed the synergistic steric interactions involving the Ind* ligand and 
directing group on the facial selectivity. 
                                                                




Figure 1.6 Stereochemical model for diastereoselectivity. Gibbs energies in kcal/mol. 
1.2.5 Derivatizations of Product 
 The prevalence of nitrogen-containing heterocycles in pharmaceuticals led us to 
investigate the derivatization of the dihydroisoquinolones bearing [4.1.0] bicycles. 33  For 
example, the chloro- and O-triflate substituted dihydroisoquinolines (17 and 18), which are 
versatile functional group handles for further cross-coupling reactions could be easily prepared 
from the dihydroisoquinolone products in good yields, allowing for easy incorporation of these 
bicycles into pharmaceuticals or bio-active molecules. 
                                                                
33 Examples of [4.1.0] dihydroisoquinolone moeity in bioactive molecules and its synthesis, see: (a) Cromarty, A.; 
Haque, K. E.; Proctor, G. R., J. J. Chem. Soc. 1971, 3536–3540. (b) Lantos, I.; Bhattacharjee, D.; Eggleston, D. S. J. 
Org. Chem. 1986, 51, 4147-4150. (c) Perchonock, C. D.; Lantos, I.; Finkelstein, J. A.; Holden, K. G. J. Org. Chem. 




Scheme 1.7 Derivatization of Product 
1.3 Conclusion 
 In summary, we have developed a heptamethylindenyl (Ind*) ligand that enables high 
diastereoselectivity for cyclopropene insertion in the Rh(III)-catalyzed synthesis of 
cyclopropa[c]dihydroisoquinolone. The steric interaction of the ligand on rhodium and the ester 
substitution of O-substituted benzhydroxamate work cooperatively to improve the 
diastereoselectivity of cyclopropene insertion.34 Mechanistically, the C–H activation proceeds 
via a concerted metallation-deprotonation pathway and is the turnover-limiting step. This 
methodology is useful for the rapid synthesis of nitrogen-containing heterocycles with a [4.1.0] 




                                                                
34 Our group studied the correlation of selectivity to Cp ligand properties. This studies reveal the ability of Ind* ligand to 
accommodate the slippage, thus improves the diastereoselectivity, see: Piou, T.; Romanov-Michailidis, F.; Romanova-
Michaelides, M.; Jackson, K. E.; Semakul, N.; Taggart, T. D.; Newell, B. S.; Rithner, C. D.; Paton, R. S.; Rovis, T., 




Development of Stereoselective [4.2.0] Dihydroisoquinolones Synthesis via Rh(III)-Catalyzed 
C-H Activation and [4+2] Annulation with Cyclobutenes 
 
2.1 Introduction 
 Since cyclobutane frameworks are occasionally found in natural products and bioactive 
molecules (Figure 2.1), the synthesis of these motifs has become the topic of some interest.35 
Specifically, these motifs have been utilized in the drug discovery and development, partly due 
to the structural rigidity and the defined spatial arrangement and of the cyclobutane ring.36 In 
addition, nitrogen heterocycles such as isoquinolones and pyridones are of particular interest due 
to their prevalence in natural products and drug-like molecules. Targeting new synthetic methods 
towards these cyclobutane-fused nitrogen heterocycles would be potentially useful.  
 
                                                     
35 Recent comprehensive reviews in the synthesis of cyclobutane, see: (a) Xu, Y.; Conner, M. L.; Brown, M. K. 
Angew. Chem. Int. Ed. 2015, 54, 11918-11928. (b) Poplata, S.; Troster, A.; Zou, Y. Q.; Bach, T. Chem. Rev. 2016, 
116, 9748-9815. 
36 (a) Blakemore, D. C.; Bryans, J. S.; Carnell, P.; Carr, C. L.; Chessum, N. E. A.; Field, M. J.; Kinsella, N.; 
Osborne, S. A.; Warren, A. N.; Williams, S. C. Bioorg. Med. Chem. Lett. 2010, 20, 461-464. (b) Marson, C. M. 





































 In this regard, Yudin and coworkers investigated the [3,3]-sigmatropic rearrangement of 
N-vinyl--lactams 1 to generate eight-membered lactams 2 (eq 1). 37  During this study, the 
formation of a fused [4.2.0] aminocyclobutane-containing -lactam was observed as a byproduct, 
which is thought to proceed through a 6π-electrocyclization of the eight-membered lactam 3 
(Scheme 2.1). After extensive optimization, the latter product could be obtained by using CuI 
and Cs2CO3 as additives under microwave heating. However, harsh reaction conditions limited 
functional group tolerance. 
                                                     
37 (a) Cheung, L. L. W.; Yudin, A. K. Org. Lett. 2009, 11, 1281-1284. (b) Cheung, L. L. W.; Yudin, A. K. Chem. 





 Bach and coworkers have demonstrated the enantioselective synthesis of [4.2.0] 
dihydroisoquinolones (eq 2).38 They employed a chiral hydrogen-bonding template T to render 
the intermolecular [2+2] photocycloaddition of isoquinolones (4) and alkenes (5) 
enantioselective to generate enantioenriched fused [4.2.0] dihydrosioquinolones (6). However, 
the superstoichiometric amount of the chiral template (2.5 equiv.) and alkene (10 equiv.) are 














-75 °C, 2-3 h
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38 (a) Coote, S. C.; Bach, T. J. Am. Chem. Soc. 2013, 135, 14948-14951. (b) Coote, S. C.; Pothig, A.; Bach, T. 
Chem. Eur. J. 2015, 21, 6906-6912. For intramolecular [2+2] photocycloaddition, see: Austin, K. A. B.; Herdtweck, 





Cyclobutenes have been utilized as monomers in polymer chemistry due to their high 
strain energy (30.6 kcal/mol).39 These molecules can be accessible in a few steps from cheap 
starting materials. In contrast, the use of cyclobutenes to access functionalized cyclobutanes has 
been underexplored.40 Only a few groups have demonstrated that cyclobutenes can be used to 
provide decorated cyclobutanes (Scheme 2.2). In this vein, RajanBabu found that cyclobutene 7 
is an effective substrate for the nickel-catalyzed hydrovinylation to generate vinylated 
cyclobutane 8 in moderate yield (eq 3). 41  Tortosa and coworkers demonstrated an elegant 
enantioselective and diastereoselective copper-catalyzed hydroboration of cyclobutene 9 to 
                                                     
39  Recent review of cyclobutenes in polymer chemistry, see: Le, D.; Morandi, G.; Legoupy, S.; Pascual, S.; 
Montembault, V.; Fontaine, L. Eur. Polym. J. 2013, 49, 972-983. 
40 Asymmetric synthesis of cyclobutene and its utilities, see: Misale, A.; Niyomchon, S.; Maulide, N. Acc. Chem. 
Res. 2016, 49, 2444-2458. 
41 Liu, W.; RajanBabu, T. V. J. Org. Chem. 2010, 75, 7636-7643. 
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furnish chiral cyclobutylboronate 10 (eq 4).42 More recently, Marek and coworkers developed a 
highly regio- and diastereoselective zirconocene-catalyzed carbomagnesiation of cyclobutene 11 
to afford cyclobutylmagnesium intermediate. This intermediate is configurationally stable for 
transmetallation to a metal catalyst. Thus, this process allows subsequent functionalization to 
generate polysubstituted cyclobutanes 12 (eq 3).43 
 Strained alkenes such as cyclopropene are effective coupling partners with O-pivaloyl 
benzhydroxamates to generate [4.1.0] dihydroisoquinolones (Chapter 1).44 Expanding on this, we 
felt that Rh(III)-catalyzed C-H activation of O-pivaloyl benzhydroxamate and N-pivaloyloxy 
acrylamide precursor (13) with cyclobutene (14) would provide an efficient route for accessing 
[4.2.0] dihydroisoquinolones and dihydropyridones (15) (eq 6). In addition, an enantioselective 
variant could be developed by using a streptavidin-based metalloenzyme.  
 
2.2 Results and Discussion 
2.2.1 Substrate Scope 
 We began our study by examining the Rh(III)-catalyzed coupling of O-pivaloyl 
benzhydroxamate 13a with cyclobutene 14a in the presence of [Cp*RhCl2]2 (1 mol%), CsOPiv 
(0.25 mol%) in MeOH. To our delight, cyclobutene 14a underwent the [4+2] annulation and 
delivered [4.2.0] dihydroisoquinolone 15aa in an excellent yield and diastereoselectivity (>20:1 
                                                     
42 Guisan-Ceinos, M.; Parra, A.; Martin-Heras, V.; Tortosa, M. Angew. Chem. Int. Ed. 2016, 55, 6969-6972. 
43 Roy, S. R.; Eijsberg, H.; Bruffaerts, J.; Marek, I. Chem. Sci. 2017, 8, 334-339. 
44 (a) Hyster, T. K.; Rovis, T. Synlett 2013, 24, 1842-1844. (b) Semakul, N.; Jackson, K. E.; Paton, R. S.; Rovis, T. 
Chem. Sci. 2017, 8, 1015-1020. 
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dr). This transformation was applied to a broad scope of O-pivaloyl arylhydroxamate substrates 
(Table 2.1). para-Substituents with electron donating group and  electron withdrawing group (-
OMe (13b), -Cl (13c), -Br (13d), and -CF3 (13e)) fare well in the transformation providing good 
yields of products (15ba-15ea). Of note, the halogen functional groups (15ca and 15da) are a 
handle for further cross coupling reactions. The relative trans diastereomer of the product 15ea 

























The reaction is robust since ortho-substituent (13f) was also capable of furnishing the product 
15fa in 42% yield. meta-Methyl and trifluoromethyl substituted  benzamides (13g and 13h) gave 
the dihydroisoquinolone products 15ga and 15gh in good yield. These products arise from the C-
H activation at the less sterically hindered position. However, the mixture of regioisomeric 
products (15ia:15ia' ca. 1.5:1 ratio) was obtained when meta-methoxy substrate 13i was used. 
This result may be explained by a combination of steric effects and kinetic acidity issues. 
Benzamide derived from gallic acid derivative 13j also provides the corresponding product 15ja 
in good yield. In addition, we were pleased to find that O-pivaloyl heteroarylhydroxamate 
substrates such as furan (13k and 13l) and thiophene (13m) were capable substrates furnishing 
the corresponding products (15ka-15ma) in yields ranging from 45-87%. However, pyridine 
derivatives such as N-pivaloyloxy nicotinamide and N-pivaloyloxy isonicotinamide were found 
to be inactive, presumably due to the coordinative inhibition of pyridine moiety to Rh(III) 
catalyst. Attempts to heating the reaction (up to 60 C) led to the decomposition of the 






                                                     




 The substrate scope regarding 3,4-disubstituted cyclobutenes was then investigated 
(Table 2.2). Tolerance of unprotected alcohols was demonstrated by the good reactivity of 
cyclobutene 14b, providing the product 15ab in good yield. Protected alcohols derived from 
cyclobutene 14b (i.e. methyl ether 14c, benzyl ether 14d, acetyl 14e and silyl protected alcohols 
1f) furnished the corresponding products 15ac-15ag in 86-99% yields. Finally, cyclobutene 14g 
provided the product 15ag in 95% yield. 
Table 2.2 Cyclobutene Scope 
 
 We also found that N-pivaloyloxy acrylamides and cyclobutenes react to give [4.2.0] 
dihydropyridone products in excellent diastereoselectivity (Table 2.3). The preliminary scope 
demonstrates that the α-substituted substrates (alkyl 16a-b and aryl 16c) react to give 
corresponding dihydropyridone products 17aa-17ca in moderate to good yields (49-86%). This 
example demonstrates that Rh(III)-catalyzed C-H activation can be used as an efficient tool for 
synthesizing cyclobutane-fused N-heterocycles which are difficult to access by other means.  
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Table 2.3 N-Pivaloyloxy Acrylamide Scope 
 
It should be noted that the observed trans-derived product agrees with the explanation 
that benzamidation preferentially occurs at the less sterically hindered alkene face. The high 
diastereoselectivity of trans product is thought to proceed through trans-exo or trans-endo 
transition states as the stereochemical model was proposed in Figure 2.2. 
 




2.2.2 Efforts Towards Enantioselective Benzamidation of Cyclobutenes 
 We were interested in developing an asymmetric transformation by using a streptavidin-
based metalloenzyme technology (Table 2.3).46 When the O-pivaloyl benzhydroxamate 13 and 
cyclobutene 14a were subjected to the optimal conditions for the metalloenzyme, we found the 
dihydroisoquinolone product 15aa formation in <5% yield. We inspected the crude reaction 
mixture by 1H-NMR spectroscopy. However, we did not see cyclobutene 14a. Instead, we 
detected the full conversion of cyclobutene 14a to cyclobutene epimer epi-14a. We speculate 
that the formation of thermodynamically stable cyclobutene epimer epi-14a occurs via the base-
mediated epimerization. In addition, the cyclobutene epi-14a was found to be an ineffective 
substrate in the transformation. To circumvent the problem, we used a cyclobutene that cannot 
epimerize to study the reaction. Gratifyingly, cyclobutene 14b with unprotected alcohols 
undergoes the benzamidation and provides the product 15ab in 70% yield and 72:28 er. 
Cyclobutene with diacetyl groups 14e also furnished the products in an excellent yield and the 
same level of enantioselectivity. Cyclobutene with dimethoxy groups 14c also reacts to give the 
product 15ac in good yield with a slightly increased enantioselectivity (80:20 er). However, 
cyclobutene with dibenzyl broups 14d was found to be inactive, probably due to its inherent 






                                                     
46 Hyster, T. K.; Knorr, L.; Ward, T. R.; Rovis, T. Science 2012, 338, 500-503. 
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 In summary, we have successfully developed an efficient route to access [4.2.0] nitrogen 
heterocycles via Rh(III)-catalyzed C-H activation of benzamide and acrylamide substrates 
followed by the [4+2] annulation with cyclobutenes. The transformation appears to be highly 
diastereoselective with a good degree of functional group tolerant. Furthermore, an asymmetric 
variant was preliminarily investigated using a streptavidin-based metalloenzyme to provide the 





Rh(III)-Catalyzed Coupling of N-Pivaloyloxy Acrylamides with Alkenes via C-H Activation:  
Direct Modular Assembly of Piperidones 
 
3.1 Introduction 
3.1.1 The Importance of Nitrogen Heterocycles  
 The ,-unsaturated--lactam (or piperidone) motif is present in an array of complex 
molecules and serves as a key intermediate towards accessing other alkaloids including 
piperidine (Figure 3.1).47 Of interest is that among 640 FDA approved small molecule drugs that 
containing N-heterocycle, piperidine is the most common N-heterocycles, outcompeting even the 
ubiquitous pyridine.48 In addition, recent studies found that the degree of saturation (complexity) 
as well as the presence of stereocenters correlate with the success rate of drug discovery.49  
 
Figure 3.1 
                                                     
47 (a) Huang, C.-G.; Chang, B.-R.; Chang, N.-C. Tetrahedron Lett. 2002, 43, 2721–2723. (b) Baran, P. S.; Burns, N. 
Z. J. Am. Chem. Soc. 2006, 128, 3908-3909. (c) Amat, M.; Pérez, M.; Minaglia, A. T.; Bosch, J. J. Org. Chem. 
2008, 73, 6920–6923. (d) Hanessian, S.; Riber, L.; Marin, J. Synlett 2009, 1, 71-74. (e) Albrecht, D.; Vogt, F.; Bach, 
T. Chem. Eur. J. 2010, 16, 4284–4296. 
48 Vitaku, E.; Smith, D. T.; Njardarson, J. T. J. Med. Chem. 2014, 57, 10257-10274. For a comprehensive review on 
piperidine synthesis, see: Nebe, M.M.; Opatz, T. Adv. Heterocycl. Chem. 2017, 122, 191-244. 
49 Lovering, F.; Bikker, J.; Humblet, C. J. Med. Chem. 2009, 52, 6752-6756.  
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 Because of aforementioned reasons, extensive efforts targeting ,-unsaturated--lactams 
have been demonstrated (Figure 3.2).50 Among intramolecular cyclizations that involve 
nucleophilic attack by the nitrogen atom, one of the synthetic strategies for ,-unsaturated--
lactam formation is C-C double bond construction. This avenue has been exploited by ring 
closing metatheses,51 McMurry couplings,52 and aldol condensations.53 Nevertheless, there are 
still limitations associated with the availability of these precursors, the harsh reaction conditions, 
and elevated temperatures. Two-component approaches such as cycloadditions or annulations are 
inherently more attractive. Recently, organocatalytic [4+2] cycloaddition approaches have been 
devised, as exemplified by transformations with N-heterocyclic carbene,54 cinchona alkaloid, 55 
and chiral phosphoric acid catalysis. 56 However, these strategies are limited to specific classes of 
precursors as well as practicality issues. To address these drawbacks, a new and efficient 
methodology that enables access to ,-unsaturated--lactams from simple precursors would 
prove useful and open many avenues to the field.  
                                                     
50 Weintraub, P. M.; Sabol, J. S.; Kane, J. A.; Borcherding, D. R. Tetrahedron 2003, 59, 2953-2989. 
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Chem. 2010, 909-919. (d) Cogswell, T. J.; Donald, C. S.; Long, D.-L.; Marquez, R. Org. Biomol. Chem. 2015, 13, 
717–728. (e) Han, S.-J.; Stoltz, B. M. Tetrahedron Lett. 2016, 57, 2233-2235. 
52 Momoi, Y.; Okuyama, K.; Toya, H.; Sugimoto, K.; Okano, K.; Tokuyama, H. Angew. Chem. Int. Ed. 2014, 53, 
13215. 
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In this context, the C-H activation and annulation approach would provide direct access 
to ,-unsaturated--lactams from acrylamide and alkene precursors. This strategy is attractive 
because of easily accessible acrylamides and the abundance of alkenes. Daugulis developed a 
cobalt-catalyzed aminoquinoline-directed C-H activation of acrylamides and styrene to provide 
-lactams (Scheme 3.1).57 Nonetheless, an extra step is required for the removal of a directing 
group to reveal free lactams. Despite progress in this area, a practical synthesis of piperidones 
from simple starting materials has not been developed. 
 
Scheme 3.1 
                                                     
57 Grigorjeva, L.; Daugulis, O. Org. Lett. 2014, 16, 4684-4687. 
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3.1.2 Rh(III)-catalyzed C-H Activation in Nitrogen Heterocycles Syntheses 
 Rh(III)-catalyzed C-H activation annulation has been used to synthesize several N-
heterocycles and has become an important tool in synthesis.58 Seminal work by Fagnou,59 Miura, 
Satoh,60 Rovis61 and Li62 have demonstrated the directed C-H activation of benzamides with 
alkynes to deliver isoquinolones (Scheme 3.2, eqs 3 and 4).  Furthermore, Glorius,63 and 
Fagnou64 have developed the N-acyloxy hydroxamate directing group, which allows for alkene 
insertion and subsequent N-O bond cleavage/C-N bond formation to deliver dihydroisoquinolone 
(eq 5). In addition, this process generates a stereocenter for which the catalytic asymmetric 
variants were developed by Rovis and Ward65 as well as Cramer.66 
                                                     
58 For selected reviews, see: (a) Colby, D. A.; Bergman, R. G.; Ellman, J. A. Chem. Rev. 2010, 110, 624-655. (b) 
Satoh, T.; Miura, M. Chem. Eur. J. 2010, 16, 11212-11222. (c) Patureau, F. W.; Wencel-Delord, J.; Glorius, F. 
Aldrichimica Acta 2012, 45, 31-41. (d) Song, G. Y.; Wang, F.; Li, X. W. Chem. Soc. Rev. 2012, 41, 3651-3678. (e) 
Song, G. Y.; Li, X. W. Acc. Chem. Res. 2015, 48, 1007-1020. (f) Zhu, C.; Wang, R.; Falck, J. R. Chem. Asian. J. 
2012, 7, 1502-1514. (g) Gensch, T.; Hopkinson, M. N.; Glorius, F.; Wencel-Delord, J. Chem. Soc. Rev., 2016, 45, 
2900. (h) Gulías, M.; Mascareñas, J. L. Angew. Chem. Int. Ed. 2016, 55, 11000-11019. 
59 Guimond, N.; Gouliaras, C.; Fagnou, K. J. Am. Chem. Soc. 2010, 132, 6908-6909. 
60 Mochida, S.; Umeda, N.; Hirano, K.; Satoh, T.; Miura, M. Chem. Lett. 2010, 39, 744-746. 
61 Song, G.; Chen, D.; Pan, C. L.; Crabtree, R. H.; Li, X. J. Org. Chem. 2010, 75, 7487-7490. 
62 Hyster, T. K.; Rovis, T. J. Am. Chem. Soc. 2010, 132, 10565-10569. 
63 Rakshit, S.; Grohmann, C.; Besset, T.; Glorius, F. J. Am. Chem. Soc. 2011, 133, 2350-2353.  
64 Guimond, N.; Gorelsky S. I.; Fagnou, K. J. Am. Chem. Soc. 2011, 133, 6449-6457. 
65 Hyster, T. K.; Knorr, L.; Ward, T. R.; Rovis, T. Science 2012, 338, 500-503. 





















































 The above strategies effectively deliver bicyclic nitrogen heterocycles, with a 
disproportionate emphasis on aromatic structures. Vinylic C-H activation of acrylamides with 
alkenes would provide access to valuable monocyclic heterocycles with a stereocenter. Several 
examples regarding to vinylic C-H bond activation of acrylamides are documented. Specifically, 
Li,67 and Rovis68 have reported the directed C-H activation annulation between acrylamides with 
alkynes to access pyridones (Scheme 3.3, eq 6).69 However, transformations between acrylamide 
derivatives with alkenes only proceed through -elimination pathways to generate -
functionalization products (eqs 7-12).70 Inspired by the use of the N-acyloxy directing group that 
                                                     
67 Su, Y.; Zhao, M. A.; Han, K. L.; Song, G. Y.; Li, X. W. Org. Lett. 2010, 12, 5462-5465. 
68 Hyster, T. K.; Rovis, T. Chem. Sci. 2011, 2, 1606-1610. 
69 Intramolecular annulation with alkyne, see: (a) Xu, X.; Liu, Y.; Park, C. M. Angew. Chem. Int. Ed. 2012, 51, 
9372–9376. (b) Quinones, N.; Seoane, A.; Garcia-Fandino, R. Mascarenas, J. L.; Gulias, M. Chem. Sci., 2013, 4, 
2874–2879. 
70 (a) Besset, T.; Kuhl, N.; Patureau, F. W.; Glorius, F. Chem. Eur. J. 2011, 17, 7167-7171. (b) Zhang, J.; Loh, T. P. 
Chem. Commun., 2012, 48, 11232. (c) Zhang, S.-S.; Wu, J.-Q.; Lao, Y.-X.; Liu, X.-G.; Liu, Y.; Lv, W.-X.; Tan, D.-
H.; Zeng, Y.-F.; Wang, H. Org. Lett. 2014, 16, 6412−6415. (d) Wu, J.-Q.; Qiu, Z.-P.; Zhang, S.-S.; Liu, J.-G.; 
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prevents -hydride elimination and promotes C-N bond formation, Rh(III)-catalyzed C-H 
activation of N-pivaloyloxy acrylamides with alkene coupling partners was seen as an attractive 
strategy as this would generate unprotected ,-unsaturated--lactams (eq 13). However, this 
particular approach has proven challenging as no examples of this transformation have been 
reported to date. The challenges that are inherent with N-pivaloyloxy acrylamides may be 
attributed to the reactivity of acrylamide as a good Michael acceptor and their decomposition 
under the reaction conditions relative to their more stable N-alkyl and N-methoxy counterparts. 
Herein, we disclose an intermolecular Rh(III)-catalyzed redox-neutral [4+2] annulation between 
N-pivaloyloxy -substituted acrylamides and simple alkene coupling partners to generate 
synthetically useful ,-unsaturated--lactams.  
                                                                                                                                                                           
Lao,Y.-X.; Gu, L.-Q.; Huang, Z.-S.; Li, J.; Wang, H. Chem. Commun., 2015, 51, 77-80. (e) Zhang, S.-S.; Wu, J.-Q.; 








3.2 Results and Discussion 
3.2.1 Reaction Discovery 
Thanks to the cyclopropene's reactivity, the Rh(III)-catalyzed [4+2] annulation of N-
pivaloyloxy acrylamide 1 with cyclopropene 2 provided the dihydropyridone product 3 in 30% 
yield (2:1 dr, eq 14).  
 
 
 The reaction conditions were optimized using high-throughput experimentations (HTE) 
with different bases (CsOAc, CsOPiv) and solvents (MeOH, EtOH, tAmylOH, DCE, dioxane, 
MeCN, TFE, HFIP). The product formation was analyzed by LC/MS with multiple injections in 
a single experimental run (MISER). The optimal condition, [Cp*RhCl2]2 (2 mol%), CsOPiv 
(0.25 equiv), MeCN (0.2 M) at 60 C, gave a product in 37 % yield (Table 3.1, entry 1). 
Increasing the concentration to 0.3 M gave the similar yield (entry 2). Other precatalysts such as 
Cp*Rh(OAc)2 and [Cp*Rh(MeCN)3](SbF6)2 are also effective (entry 3, 4). To prevent the 
decomposition of N-pivaloyloxy acrylamide, the reaction was conducted at room temperature, 
which revealed the product with slightly improved yield (entry 5, 6). The use of excess amount 







Table 3.1 Reaction Condition Optimizationsa,c 
 
 Previous works in the field demonstrated that the reactivity and selectivity of Rh(III)-
catalyzed reaction could be improved using the ligand development (cf. Chapter 1). Again, the 
similar approach should solve the reactivity and diastereoselectivity problems in this case. The 
representative library of Cp ligands was examined and the results are summarized in Table 3.2. 
We observed the reactivity of the transformation is affected by the steric and electronic 
properties of Cp ligand. The electron-deficient Cp ligands (Cp*bisCF3Ar, Cp*C6H5, and Cp*CF3) are 
less reactive and gave little or no yield. We also found that heptamethylindenyl (Ind*), 1,3-di-
tert-butylcyclopentadienyl (Cpt), and 1,3-dimethyl-2,4,5-triphenylcyclopentadienyl (CpPh3Me2) 
ligands were unsuccessful in this transformation. Among the Cp precatalysts investigated in the 
study, Cp*Ph, Cp*chex, Cp*iPr, Cp*tBu, Cp*1,3-diPh, Cp*p-OMeAr, Cp*Bn  and Cp*Ar are the most 
effective ligands which provide the corresponding product in 46-70% yield. Other ligands i.e. 
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CpMe,tBu-Cy, Cp*1,2-diPh, CpMe,chex-Cy and CpTM delivered the product in low yields (27-39%). 
Disappointingly, the diastereoselectivity did not improve by tuning steric or electronic properties 
of the Cp ligands.  




 After obtaining the optimal condition for reactivity, a preliminary scope of substituted N-
pivaloyloxy acrylamides was studied (Table 3.3). α-substituted N-pivaloyloxy acrylamides (1b 
and 1c) performed well, generating the products 3ba and 3ca in moderate to good yields. 
Cyclohexenyl carboxamide 1d delivered the product 3da with excellent diastereocontrol. The 
steric properties of the substrate 1d may render the diastereoselectivity similar to the aryl 
counterpart. However, other α,β-substituted N-pivaloyloxy acrylamides (1e and 1f) only gave 
trace product. β-Substituted N-pivaloyloxy acrylamides (1g, 1h, and 1i) are unreactive substrates 
in this transformation.  




 Next, we explored less strained cycloalkenes and acyclic olefin partners using optimal 
conditions (Table 3.4). We chose N-pivaloyloxy α-benzylacrylamide 4 as a model substrate. We 
were pleased to see that norbornadiene (5a), norbornene (5b), and cyclopentene (5c) reacted 
under the optimal condition generating the δ-lactam products in low yield (19-28% yield). 
However, cyclohexene (5d) is unreactive. Acyclic alkenes were also investigated (entries 5-10). 
Styrene (5e), ethyl acrylate (5f), dimethyl fumarate (5g) and dimethyl maleate (5h) were not 
reactive coupling partners, however, we were excited to see that aliphatic alkenes (i.e. allyl 
benzene (5i) and 1-heptene (5j)) underwent the transformation and provided the products 6ai and 
6aj in low yields with ca. 2:1 regioisomeric ratio. We noticed the reactant decomposed under the 
reaction conditions during these studies. However, attempts at isolation and identification of the 
side products were unsuccessful. 
 We next prepared acrylamide precursor 4a which contains para-bromo group to aid in 
the characterization of byproducts (eq 15). After subjecting 4a to the optimal conditions, 4a 
partially decomposed to methyl benzyl ketone 7 and N-O bond cleavage product 8. Methyl 
benzyl ketone 7 may be produced through the base-mediated Lossen rearrangement/hydrolysis. 
The formation of byproduct 8 may be argued by the formation of Rh(I) species via the oxidation 
of dihydropyridone 6 to form the corresponding pyridone as detected by UPLC/MS. Then, Rh(I) 













3.2.2 Reaction Optimization 
Table 3.5 Optimization of Reaction Conditionsa 
 
 We reoptimized the reaction conditions by using Cp*Rh(OAc)2 as the precatalyst to avoid 
any excess base that may result in the decomposition of 1a. Under this reaction condition, 9a 
reacts with 10a to provide 11aa in low yield (Table 3.5, entry 1). However, we also observed 
decomposition of reactant 9a to byproducts 12 and 13. In addition, we surmised that solvent 
acidity may alleviate the starting material decomposition. The yield was substantially improved 
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when the hexafluoroisopropanol (HFIP, pKa = 9.3) was employed as the solvent (entry 2). We 
were pleased to find that trifluoroethanol (TFE, pKa = 12.5) was the optimal solvent as 
dihydropyridones were furnished in high yield (entry 3). Additionally, less decomposition 
byproducts were observed. The use of Cp*Rh(OAc)2 as a precatalyst proved problematic due to 
its inherent hygroscopicity and practicality when extending to other Cpx ligands. Fortunately, 
[Cp*RhCl2]2/CsOAc combination also works comparatively well (entry 4). Next, styrene 10b 
was found to be an amenable coupling partner, providing the corresponding product 11ab in 
good yield and regioselectivity (entry 5). The optimal catalyst loading remained at 2.5 mol% 
[Cp*RhCl2]2, as lowering the catalyst loading resulted in incomplete conversion after 24 h 
(entries 6-8). It should be noted that the process is practical and operationally simple, as it is not 
sensitive to air or moisture. 
3.2.3 Substrate Scope 
 Having optimized the reaction conditions, we next explored the N-pivaloyloxy 
acrylamides scope using styrene 10b as the coupling partner (Table 3.6). An array of -alkyl 
substituted acrylamides (9a-9d) engaged in reactivity, providing the corresponding -lactams in 
good to high yields (11ab-11db). More specifically, N-pivaloyloxy -benzyl (9a) and -(para-
bromo)-benzyl acrylamides (9b) underwent the annulation to deliver 11ab and 11bb in high 
yields. N-pivaloyloxy methacrylate (9c) also proved fruitful as the desired annulation product 
11cb was afforded in good yield. N-pivaloyloxy acrylamide 9d, derived from the itaconic acid, 
provided the product 11db in 94% yield. Next, N-pivaloyloxy -arylacrylamides (9e-9j) were 
found to be reactive, providing the products (11eb-11jb) in moderate to high yield. Substituents 
at para- (9e-9h), meta- (9i), and ortho- (9j) positions were well tolerated. Bromoarene derived 
products (11bb and 11hb) are of considerable interest as the halogen provides a handle for cross-
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coupling reactions. Interestingly, N-pivaloyloxy -ethoxyacrylamide (9k) was also competent as 
the corresponding product (11kb) was acquired in 58% yield. ,-disubstituted N-pivaloyloxy 
acrylamides (9l and 9m) gave only trace amount of product according to UPLC/MS analysis. N-
pivaloyloxy acrylamide (9n) and -substituted acrylamides (9o and 9p) did not react under the 
optimal conditions.  













































































a Reaction conditions: 9 (0.10 mmol), 10 (0.11 mmol), [Cp*RhCl2]2 (2.5 mol%), CsOAc 




A styrene scope was next investigated with substrate 1a as the coupling partner (Table 
3.6). Good regioselectivity could be obtained in all cases, partly due to the electronic bias of 
styrene substrates. First, para-substituted styrene derivatives (10c-10h) were examined. The 
electronic nature of the substituents influenced product yield. More specifically, electron-
donating groups at the para-position (10c and 10d) provided higher yields compared to electron-
withdrawing substituents (10e and 10h). Meta-substituted styrenes (10i-10n) were also tolerated 
as the corresponding -lactams (11ai-11an) were furnished in modest to good yields (35-88%). 
3-Vinylbenzaldehyde (10n) was compatible as 11an was provided in 30% yield. This example 
demonstrates that the transformation can tolerate an unprotected carboxaldehyde functional 
group. 2-Vinylnapthalene (10o) also reacted to provide 11ao in good yield. Most ortho-
substituted styrenes proved fruitless. These substrates may be too sterically cumbersome to 
promote the reactivity. However, less sterically hindered 2-fluorostyrene (10p) furnished the 
product 11ap in moderate yield. Electron-deficient pentafluorostyrene 10q was a capable 
coupling partner as 11aq was provided in a moderate yield. 4-Vinylpyridine was an ineffective 
substrate, likely due to the inhibitory coordination of pyridine on Rh(III). It should also be noted 
















Interestingly, this reaction showed generality for a variety of cyclic alkenes that 
efficiently generate fused--lactams (Table 3.8). Strained cyclic alkenes such as norbornadiene 
(12a) and norbornene (12b) engaged under optimal conditions providing fused-bicyclic 
structures (13aa and 13ab) in high yield. Less strained cyclic alkenes such as cyclopentene (12c) 
and indene (12d) were also competent substrates as they delivered useful fused--lactams (13ac 
and 13ad) in good yields. Furthermore, 1,3-cyclohexadiene (12e) reacted to give a fused-lactam 
product 13ae in good yield. However, the less strained cyclohexene coupling partner (12f) 
provided only trace product 13af. Dihydronaphthalene (12g) was also a competent substrate and 
afforded product 13ag in 63% yield. Cyclooctene (12h) also reacted to give 75% yield of product 
13ah.  





So far, unactivated alkenes have proven to be challenging substrates in the selective 
functionalization due to the lack of the electronic bias relative to styrenes (Table 3.9).71 These 
alkenes, in theory, should produce a regioisomeric mixture of 5- and 6-substituted ,-
unsaturated--lactams. Vinyl cyclohexane 10r gave predominantly the 6-substituted product 11ar 
when subjected to optimized reaction conditions. To our surprise, vinyl cyclopentane 10s gave 
the 5-substitued product 11as' as the major regioisomer under optimal conditions. The steric bulk 
of the di-1,3-di-tert-butylcyclopentadienyl ligand (Cpt)72 improved the regioselectivity of 
product 11as' to >10:1 rr. Allylbenzene (10a) gave 5-substituted product 11aa' as a major 
regioisomer (2:1 rr). Again, the Cpt ligand improved the regioisomeric ratio substantially to 
>10:1 rr favoring 11aa'. Other aliphatic alkenes such as 4-phenyl-1-butene (10t) and 1-heptene 
(11u) gave the corresponding products (11at' and 11au') in sufficient yields. Bromo- (10v), 
ester- (10w) functional groups were tolerated as the corresponding annulation products (11av' 
and 11aw') were afforded in moderate yields. These results demonstrate a dichotomy of alkene 
insertion to access regioisomeric products from different alkenes. However, the reason for this 






                                                     
71 Selected examples: (a) Tsai, A. S.; Brasse, M.; Bergman, R. G. Ellman, J. A. Org. Lett., 2011, 13, 540–542. (b) 
Neely, J. M.; Rovis, T. J. Am. Chem. Soc., 2013, 135, 66−69. (b) Takahama, Y.; Shibata, Y.; Tanaka, K. Chem. Eur. 
J., 2015, 21, 9053-9056. 
72 (a) Hyster, T. K.; Rovis, T. Chem. Sci., 2011, 2, 1606-1610. (b) Hyster, T. K.; Dalton, D. M.; Rovis, T. Chem. Sci., 
2015, 6, 254-258. 
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Table 3.9 Unactivated Alkene Scope a 
 
3.2.4 Mechanistic Studies 
 During the investigation of the scope, N-pivaloyloxy acrylamide 9n and ethyl acrylate 
10x were found to be incompetent substrates under the optimal condition. We speculate that they 
might be a good ligand on rhodium. Control experiments employing N-pivaloyloxy acrylamide 
9a and ethyl acrylate 10a as additives under the optimal condition (using 9n and 10x) completely 
shut down the reaction, no annulation products 11aa and 11aa’ were observed in both cases 
(Table 3.10). These results indicate that an inhibitory effect of the N-pivaloyloxy acrylamide 9n 








 An isotope experiment was performed to investigate the reaction mechanism (Scheme 
3.4). The reversibility of the C-H activation was determined by running the reaction in the 
absence of any alkene coupling partner in TFE-d1. After 1 h, 65% deuterium incorporation at the 
C-H bond cis to amide was observed, as determined by 1H-NMR (eq 16). Additionally, an 
experiment with styrene 10b was conducted using TFE-d1. After 1 h (ca. 60% conversion), 51% 
deuterium incorporation to 9a-d at the C-H bond cis to the amide was observed. The KIE value 
(PH/PD) of 2.3 was calculated (eq 17). However, the reversibility of C-H activation may be taken 
into account for KIE value. The results together suggest that the C-H activation is fast, 
reversible, and may not be involved in the turnover-limiting step. Finally, N-methoxy -benzyl 
acrylamide 9q did not give any product, implying that the N-pivaloyloxy group is essential for 































































































Scheme 3.4 Mechanistic experiments 
 With these preliminary mechanistic results, a plausible catalytic cycle for this reaction is 
proposed in Figure 3.3. Initially, coordination of the amide to rhodium by deprotonation of the 
N-H bond by acetate base generates intermediate I. This brings the rhodium in proximity to the 
vinylic C-H bond. The reversible C-H activation occurs, presumably via the concerted-
metallation deprotonation (CMD) mechanism, providing five-membered rhodacycle II. 
Subsequent alkene coordination and irreversible migratory insertion give seven-membered 
rhodacycle IV. N-Acyloxy coordination to Rh(III) precludes the -hydride elimination. Instead, 
N-O bond cleavage occurs via the transient Rh(V) nitrenoid intermediate V.73 Finally, reductive 
                                                     
73 Xu, L.; Zhu, Q.; Huang, G.; Cheng, B.; Xia, Y. J. Org. Chem., 2012, 77, 3017–3024. 
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elimination and C-N bond formation regenerates Rh(III) to close the catalytic cycle. An 
alternative mechanism involving C-N bond formation to generate Rh(I) intermediate V' and N-O 































































Figure 3.3 Proposed reaction mechanism 
3.2.5 Product Derivatization 
The derivatization of these -lactams highlights their synthetic utility to access other 
nitrogen heterocycles (Scheme 3.4). The Pd/C-catalyzed hydrogenation of C-C double bond of 
11ad and 13ad afforded piperidones 14ad and 14ac in good diastereoselectivity. In addition, the 






 In summary, we have developed an intermolecular Rh(III)-catalyzed C-H activation 
reaction for the synthesis of ,-unsaturated--lactams from N-pivaloyloxy -substituted 
acrylamides and alkenes. Preliminary mechanistic studies suggest that the reaction proceeds 
through the reversible C-H activation, irreversible alkene migratory insertion, and N-O bond 
cleavage/C-N bond formation pathways. We believe that this transformation should not only 
provide applications for expedient access of ,-unsaturated--lactams and related alkaloids 
from simple manipulations, but also serve as a starting point for the development of 






Development of Stereoselective Cyclopropene Benzamidation via Rh(III)-Catalyzed C-H Activation74 
 
1. General methods 
Unless otherwise noted, reactions were performed in flame-dried glassware and carried out under 
an atmosphere of nitrogen with magnetic stirring. Tetrahydrofuran (THF), diethyl ether (Et2O), and 
dichloromethane (DCM) were degassed with argon and passed through two columns of neutral alumina. 
Toluene was degassed with argon and passed through one column of neutral alumina and one column of 
Q5 reagent. Flash column chromatography was performed on SiliCycle Inc.® silica gel 60 (230-400 
mesh). Thin Layer chromatography was performed on SiliCycle Inc.® 0.25 mm silica gel 60-F plates. 
Visualization was accomplished with UV light (254 nm), KMnO4, or CAM. 1H-NMR and 13C-NMR 
spectra were recorded on a Varian 400 MHz spectrometers or a Bruker Avance III 500 (500 MHz) at 
ambient temperature. 1H-NMR data are reported as the following: chemical shift in parts per million (δ, 
ppm) from chloroform (CHCl3) taken as 7.26 ppm, integration, multiplicity (s=singlet, d=doublet, 
t=triplet, q=quartet, m=multiplet, dd=doublet of doublets) and coupling constant (J in Hz unit). 13C-NMR 
is reported as the following: chemical shifts are reported in ppm from CDCl3 taken as 77.0 ppm. Several 
spectra contain a probe-shielding artifact that consistently appeared on all spectra taken at that instrument 
over a period of months. Mass spectra were obtained on an Agilent Technologies 6130 Quadrupole Mass 
Spec (LRMS, ESI+APCI). Infrared spectra (IR) were obtained on Bruker Tensor 27 FT-IR spectrometer.  
2. Preparation of starting materials and rhodium precatalysts 
O-pivaloyl arylhydroxamates,75 O-Boc arylhydroxamates76 and 3,3-disubstituted cyclopropenes77-
78 were prepared by previously reported procedure. Catalyst Synthesis: [Cp*RhCl2]279, [Cp*t-BuRhCl2]280, 
                                                          
74 Adapted from: Semakul, N.;  Jackson, K. E.; Paton, R. P.; Rovis, T. Chem. Sci. 2017, 8, 1015-1020.  
75 (a) Guimond, N,; Gorelsky, S. I.; Fagnou, K. J. Am. Chem. Soc. 2011, 133, 6449-6457. (b) Wang, H.; Glorius, F. 
Angew. Chem. Int. Ed. 2012, 51, 7318-7322. (c) Hyster, T. K.; Ruhl, K. E.; Rovis, T. J. Am. Chem. Soc. 2013, 135, 
5364-5367. 
76 (a) Guimond, N,; Gorelsky, S. I.; Fagnou, K. J. Am. Chem. Soc. 2011, 133, 6449-6457. (b) Ye, B.; Cramer, N. 
Science 2012, 338, 504-506. 
77 Rubin, M.; Gevorgyan, V. Synthesis 2004, 796-800. 
78 Phan, D. H. T.; Kou, K. G. M.; Dong, V. M. J. Am. Chem. Soc. 2010, 132, 16354-16355.  
79 Fujita, K.; Takahashi, Y.; Owaki, M.; Yamamoto, K.; Yamaguchi, R. Org. Lett. 2004, 6, 2785-2788.  
80 Piou, T.; Rovis, T. Nature 2015, 527, 86-90. 
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[Cp*CF3RhCl2]281, [Cp*bisCF3ArRhCl2]282 and [CpiPrRhCl2]283 were synthesized by reported procedures. 
[CptRhCl2]2 was purchased from Sigma-Aldrich (RNI00147).  
Synthesis of heptamethylindenyl rhodium chloride dimer [Ind*RhCl2]2 
 
To a flame-dried round bottom flask charged with a stir bar, 2,3,4,5,6,7-hexamethylindan-1-one84 
(700 mg, 3.23 mmol, 1 equiv.), Et2O (11 mL, 0.3 M) were added and cooled to 0C. 3 M MeMgBr (2.16 
mL, 6.47 mmol, 2 equiv.) was added to the solution dropwise. The reaction was mixture was warmed to 
room temperature and refluxed for 2.5 h. At 0C, H2O was added to the reaction mixture following by 
conc HCl and stirred at room temperature for 12 h. The reaction was extracted with Et2O (3 times), 
washed with satd NaHCO3, H2O, brine, dried over MgSO4, filtered and solvent was evaporated under 
reduced pressure. The crude product was purified by column chromatography using 5% Et2O/hexane as 
an eluent to afford heptamethylindene (Ind*H)85 (334 mg, 48% yield). The characterizations were agreed 
with the previously report. 1H-NMR (CDCl3, 400 MHz)  3.28 (m, 1H), 2.61 (s, 3H), 2.42 (s, 3H), 2.35 
(s, 9H), 2.05 (s, 3H), 1.33 (d, J = 4 Hz, 3H). 13C-NMR (CDCl3, 100 MHz)  144.9, 142.9, 140.9, 133.8, 
132.0, 130.8, 128.4, 126.5, 46.4, 16.7, 16.4, 16.2, 16.1, 16.0, 15.3, 12.3. 
Heptamethylindene (Ind*H) (1.26 equiv., 1.2 mmol, 260 mg) was dissolved in EtOH (0.063 M, 15 
mL) and a few drops of water. RhCl3H2O (1 equiv., 0.95 mmol, 250 mg) was added to the reaction 
mixture which was subsequently refluxed for 72 h. The mixture was cooled to room temperature and the 
solvent was evaporated to dryness. The crude product was washed several times with hexane to remove 
excess ligand. The crude solid was redissolved in CH2Cl2 and filtered through Celite. The filtrate was 
concentrated which give [Ind*RhCl2]2 complex as a red-brown solid (60 mg, 48% yield). The 
characterizations were agreed with the previously report86. 1H-NMR (CDCl3, 400 MHz)  2.54 (s, 6H), 
                                                          
81 Gassman, P. G.; Mickelson, J. W.; Sowa, J. R. J. Am. Chem. Soc. 1992, 114, 6942-6944. 
82 Davis, T. A.; Wang, C. Q.; Rovis, T. Synlett 2015, 26, 1520-1524. 
83 Piou, T.; Rovis, T. J. Am. Chem. Soc. 2014, 136, 11292-11295. 
84 Arnold, T. A.-Q.; Buffet, J.-C.; Turner, Z. R.; O'Hare, D. J. Organomet. Chem. 2015, 792, 55-56. 
85 O’Hare, D.; Green, J. C.; Marder, T.; Collins, S.; Stringer, G.; Kakkar, A. K.; Kaltsoyannis, N.; Kuhn, A.; Lewis, 
R.; Mehnert, C.; Scott, P.; Kurmoo, M.; Pugh, S. Organometallics 1992, 11, 48-55. 
86 Kakkar, A. K.; Stringer, G.; Taylor, N. J.; Marder, T. B. Can. J. Chem. 1995, 73, 981-988. 
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2.07 (s, 6H), 1.97 (s, 6H), 1.59 (s, 3H). 13C-NMR (CDCl3, 126 MHz)  143.7, 130.4, 102.6, 95.2 (d), 
81.0(d), 18.5, 17.8, 13.4, 10.3. IR (neat, cm-1) 2922.6, 2852.3. 
3. General procedures for Rh(III)-catalyzed amidoarylation O-substituted arylhydroxamate with 
cyclopropene 
 Without any precaution of air and moisture, O-substituted arylhydroxamate (0.1 mmol, 1 eq), 
[ind*RhCl2]2 (0.001 mmol, 1 mol%), CsOPiv (0.025 mmol, 0.25 equiv) and MeOH (1 mL, 0.1 M) were 
weighed into a dram vial charged with a stir bar. The mixture was stirred for 30 seconds and 
cyclopropene (0.11 mmol, 1.1 equiv) was then added. The reaction was stirred at room temperature for 16 
h until the starting material was consumed (monitoring by TLC). The reaction was quenched with 
saturated NaHCO3 and extracted 3 times with EtOAc. The organic layer was washed with brine, dried 
over MgSO4, filtered, and solvent was evaporated to obtain crude product. The crude product was purified 
by column chromatography using 1/3 to 2/1 EtOAc/hexane to obtain the desired product.  
Condition A: using O-pivaloyl arylhydroxamate 
Condition B: using O-Boc arylhydroxamate 
4. Product characterizations 
(1S,1aR,7bR)-1-methyl-1-phenyl-1,1a,2,7b-tetrahydro-3H-cyclopropa[c]isoquinolin-3-one 
General procedure B, O-Boc arylhydroxamate (0.1 mmol, 23.7 mg) reacted with 
cyclopropene (0.11 mmol, 14.3 mg) gives the desired dihydroisoquinolone (>20:1 dr 
of the crude reaction mixture). The major diastereomer was obtained after purification 
by column chromatography using 1/3 to 2/1 EtOAc/hexane as a white solid (17.9 mg, 
68% yield).  
1H-NMR (CDCl3, 400 MHz):  8.20 (d, J = 8.0 Hz, 1H), 7.51 (t, J = 8.0 Hz, 1H), 7.44-7.32 (m, 6H), 
7.28-7.24 (m, 1H), 6.99 (br. s, NH), 3.49 (dd, J = 8.0, 4.0 Hz, 1H), 2.72 (d, J = 8.0 Hz, 1H), 1.13 (s, 3H) 
13C- NMR (CDCl3, 100 MHz):  164.1, 144.8, 136.4, 132.5, 129.5, 128.7, 128.2, 126.95, 126.86, 126.78, 
126.5, 40.7, 26.7, 24.9, 13.1 
IR (neat, cm-1) 3174, 2923, 1658, 1599 
LRMS m/z (ESI+APCI) calcd for C17H15NO [M+H]: 250.1; Found: 250.1 
(1S,1aR,7bR)-1,6-dimethyl-1-phenyl-1,1a,2,7b-tetrahydro-3H-cyclopropa[c]isoquinolin-3-one 
General procedure A, O-Piv arylhydroxamate (0.1 mmol, 23.5 mg) reacted with 
cyclopropene (0.11 mmol, 14.3 mg) gives the desired dihydroisoquinolone 
(>20:1 dr of the crude reaction mixture). The major diastereomer was obtained 
after purification by column chromatography using 1/3 to 2/1 EtOAc/hexane as 
an off-white solid (21.0 mg, 90 % yield). 
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General procedure B, O-Boc arylhydroxamate (0.1 mmol, 25.1 mg) reacted with cyclopropene (0.11 
mmol, 14.3 mg) gives the desired dihydroisoquinolone (>20:1 dr of the crude reaction mixture). The 
major diastereomer was obtained after purification by column chromatography using 1/3 to 2/1 
EtOAc/hexane as a white solid (17.9 mg, 68% yield).  
1H-NMR (CDCl3, 400 MHz):  8.05 (d, J = 8.0 Hz, 1H), 7.39-7.32 (m, 4H), 7.28-2.22 (m, 2H), 7.17 (d, J 
= 8.0 Hz, 1H), 6.89 (br. s, 1H), 3.47 (dd, J = 8.0, 4.0 Hz, 1H), 2.67 (d, J = 8.0 Hz, 1H), 2.41 (s, 3H), 1.13 
(s, 3H)  
13C- NMR (CDCl3, 100 MHz):  164.3, 144.9, 143.1, 136.3, 130.0, 128.7, 128.2, 127.9, 126.8, 126.4, 
124.3, 40.7, 26.7, 25.0, 21.6, 13.2 
IR (neat, cm-1) 3176, 3024, 2919, 1575, 1614 
LRMS m/z (ESI+APCI) calcd for C18H17NO [M+H]: 264.1; Found: 264.2 
(1S,1aR,7bR)-6-methoxy-1-methyl-1-phenyl-1,1a,2,7b-tetrahydro-3H-cyclopropa[c]isoquinolin-3-
one  
General procedure A, O-Piv arylhydroxamate 1e (0.1 mmol, 25.1 mg) reacted 
with cyclopropene 2c (0.11 mmol, 14.3 mg) gives the desired 
dihydroisoquinolone (>20:1 dr of the crude reaction mixture). The major 
diastereomer was obtained after purification by column chromatography using 
1/3 to 2/1 EtOAc/hexane as an off-white solid (24.9 mg, 89 % yield). 
General procedure B, using O-Boc arylhydroxamate 1e’ (0.1 mmol, 26.7 mg) gives the desired 
dihydroisoquinolone (>20:1 dr of the crude reaction mixture). The major diastereomer was obtained after 
purification by column chromatography using 1/3 to 2/1 EtOAc/hexane as an off-white solid (17.9 mg, 
64% yield). 
1H-NMR (CDCl3, 400 MHz):  8.13 (d, J = 8.0 Hz, 1H), 7.39-7.31 (m, 4H), 7.27-7.23 (m, 1H), 6.89-6.83 
(m, 2H), 6.83 (br. s, 1H), 3.88 (s, 3H), 3.47 (dd, J = 8.0, 4.0 Hz, 1H), 2.67 (d, J = 8 Hz), 1.15 (s, 3H)  
13C- NMR (CDCl3, 100 MHz):  164.1, 162.8, 144.9, 138.5, 130.4, 128.7, 126.7, 126.4, 119.9, 114.0, 
112.9, 55.4, 41.0, 27.0, 25.2, 13.1 
IR (neat, cm-1) 3189, 3024, 2927, 1445, 1603, 1445, 1266 
LRMS m/z (ESI+APCI) calcd for C18H17NO2 [M+H]: 280.1; Found: 280.1 
(1S,1aR,7bR)-1-methyl-1-phenyl-6-(trifluoromethyl)-1,1a,2,7b-tetrahydro-3H-
cyclopropa[c]isoquinolin-3-one  
General procedure A, O-Piv arylhydroxamate (0.1 mmol, 28.9 mg) reacted with 
cyclopropene (0.11 mmol, 14.3 mg) gives the desired dihydroisoquinolone 
(10.2:1 dr of the crude reaction mixture). The major diastereomer was obtained 
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after purification by column chromatography using 1/3 to 2/1 EtOAc/hexane as an off-white solid (25.1 
mg, 77 % yield). 
General procedure B, using O-Boc arylhydroxamate (0.1 mmol, 30.0 mg) gives the desired 
dihydroisoquinolone (17:1 dr of the crude reaction mixture). The major diastereomer was obtained after 
purification by column chromatography using 1/3 to 2/1 EtOAc/hexane as an off-white solid (21.2 mg, 
67% yield). 
1H-NMR (CDCl3, 400 MHz):  8.32 (d, J = 8.0 Hz, 1H), 7.70 (s, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.41-7.35 
(m, 5H), 7.30-7.27 (m, 1H), 3.56 (dd, J = 8.0, 4.0 Hz, 1H), 2.76 (d, J = 8.0 Hz, 1H), 1.14 (s, 3H) 
13C- NMR (CDCl3, 100 MHz):  163.1, 144.1, 140.4, 130.1, 129.4 (q), 128.8, 128.8 (q), 127.5, 126.9, 
126.8, 126.3 (q), 125.4 (q), 40.8, 26.4, 25.9, 13.2 
19F-NMR (CDCl3, 386 MHz):  -63.1 
IR (neat, cm-1) 3200, 1560, 1311, 1168, 1127 
LRMS m/z (ESI+APCI) calcd for C18H14F3NO [M+H]: 318.1; Found: 318.1 
(1S,1aR,7bR)-6-chloro-1-methyl-1-phenyl-1,1a,2,7b-tetrahydro-3H-cyclopropa[c]isoquinolin-3-one  
General procedure A, O-Piv arylhydroxamate (0.1 mmol, 25.6 mg) reacted with 
cyclopropene (0.11 mmol, 14.3 mg) gives the desired dihydroisoquinolone (8.5:1 
dr of the crude reaction mixture). The major diastereomer was obtained after 
purification by column chromatography using 1/3 to 2/1 EtOAc/hexane as an off-
white solid (20.8 mg, 73 % yield). 
General procedure B, using O-Boc arylhydroxamate (0.1 mmol, 27.2 mg) gives the desired 
dihydroisoquinolone (>20:1 dr of the crude reaction mixture). The major diastereomer was obtained after 
purification by column chromatography using 1/3 to 2/1 EtOAc/hexane as an off-white solid (17.6 mg, 
63% yield). 
1H-NMR (CDCl3, 400 MHz):  8.11 (d, J = 8.0 Hz), 7.41-7.23 (m, 7H), 6.79 (br. s, 1H), 3.48 (dd, J = 8.0, 
4.0 Hz, 1H), 2.64 (d, J = 8 Hz, 1H), 1.11 (s, 3H) 
13C- NMR (CDCl3, 100 MHz):  163.2, 144.3, 138.7, 138.2, 129.9, 129.3, 128.8, 127.4, 126.9, 126.7, 
125.4, 40.7, 26.2, 25.7, 13.3 
IR (neat, cm-1) 3173, 2921, 1490, 1596 
LRMS m/z (ESI+APCI) calcd for C17H14ClNO [M+H]: 284.1; Found: 284.1 
(1S,1aR,7bR)-6-bromo-1-methyl-1-phenyl-1,1a,2,7b-tetrahydro-3H-cyclopropa[c]isoquinolin-3-one  
General procedure A, O-Piv arylhydroxamate (0.1 mmol, 30.0 mg) reacted with 
cyclopropene (0.11 mmol, 14.3 mg) gives the desired dihydroisoquinolone 
(11.2:1 dr of the crude reaction mixture). The major diastereomer was obtained 
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after purification by column chromatography using 1/3 to 2/1 EtOAc/hexane as an off-white solid (27.3 
mg, 83 % yield). 
1H-NMR (CDCl3, 400 MHz):  8.05 (d, J = 8.0 Hz, 1H), 7.60 (s, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.40-7.30 
(m, 4H), 7.27 (t, J = 8.0 Hz, 1H), 6.82 (br. s, 1H), 3.50 (dd, J = 8.0, 4.0 Hz, 1H), 2.66 (d, J = 8.0 Hz, 1H), 
1.14 (s, 3H)  
13C- NMR (CDCl3, 100 MHz):  163.4, 144.3, 138.4, 132.2, 130.4, 130.0, 128.8, 127.3, 126.9, 126.7, 
125.8, 40.7, 26.2, 25.7, 13.3 
IR (neat, cm-1) 2924, 1668, 1591, 1469, 1444, 1371, 765, 700 
LRMS m/z (ESI+APCI) calcd for C17H14BrNO [M+H]: 328.0; Found: 328.0, 330.0 
(1S,1aR,7bS)-5,6,7-trimethoxy-1-methyl-1-phenyl-1,1a,2,7b-tetrahydro-3H-
cyclopropa[c]isoquinolin-3-one  
General procedure A, O-Piv arylhydroxamate (0.1 mmol, 31.1 mg) reacted 
with cyclopropene (0.11 mmol, 14.3 mg) gives the desired dihydroisoquinolone 
(>20:1 dr of the crude reaction mixture). The major diastereomer was obtained 
after purification by column chromatography using 1/3 to 2/1 EtOAc/hexane as 
an off-white solid (20.5 mg, 62 % yield). 
1H-NMR (CDCl3, 400 MHz):  7.55 (s, 1H), 7.42-7.34 (m, 4H), 7.26-7.23 (m, 1H), 6.87 (br. s, 1H), 3.97 
(s, 3H), 3.93 (s, 3H), 3.91 (s, 3H), 3.39 (dd, J = 8.0, 4.0 Hz, 1H), 2.87 (d, J = 8.0 Hz, 1H), 1.13 (s, 3H)  
13C- NMR (CDCl3, 100 MHz):  163.7, 152.3, 151.9, 145.9, 144.9, 128.7, 127.1, 126.5, 123.7, 122.3, 
106.7, 61.1, 61.0, 56.1, 40.6, 23.9, 21.2, 13.6 
IR (neat, cm-1) 3200, 2937, 1575, 1597, 1576, 1479, 1113 
LRMS m/z (ESI+APCI) calcd for C20H21NO4 [M+H]: 340.2; Found: 340.2 
(1S,1aR,7bR)-1-methyl-1-phenyl-5-(trifluoromethyl)-1,1a,2,7b-tetrahydro-3H-
cyclopropa[c]isoquinolin-3-one  
General procedure A, O-Piv arylhydroxamate (0.1 mmol, 28.5 mg) reacted with 
cyclopropene (0.11 mmol, 14.3 mg) gives the desired dihydroisoquinolone 
(single regioselectivity, >20:1 dr of the crude reaction mixture). The major 
diastereomer was obtained after purification by column chromatography using 
1/3 to 2/1 EtOAc/hexane as an off-white solid (28.3 mg, 85 % yield). 
1H-NMR (CDCl3, 400 MHz):  8.50 (s, 1H), 7.80 (br. s, NH), 7.75 (d, J = 8 Hz, 1H), 7.57 (d, J = 8 Hz, 
1H), 7.42-7.33 (m, 4H), 7.29 (d, J = 8 Hz, 1H), 3.58 (dd, J = 8.0, 4.0 Hz, 1H), 2.75 (d, J = 8.0 Hz), 1.14 
(s, 3H) 
13C- NMR (CDCl3, 100 MHz):  163.1, 144.1, 140.4, 130.1, 129.4 (q), 128.8, 128.8 (q), 127.5 (q), 126.9 
(q), 126.8, 125.4, 123.8, 40.8, 26.4, 25.9, 13.2. 
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19F-NMR (CDCl3, 386 MHz):  -61.8 
IR (neat, cm-1) 3193, 3060, 2928, 1669, 1617, 1502, 1167, 1125 
LRMS m/z (ESI+APCI) calcd for C18H14F3NO [M+H]: 318.1; Found: 318.1 
(1S,1aR,9bR)-1-methyl-1-phenyl-1,1a,2,5,6,7,8,9b-octahydro-3H-benzo[g]cyclopropa[c]isoquinolin-
3-one  
General procedure A, O-Piv arylhydroxamate (0.1 mmol, 27.5 mg) reacted with 
cyclopropene (0.11 mmol, 14.3 mg) gives the desired dihydroisoquinolone 
(8.5:1 regioselectivity, >20:1 dr of the crude reaction mixture). The mixture of 
product (8.5:1 regioselectivity, >20:1 dr) was obtained after purification by 
column chromatography using 1/3 to 2/1 EtOAc/hexane as an off-white solid 
(28.6 mg, 94 % yield). 
1H-NMR (CDCl3, 400 MHz):  7.90 (s, 1H), 7.38-7.32 (m, 4H), 7.25-7.22 (m, 
1H), 7.11 (s, 1H), 3.45 (dd, J = 8.0, 4.0 Hz, 1H), 2.81 (m, 4H), 2.64 (d, J = 8.0 Hz, 1H), 1.82 (m, 4H), 
1.13 (s, 3H)  
13C- NMR (CDCl3, 100 MHz):  164.7, 145.1, 142.4, 136.2, 133.1, 129.9, 128.7, 128.6, 126.8, 126.7, 
126.3, 40.7, 29.5, 29.0, 26.5, 24.6, 23.0, 22.9, 13.1 
IR (neat, cm-1) 3190, 2926, 1660, 1613, 1445, 909, 731 
LRMS m/z (ESI+APCI) calcd for C21H21NO [M+H]: 303.2; Found: 303.2 
General procedure A, O-Piv arylhydroxamate (0.1 mmol, 23.5 mg) reacted with 
cyclopropene (0.11 mmol, 14.3 mg) gives the desired dihydroisoquinolone (3:1 
regioselectivity, >20:1 dr of the crude reaction mixture). The mixture of products 
(3:1 regioselectiviy, >20:1 dr) was obtained after purification by column 
chromatography using 1/3 to 2/1 EtOAc/hexane as an off-white solid (25.5 mg, 
92 % yield). 
1H-NMR (CDCl3, 400 MHz): (See spectra) 
13C- NMR (CDCl3, 100 MHz): (See spectra) 
IR (neat, cm-1) 3196, 3025, 2923, 1665, 1613, 1500 
LRMS m/z (ESI+APCI) calcd for C18H17NO [M+H]: 264.1; Found: 264.1 
General procedure A, O-Piv arylhydroxamate (0.1 mmol, 
25.1 mg) reacted with cyclopropene (0.11 mmol, 14.3 
mg) gives the desired dihydroisoquinolone (1:1 
regioselectivity, >20:1 dr of the crude reaction mixture). 
The mixture of product was obtained after purification by 
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column chromatography using 1/3 to 2/1 EtOAc/hexane as an off-white solid (25.1 mg, 86 % yield). 
1H-NMR (CDCl3, 400 MHz): (See spectra) 
13C- NMR (CDCl3, 100 MHz): (See spectra) 
IR (neat, cm-1) 3187, 2932, 1668, 1581, 1494, 1263, 1057, 1032, 752 
LRMS m/z (ESI+APCI) calcd for C18H17NO2 [M+H]: 280.1; Found: 280.1 
(1S,1aR,7bR)-1-methyl-1-(p-tolyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c]isoquinolin-3-one  
General procedure B, O-Boc arylhydroxamate (0.1 mmol, 23.7 mg) reacted with 
cyclopropene (0.11 mmol, 15.9 mg) gives the desired dihydroisoquinolone (>20:1 dr 
of the crude reaction mixture). The major diastereomer was obtained after purification 
by column chromatography using 1/3 to 2/1 EtOAc/hexane as an off-white solid (15.3 
mg, 58 % yield). 
1H-NMR (CDCl3, 400 MHz):  8.19 (d, J = 8.0 Hz, 1H), 7.50 (t, J = 8.0 Hz, 1H), 7.42 
(d, J = 8.0 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.24-7.15 (m, 4H), 6.91 (br. s, 1H), 3.45 
(dd, J = 8.0, 4.0 Hz, 1H), 2.68 (d, J = 8.0 Hz, 1H), 2.35 (s, 3H), 1.11 (s, 3H)  
13C- NMR (CDCl3, 100 MHz):  164.1, 141.8, 136.5, 136.2, 132.4, 129.44, 129.39, 128.2, 126.87, 
126.85, 126.7, 40.6, 26.6, 24.7, 21.0, 13.2 
IR (neat, cm-1) 3188, 3028, 2919, 1662, 1597, 1479, 1341, 777 
LRMS m/z (ESI+APCI) calcd for C18H17NO [M+H]: 264.1; Found: 264.2 
(1S,1aR,7bR)-1-(4-methoxyphenyl)-1-methyl-1,1a,2,7b-tetrahydro-3H-cyclopropa[c]isoquinolin-3-
one  
General procedure B, O-Boc arylhydroxamate 1d (0.1 mmol, 23.7 mg) reacted with 
cyclopropene 2e (0.11 mmol, 17.6 mg) gives the desired dihydroisoquinolone (>20:1 
dr of the crude reaction mixture). The major diastereomer was obtained after 
purification by column chromatography using 1/3 to 2/1 EtOAc/hexane as an off-
white solid (18.7 mg, 67 % yield). 
1H-NMR (CDCl3, 400 MHz):  8.19 (d, J = 8 Hz, 1H), 7.50 (t, J = 8 Hz, 1H), 7.42 (d, 
J = 8 Hz, 1H), 7.36 (t, J = 8 Hz, 1H), 7.27 (d, J = 8 Hz, 2H), 7.11 (brs, 1H), 6.90 (d, J 
= 8 Hz, 2H), 3.81 (s, 3H), 3.44 (dd, J = 4, 8 Hz, 1H), 2.65 (d, J = 8 Hz, 1H), 1.09 (s, 3H)  
13C- NMR (CDCl3, 100 MHz):  164.2, 158.2, 137.0, 136.6, 132.4, 129.4, 128.1, 128.1, 126.8, 114.1, 
55.3, 40.5, 26.4, 24.5, 13.6  
IR (neat, cm-1) 3196, 3039, 2929, 2830, 1662, 1513, 1240, 1178, 1030, 777, 737 






General procedure B, O-Boc arylhydroxamate (0.1 mmol, 23.7 mg) reacted with 
cyclopropene (0.11 mmol, 23.0 mg) gives the desired dihydroisoquinolone (>20:1 dr 
of the crude reaction mixture). The major diastereomer was obtained after purification 
by column chromatography using 1/3 to 2/1 EtOAc/hexane as an off-white solid (17.1 
mg, 52 % yield). 
1H-NMR (CDCl3, 400 MHz):  8.19 (d, J = 8.0 Hz, 1H), 7.51 (t, J = 8.0 Hz, 1H), 7.48 
(d, J = 8.0 Hz, 2H), 7.42-7.34 (m, 2H), 7.20 (d, J = 8.0 Hz, 2H), 7.10 (br. s, 1H), 6.90 
(d, J = 8.0 Hz, 2H), 3.46 (dd, J = 8.0, 4.0 Hz, 1H), 2.67 (d, J = 8.0 Hz, 1H), 1.10 (s, 3H)  
13C- NMR (CDCl3, 100 MHz): 164.0, 143.9, 136.0, 132.5, 131.8, 129.4, 128.6, 128.2, 127.1, 126.8, 
120.3, 40.6, 26.7, 24.6, 13.0 
IR (neat, cm-1) 3171, 3028, 2921, 1662, 1490, 1437 
LRMS m/z (ESI+APCI) calcd for C17H14BrNO [M+H]: 328.0, 330.0; Found: 328.0, 330.1 
(1S,1aR,7bR)-1-(3-methoxyphenyl)-1-methyl-1,1a,2,7b-tetrahydro-3H-cyclopropa[c]isoquinolin-3-
one  
General procedure B, O-Boc arylhydroxamate (0.1 mmol, 23.7 mg) reacted with 
cyclopropene (0.11 mmol, 17.6 mg) gives the desired dihydroisoquinolone (13.5:1 
dr of the crude reaction mixture). The major diastereomer was obtained after 
purification by column chromatography using 1/3 to 2/1 EtOAc/hexane as an off-
white solid (16.2 mg, 58 % yield). 
1H-NMR (CDCl3, 400 MHz):  8.20 (d, J = 8.0 Hz, 1H), 7.50 (t, J = 8.0 Hz, 1H), 
7.41 (d, J = 8.0 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.30 (t, J = 8.0 Hz, 1H), 6.92 (d, J 
= 8.0 Hz, 1H), 6.88 (s, 1H), 6.80 (d, J = 8.0 Hz, 1H), 3.84 (s, 3H), 3.45 (dd, J = 8.0, 4.0 Hz, 1H), 2.71 (d, 
J = 8.0 Hz, 1H), 1.12 (s, 3H)  
13C- NMR (CDCl3, 100 MHz):  164.1, 159.9, 146.5, 136.3, 132.5, 129.7, 129.5, 128.2, 126.95, 126.89, 
119.0, 113.2, 111.2, 55.3, 40.8, 26.8, 24.9, 13.0 
IR (neat, cm-1) 2952, 1633, 1560, 1482, 1341, 1291, 1039, 773, 699 
















General procedure B, O-Boc arylhydroxamate (0.1 mmol, 23.7 mg) reacted with 
cyclopropene (0.11 mmol, 19.8 mg) gives the desired dihydroisoquinolone (>20:1 dr 
of the crude reaction mixture). The major diastereomer was obtained after 
purification by column chromatography using 1/3 to 2/1 EtOAc/hexane as an off-
white solid (23.3 mg, 78% yield). 
1H-NMR (CDCl3, 400 MHz):  8.23 (d, J = 8 Hz), 7.87-7.79 (m, 4H), 7.55-7.45 (m, 
5H), 7.39 (t, J = 8 Hz, 1H), 6.99 (brs, 1H), 3.61 (dd, J = 4, 8 Hz, 1H), 2.82 (d, J = 8 
Hz, 1H), 1.22 (s, 3H)  
13C- NMR (CDCl3, 100 MHz):  164.1, 142.1, 136.4, 133.4, 132.5, 132.1, 129.5, 128.6, 128.2, 127.6, 
127.0, 126.9, 126.4, 125.8, 125.38, 125.36, 40.5, 26.5, 25.4, 13.4  
IR (neat, cm-1) 3185, 3042, 2924, 1665, 1600, 777 
LRMS m/z (ESI+APCI) calcd for C21H17NO [M+H]: 300.1; Found: 300.2 
methyl (1R,1aR,7bR)-3-oxo-1-phenyl-1a,2,3,7b-tetrahydro-1H-cyclopropa[c]isoquinoline-1-
carboxylate  
General procedure B, O-Boc arylhydroxamate (0.1 mmol, 23.7 mg) reacted with 
cyclopropene (0.11 mmol, 19.2 mg) gives the desired dihydroisoquinolone (8:1 dr 
of the crude reaction mixture). The major diastereomer (>10:1 dr purity) was 
obtained after purification by column chromatography using 1/3 to 2/1 
EtOAc/hexane as an off-white solid (22.0 mg, 75% yield). 
1H-NMR (CDCl3, 400 MHz):  8.19 (d, J = 8 Hz, 1 Hz), 7.56-7.50 (m, 2H), 7.48-7.30 (m, 5H), 3.48 (dd, 
J = 8.0, 4.0 Hz), 3.36 (s, 3H), 3.11 (d, J = 8.0 Hz, 1H)  
13C- NMR (CDCl3, 100 MHz):  167.5, 163.8, 138.0, 134.2, 133.4, 132.5, 129.2, 129.1, 128.8, 127.9, 
127.7, 127.0, 52.2, 41.7, 35.6, 28.2 
IR (neat, cm-1) 3057, 2950, 1726, 1670, 1445, 909, 731 











General procedure B, O-Boc arylhydroxamate (0.1 mmol, 23.7 mg) reacted with 
cyclopropene (0.11 mmol, 17.2 mg) gives the desired dihydroisoquinolone (>20:1 dr of 
the crude reaction mixture). The major diastereomer was obtained after purification by 
column chromatography using 1/3 to 2/1 EtOAc/hexane as an off-white solid (19.8 mg, 
72% yield). 
1H-NMR (CDCl3, 400 MHz):  8.18 (d, J = 8.0 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.36 
(t, J = 8.0 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.24-7.12 (m, 3H), 6.79 (br. s, NH), 6.68 (d, J = 8.0 Hz), 
3.50 (dd, J = 8.0, 4.0 Hz), 2.83 (t, J  = 8.0 Hz, 2H), 2.78 (d, J = 8.0 Hz, 1H), 1.75-1.55 (m, 2H), 1.35-1.26 
(m, 2H) 
13C- NMR (CDCl3, 100 MHz):  164.0, 139.1, 137.9, 136.0, 132.5, 129.5, 129.0, 128.1, 127.04, 127.00, 
126.6, 125.3, 119.6, 43.7, 30.7, 30.2, 22.9, 21.6, 21.3 
IR (neat, cm-1) 2920, 1657, 1598, 1479, 1344, 751 
LRMS m/z (ESI+APCI) calcd for C19H17NO [M+H]: 275.1; Found: 276.1 
(1R,1aR,7bR)-1-benzyl-1-methyl-1,1a,2,7b-tetrahydro-3H-cyclopropa[c]isoquinolin-3-one  
General procedure B, O-Boc arylhydroxamate (0.1 mmol, 23.7 mg) reacted with 
cyclopropene 2j (0.11 mmol, 15.9 mg) gives the desired dihydroisoquinolone (2.3:1 dr 
of the crude reaction mixture). The mixture of product was obtained after purification 
by column chromatography using 1/3 to 2/1 EtOAc/hexane as an off-white solid (16.8 
mg, 64% yield). 
1H-NMR (CDCl3, 400 MHz): (See spectra) 
13C- NMR (CDCl3, 100 MHz): (See spectra) 
LRMS m/z (ESI+APCI) calcd for C18H17NO [M+H]: 264.1; Found: 264.1 
5. Mechanistic studies 
C-H activation reversibility 
 
 A 1-dram vial was charged with a stir bar, O-pivaloyl benzhydroxamate (0.1 mmol, 1 equiv., 22.1 
mg), [Ind*RhCl2]2 (0.001 mmol, 1 mol%, 0.7 mg) and CsOPiv (0.025 mmol, 0.25 equiv., 5.9 mg) were 








determined the deuterium incorporation by 1H-NMR spectroscopy using 1,3,5-trimethoxybenzene as an 
internal standard.  
Electronic preference of the reaction 
 
A 1-dram vial charged with a stir bar, O-pivaloyl benzhydroxamate (0.05 mmol, 0.5 equiv., 11.1 mg), O-
pivaloyl p-bromo benzhydroxamate (0.05 mmol, 0.5 equiv., 15.0 mg), [Ind*RhCl2]2 (0.001 mmol, 1 
mol%, 0.7 mg) and CsOPiv (0.025 mmol, 0.25 equiv., 5.9 mg) were weighed. The mixture was dissolved 
in CH3OH and stirred for 30 sec at 0C. Then, cyclopropene (0.1 mmol, 0.5 equiv., 5.9 mg) was added 
and stirred for 30 sec at 0C. The reaction was quenched using satd. NaHCO3 and extracted 3 times with 
EtOAc. The combined organic layers were washed with brine, dried over MgSO4, filtered and solvent was 
evaporated. The crude mixture was characterized by 1H-NMR spectroscopy using 1,3,5-
trimethoxybenzene as an internal standard. 
Kinetic isotope study 
D5-benzoic acid was prepared according to the reported procedure.87 Then, O-pivaloyl D5-
benzhydroxamate was prepared. 
O-pivaloyl D5-benzhydroxamate (0.1 mmol, 0.1 equiv., 22.6 mg), cyclopropene (0.11 mmol, 0.11 equiv., 
14.3 mg), [Ind*RhCl2]2 (0.001 mmol, 1 mol%, 0.7 mg) and CsOPiv (0.025 mmol, 0.25 equiv., 5.9 mg) 
were weighed in a dram vial. The reaction mixture was stirred at room temperature for 16 h. The major 
diastereomer was obtained after purification by column chromatography using 1/3 to 2/1 EtOAc/hexane 
as an off-white solid (82% yield, >20:1 dr). 
1H-NMR (CDCl3, 400 MHz):  7.37-7.31 (m, 4H), 7.23 (t, J = 8.0 Hz, 1H), 3.45 (dd, J = 8.0, 4.0 Hz, 
1H), 2.70 (d, J = 8.0 Hz), 1.11 (s, 3H) 
LRMS m/z (ESI+APCI) calcd for C17H11D4NO [M+H]: 254.1; Found: 254.1 
 
                                                          






Parallel experiment: Two 1-dram vials were charged with a stir bar, proteo- and deutero- benzamide 
substrate (0.1 mmol, 1 equiv), [Ind*RhCl2]2 (1 mol%) and CsOPiv (0.25 equiv) were weighed. The 
mixture was dissolved in CD3OD (0.1 M, 1 mL) and stirred for 30 sec at 0C. Then, cyclopropene (0.1 
mmol, 0.5 equiv., 5.9 mg) was added and stirred for 30 sec. The reaction was quenched using satd. 
NaHCO3 and extracted 3 times with EtOAc. The combined organic layers were washed with brine, dried 
over MgSO4, filtered and solvent was evaporated. The crude mixture was characterized by 1H-NMR 




Competition experiment: A 1-dram vial were charged with a stir bar, proteo- and deutero- benzamide 
substrate (0.05 mmol, 0.5 equiv), [Ind*RhCl2]2 (0.001 mmol, 1 mol%, 0.7 mg) and CsOPiv (0.025, 0.25 
equiv., 5.9 mg) were weighed. The mixture was dissolved in CD3OD (0.1 M, 1 mL) and stirred for 30 sec 
at 0C. Then, cyclopropene (0.1 mmol, 0.5 equiv., 5.9 mg) was added and stirred for 30 sec. The reaction 
was quenched using satd. NaHCO3 and extracted 3 times with EtOAc. The combined organic layers were 
washed with brine, dried over MgSO4, filtered and solvent was evaporated. The crude mixture was 






A diastereomeric mixture of dihydroisoquinolone 5ae (1:1 dr), substrate 1f’ (0.1 mmol, 1 equiv., 30.2 
mg), [ind*RhCl2]2 (0.001, 1 mol%, 0.8 mg) CsOPiv (0.025 mmol, 0.25 equiv., 5.9 mg) were weighed in a 
dram vial charged with a stir bar. MeOH (1mL, 0.1 M) was added and the mixture was stirred for 30 
seconds and cyclopropene 4e (0.11 mmol, 14.9 L, 1.1 equiv to 1e) was then added. The reaction was 
stirred at room temperature for 16 hours and the starting material 1f’ was monitored by TLC. The reaction 
was quenched using satd. NaHCO3 and extracted 3 times with EtOAc. The combined organic layers were 
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washed with brine, dried over MgSO4, filtered and the solvent was evaporated. The crude mixture was 
characterized by 1H-NMR spectroscopy using 1,3,5-trimethoxybenzene as an internal standard. 
 
6. Derivatizations of dihydroisoquinolone products 
 (1S,1aR,7bR)-3-chloro-1-methyl-1-phenyl-1a,7b-dihydro-1H-cyclopropa[c]isoquinoline 
 
To a flamed dried round-bottom flask equipped with a stir bar and reflux condenser, dihydroisoquinolone 
(0.39 mmol, 97 mg), dry benzene and POCl3 were added. The reaction mixture was refluxed for 6 h. After 
the completion, the reaction mixture was evaporated under reduced pressure at 60C and treated with 5% 
Et3N/Et2O at -30C. After stirring for 10 minutes, the crude was passed through alumina column 
chromatography using 1:1 Et2O/hexane as an eluent to give a crude imidoyl chloride as a white solid (85 
mg, 82% yield). 
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1H-NMR (CDCl3, 400 MHz):  7.99 (d, J = 8.0 Hz, 1H), 7.55-7.45 (m, 4H), 7.42-7.36 (m, 3H), 7.28 (t, J 
= 8.0 Hz, 1H), 4.08 (d, J = 8.0 Hz, 1H), 2.75 (d, J = 8.0 Hz, 1H), 0.93 (s, 3H)  
13C- NMR (CDCl3, 100 MHz):  151.9, 145.3, 136.2, 132.5, 129.2, 128.8, 127.9, 127.8, 127.0, 126.8, 
125.0, 50.7, 31.4, 22.2, 13.4 
IR (neat, cm-1) 3024, 1614, 1599, 1567, 1218 




To a flamed-dried round equipped with a stir bar, dihydroisoquinolone (0.5 mmol, 125 mg) in CH2Cl2 (5 
mL) was added. The reaction mixture was cooled at -0C. Then, Tf2O (0.77 mmol, 0.13 mL) and pyridine 
(0.765 mmol, 61 L) was slowly added to the reaction mixture which was then stirred at the same 
temperature for 10 mins. The reaction was diluted with CH2Cl2 and washed with satd. NaHCO3. The 
combined organic extracts were dried over MgSO4 and concentrated to give a crude product. The crude 
was purified by alumina column chromatography using EtOAc as an eluent to give the desired product as 
a purple solid (152 mg, 80% yield). 
1H-NMR (CDCl3, 400 MHz):  8.19 (d, J = 8.0 Hz, 1H), 7.66 (t, J = 8.0 Hz, 1H), 7.53 (t, J = 8 Hz, 3H), 
7.47-7.38 (m, 3H), 7.30 (t, J = 8.0 Hz, 1H), 4.05 (d, J = 8.0 Hz, 1H), 2.86 (d, J = 8.0 Hz, 1H), 1.23 (s, 
3H)  
13C- NMR (CDCl3, 100 MHz):  161.7, 143.4, 136.1, 134.8, 129.8, 129.7, 129.0, 128.0, 127.9, 127.5, 
125.4, 121.2 (q), 44.7, 29.2, 25.9, 15.5 
19F- NMR (CDCl3, 381 MHz): 72.3 
IR (neat, cm-1) 3061, 1078, 1603, 1492, 1466, 1291, 1093, 792, 720, 688 






7. X-ray Structure  
CCDC 1472771 
 
Table 1 Crystal data and structure refinement. 
Identification code Rovis227-1 
Empirical formula C18H17NO2 
Formula weight 279.32 
Temperature/K 99.77 
Crystal system monoclinic 












Crystal size/mm3 0.25 × 0.124 × 0.107 
Radiation MoKα (λ = 0.71073) 
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2Θ range for data collection/° 5.97 to 66.776 
Index ranges -13 ≤ h ≤ 12, -7 ≤ k ≤ 10, -36 ≤ l ≤ 36 
Reflections collected 30307 
Independent reflections 5464 [Rint = 0.0926, Rsigma = 0.0945] 
Data/restraints/parameters 5464/0/192 
Goodness-of-fit on F2 1.033 
Final R indexes [I>=2σ (I)] R1 = 0.0685, wR2 = 0.1558 
Final R indexes [all data] R1 = 0.1350, wR2 = 0.1811 
Largest diff. peak/hole / e Å-3 0.54/-0.29 
 
Table 2 Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement Parameters 
(Å2×103). Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ tensor. 
Atom x y z U(eq) 
O1 6707.2(13) 3443.8(17) 54.8(5) 18.0(3) 
O2 9731.6(14) -2398.8(19) 511.4(6) 23.2(3) 
N3 4408.4(16) 3146(2) 448.1(6) 15.5(3) 
C4 7791.1(18) -66(2) 452.3(7) 15.0(3) 
C5 6334.4(18) 637(2) 575.3(6) 13.0(3) 
C6 5347.7(18) -415(2) 898.4(6) 13.7(3) 
C7 3777.6(18) 313(2) 1014.8(6) 13.6(3) 
C8 3308.6(18) 2188(2) 768.8(7) 14.4(3) 
C9 5837.4(18) 2508(2) 341.3(7) 13.5(3) 
C10 8283.4(19) -1830(2) 653.3(7) 15.8(3) 
C11 3616.3(18) 2012(2) 1415.3(7) 14.6(3) 
C12 2168.9(18) 2069(2) 1732.1(7) 14.2(3) 
C13 7307.4(19) -2900(3) 968.6(7) 17.5(3) 
C14 5853.7(19) -2186(2) 1085.9(7) 16.7(3) 
C15 5107.6(19) 2856(3) 1709.6(7) 17.1(3) 
C16 765.3(19) 1151(3) 1531.6(7) 18.4(4) 
C17 2171(2) 3097(3) 2237.5(8) 19.7(4) 
C18 -578(2) 1240(3) 1825.7(8) 23.0(4) 
C19 -552(2) 2286(3) 2321.1(8) 24.0(4) 
C20 826(2) 3196(3) 2525.4(8) 23.1(4) 




Table 3 Anisotropic Displacement Parameters (Å2×103). The Anisotropic displacement factor exponent 
takes the form: -2π2[h2a*2U11+2hka*b*U12+…]. 
 
Atom U11 U22 U33 U23 U13 U12 
O1 18.0(6) 14.9(6) 21.8(6) 4.6(5) 5.8(5) 2.3(5) 
O2 19.8(6) 20.0(7) 31.6(7) 5.7(5) 10.4(5) 7.9(5) 
N3 17.4(6) 12.7(7) 16.8(7) 6.0(5) 4.3(5) 4.8(5) 
C4 14.7(7) 14.6(8) 16.0(7) -1.0(6) 2.9(6) 0.7(6) 
C5 15.9(7) 10.4(8) 12.8(7) 0.5(6) 1.5(6) 1.2(6) 
C6 15.9(7) 12.2(8) 13.1(7) -2.1(6) 2.0(6) 1.0(6) 
C7 14.0(7) 13.2(8) 13.8(7) 0.3(6) 2.4(6) 1.0(6) 
C8 14.7(7) 14.4(8) 14.3(7) 2.5(6) 3.5(5) 2.7(6) 
C9 16.1(7) 10.8(8) 13.6(7) -0.8(6) 1.8(6) 1.1(6) 
C10 14.7(7) 15.7(9) 17.2(8) -2.0(6) 2.8(6) 3.3(6) 
C11 16.3(7) 14.5(8) 13.3(7) 0.7(6) 2.9(6) 1.9(6) 
C12 16.9(7) 11.9(8) 14.1(7) 0.6(6) 2.7(6) 2.1(6) 
C13 19.9(8) 13.8(8) 19.1(8) 2.6(7) 3.0(6) 3.2(7) 
C14 19.1(7) 14.1(8) 17.5(8) 2.2(6) 5.0(6) 1.6(6) 
C15 17.1(7) 17.8(9) 16.5(8) -2.5(7) 2.9(6) -0.7(7) 
C16 18.0(8) 22.7(10) 14.7(8) -2.7(7) 1.9(6) 1.2(7) 
C17 19.7(8) 18.4(9) 21.5(8) -4.2(7) 4.5(6) -2.4(7) 
C18 16.5(8) 29.6(11) 23.1(9) -3.8(8) 2.4(7) -0.6(7) 
C19 20.8(8) 29.1(11) 23.4(9) -2.4(8) 8.5(7) 1.6(8) 
C20 26.5(9) 23.8(10) 20.4(9) -7.9(7) 8.9(7) -2.8(7) 
C21 24.9(9) 26.1(11) 45.0(12) 8.2(10) 12.8(8) 14.1(8) 
  
Table 4 Bond Lengths  
Atom Atom Length/Å   Atom Atom Length/Å 
O1 C9 1.2461(19)   C7 C11 1.553(2) 
O2 C10 1.3700(19)   C8 C11 1.532(2) 
O2 C21 1.430(2)   C10 C13 1.398(2) 
N3 C8 1.435(2)   C11 C12 1.505(2) 
N3 C9 1.345(2)   C11 C15 1.510(2) 
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C4 C5 1.394(2)   C12 C16 1.402(2) 
C4 C10 1.394(2)   C12 C17 1.403(2) 
C5 C6 1.407(2)   C13 C14 1.390(2) 
C5 C9 1.489(2)   C16 C18 1.397(2) 
C6 C7 1.484(2)   C17 C20 1.391(2) 
C6 C14 1.392(2)   C18 C19 1.388(3) 
C7 C8 1.497(2)   C19 C20 1.384(3) 
  
Table 5 Bond Angles  
Atom Atom Atom Angle/˚   Atom Atom Atom Angle/˚ 
C10 O2 C21 117.45(13)   O2 C10 C13 124.44(15) 
C9 N3 C8 125.98(14)   C4 C10 C13 120.07(14) 
C10 C4 C5 119.75(15)   C8 C11 C7 58.03(10) 
C4 C5 C6 120.82(15)   C12 C11 C7 116.89(14) 
C4 C5 C9 118.01(14)   C12 C11 C8 115.43(13) 
C6 C5 C9 121.15(14)   C12 C11 C15 116.76(14) 
C5 C6 C7 120.72(15)   C15 C11 C7 118.13(13) 
C14 C6 C5 118.35(14)   C15 C11 C8 118.68(14) 
C14 C6 C7 120.88(14)   C16 C12 C11 121.99(15) 
C6 C7 C8 116.74(13)   C16 C12 C17 117.46(15) 
C6 C7 C11 121.50(14)   C17 C12 C11 120.53(15) 
C8 C7 C11 60.29(11)   C14 C13 C10 119.60(16) 
N3 C8 C7 117.95(13)   C13 C14 C6 121.41(15) 
N3 C8 C11 120.84(14)   C18 C16 C12 121.38(16) 
C7 C8 C11 61.67(11)   C20 C17 C12 120.91(16) 
O1 C9 N3 121.19(15)   C19 C18 C16 120.08(17) 
O1 C9 C5 121.36(14)   C20 C19 C18 119.22(16) 
N3 C9 C5 117.45(14)   C19 C20 C17 120.94(17) 








Table 6 Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters (Å2×103) 
Atom x y z U(eq) 
H3 4122 4252 309 19 
H4 8446 653 232 18 
H7 2913 -640 1006 16 
H8 2172 2310 618 17 
H13 7635 -4109 1102 21 
H14 5192 -2922 1299 20 
H15A 5395 2196 2068 26 
H15B 4930 4186 1787 26 
H15C 5966 2735 1465 26 
H16 726 455 1189 22 
H17 3104 3734 2385 24 
H18 -1509 584 1687 28 
H19 -1470 2376 2518 29 
H20 854 3899 2867 28 
H21A 11371 -4387 609 47 
H21B 9603 -5160 604 47 
H21C 10420 -4100 1153 47 
Experimental 
Single crystals of C18H17NO2 were obtained by the vapor diffusion method using CH3Cl and pentane. A 
suitable crystal was selected and collected on a Bruker APEX-II CCD diffractometer. The crystal was 
kept at 99.77 K during data collection. Using Olex288, the structure was solved with the XS89 structure 
solution program using Direct Methods and refined with the XL90 refinement package using Least 
Squares minimisation. 
Crystal structure determination 
Crystal Data for C18H17NO2 (M =279.32 g/mol): monoclinic, space group P21/n (no. 14), a = 
8.5035(2) Å, b = 7.1303(2) Å, c = 23.6793(6) Å, β = 95.7420(12)°, V = 1428.53(6) Å3, Z = 4, T = 
99.77 K, μ(MoKα) = 0.085 mm-1, Dcalc = 1.299 g/cm3, 30307 reflections measured (5.97° ≤ 2Θ ≤ 
66.776°), 5464 unique (Rint = 0.0926, Rsigma = 0.0945) which were used in all calculations. The final R1 
                                                          
88 Dolomanov, O.V., Bourhis, L.J., Gildea, R.J, Howard, J.A.K. & Puschmann, H. J. Appl. Cryst. 2009, 42, 339 
89 Sheldrick, G.M. Acta Cryst. 2008, A64, 112 
90 Sheldrick, G.M. Acta Cryst. 2008, A64, 112 
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was 0.0685 (I > 2σ(I)) and wR2 was 0.1811 (all data). 
 





























































































































































































Development of Stereoselective [4.2.0] Dihydroisoquinolones Synthesis via Rh(III)-Catalyzed C-H 
Activation and [4+2] Annulation with Cyclobutenes 
 
1. General Methods 
 When necessary, organic solvents were dried and/or distilled prior to use under argon. Air and 
moisture sensitive reactions were carried out in oven or flame-dried glassware. Column chromatography 
was performed on Silicycle® SilicaFlash® P60 (230-400 mesh) silica gel. Thin layer chromatography 
was performed on Silicycle® 250μm silica gel 60A plates. Visualization was accomplished with UV light 
(254 nm) or potassium permanganate. 1H, 19F, and 13C NMR spectra were collected at ambient 
temperature in CDCl3 on a Varian 400 MHz or a Bruker 300 or 500 MHz spectrometers. Chemical shifts 
are reported as parts per million (δ, ppm) and are referenced to the residual solvent peaks of the 
deuterated solvents employed. Coupling constants (J) are reported in Hz. Coupling uses the following 
abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, and m = multiplet. Mass spectra were 
obtained on an Agilent Technologies 6130 Quadropole Mass Spec (LRMS) or ACQUITY Waters 
UPLC/mass spectrometer equipped with electrospray ionization. Infrared (IR) spectra were recorded with 
neat samples on a Bruker Tensor 27 FT-IR or Perkin Elmer Paragon 1000 FT-IR spectrometer. 
2. General procedures for Rh(III)-catalyzed reaction 
 Without any precaution of air and moisture, O-pivaloyl arylhydroxamic acid (0.1 mmol, 1 equiv), 
[Cp*RhCl2]2 (0.001 mmol, 1 mol%), CsOPiv (0.025 mmol, 0.25 equiv), cyclobutene (0.11 mmol, 1.1 
equiv), and MeOH (1 mL, 0.1 M) were charged into a dram vial with a stir bar. The reaction was stirred at 
room temperature until the starting material was consumed (monitoring by TLC). The reaction was 
quenched with saturated NaHCO3 and extracted 3 times with EtOAc. The organic layer was washed with 
brine, dried over MgSO4, filtered, and solvent was evaporated to obtain crude product. The crude product 
was purified by column chromatography using 25% to 75% EtOAc/hexane/1% Et3N to obtain the 
corresponding product. 
3. Preparations of Starting Materials 
O-pivaloyl arylhydroxamates91 were prepared by previously reported procedures. 
Cyclobutenes were prepared by previously reported procedures.  
 
                                                          
91 (a) Guimond, N,; Gorelsky, S. I.; Fagnou, K. J. Am. Chem. Soc. 2011, 133, 6449-6457. (b) Wang, H.; Glorius, F. 




4. Characterizations of New Compounds 
dimethyl (1S,2S,2aS,8bR)-4-oxo-1,2,2a,3,4,8b-hexahydrocyclobuta[c]isoquinoline-1,2-dicarboxylate 
Off-white solid (28.8 mg, 99% yield) 
1H NMR (400 MHz, CDCl3) δ 8.16 (d, J = 7.9 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 
7.37 (t, J = 7.6 Hz, 1H), 7.27 (d, J = 7.9 Hz, 1H), 6.72 (s, NH), 4.70 (ddd, J = 
9.3, 7.0, 4.1, 1H), 4.07 (dd, J = 9.2, 4.1 Hz, 1H), 3.76 (s, 3H), 3.70 (s, 3H), 3.56 
(ddt, J = 9.1, 6.8, 1.0 Hz, 1H), 3.44 – 3.33 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 172.35, 171.12, 163.62, 138.35, 133.16, 128.39, 
127.85, 127.69, 126.61, 52.43, 52.17, 49.31, 49.17, 47.12, 36.53. 
LRMS (ESI) m/z calcd for C15H15NO5 [M+H]+: 290.1, found: 290.1. 
dimethyl (1S,2S,2aS,8bR)-7-methoxy-4-oxo-1,2,2a,3,4,8b-hexahydrocyclobuta[c]isoquinoline-1,2-
dicarboxylate 
Off-white solid (29.3 mg, 92% yield) 
1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 8.8 Hz, 1H), 6.87 (dd, J = 8.8, 
2.5 Hz, 1H), 6.71 (d, J = 2.5 Hz, 1H), 6.55 (s, NH), 4.66 (dddt, J = 7.9, 
6.1, 4.1, 1.0 Hz, 1H), 4.10 – 3.98 (m, 1H), 3.84 (s, 3H), 3.75 (s, 3H), 3.69 
(s, 3H), 3.55 (ddd, J = 9.8, 6.9, 1.1 Hz, 1H), 3.39 (ddd, J = 9.8, 4.2, 1.0 
Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 172.33, 171.13, 163.62, 163.32, 140.45, 130.62, 119.45, 113.62, 112.30, 
55.50, 52.42, 52.15, 49.32, 49.23, 47.02, 36.86. 
LRMS (ESI) m/z calcd for C16H17NO6 [M+H]+: 320.1, found: 320.1. 
dimethyl (1S,2S,2aS,8bR)-7-chloro-4-oxo-1,2,2a,3,4,8b-hexahydrocyclobuta[c]isoquinoline-1,2-
dicarboxylate 
Off-white solid (29.3 mg, 92% yield) 
1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 8.4, Hz, 1H), 7.35 (d, J = 8.4 
Hz, 1H), 7.27 (s, 1H), 6.70 (s, NH), 4.68 (dddt, J = 8.9, 6.8, 4.1, 0.9 Hz, 
1H), 4.05 (ddd, J = 9.4, 4.4, 1.0 Hz, 1H), 3.77 (s, 3H), 3.70 (s, 3H), 3.55 
(ddd, J = 9.8, 6.8, 1.1 Hz, 1H), 3.41 (ddd, J = 9.8, 4.3, 1.1 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 216.93, 172.01, 170.88, 162.79, 162.77, 
140.02, 139.36, 130.15, 128.22, 127.78, 125.10, 52.54, 52.25, 49.34, 49.19, 46.88, 36.36. 






Off-white solide (36.8 mg, 90% yield) 
1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 8.4 Hz, 1H), 7.51 (d, J = 8.4 
Hz, 1H), 7.43 (s, 1H), 6.59 (s, NH), 4.69 (dddt, J = 9.1, 6.4, 4.1, 1.0 Hz, 
1H), 4.11 – 4.00 (m, 1H), 3.78 (s, 3H), 3.71 (s, 1H), 3.55 (ddd, J = 9.8, 6.9, 
1.1 Hz, 1H), 3.41 (ddd, J = 9.8, 4.2, 1.1 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 172.00, 170.85, 162.85, 140.15, 131.20, 
130.78, 130.23, 127.97, 125.51, 52.55, 52.26, 49.35, 49.19, 46.88, 36.27. 
LRMS (ESI) m/z calcd for C15H14BrNO5 [M+H]+: 368.0, 370.0, found: 368.0, 370.0. 
dimethyl (1S,2S,2aS,8bR)-4-oxo-7-(trifluoromethyl)-1,2,2a,3,4,8b-
hexahydrocyclobuta[c]isoquinoline-1,2-dicarboxylate 
 Off-white solid (32.0 mg, 90% yield) 
1H NMR (400 MHz, CDCl3) δ 8.30 (d, J = 8.1, 1H), 7.64 (d, J = 8.2 Hz, 
1H), 7.54 – 7.50 (s, 1H), 6.90 (d, J = 4.0 Hz, NH), 4.73 (dddd, J = 9.2, 
6.8, 4.0, 1.1 Hz, 1H), 4.14 (dd, J = 9.2, 4.4 Hz, 1H), 3.79 (s, 3H), 3.72 (s, 
3H), 3.56 (ddd, J = 9.8, 6.7, 1.1 Hz, 1H), 3.44 (ddd, J = 9.8, 4.4, 1.0 Hz, 
1H). 
13C NMR (101 MHz, CDCl3) δ 171.89, 170.79, 162.29, 139.06, 134.59 (q), 129.62, 129.24, 124.96 (m), 
124.52 (m), 123.38 (q), 52.58, 52.30, 49.42, 49.04, 46.91, 36.32. 
19F NMR (376 MHz, CDCl3) δ -63.18. 
LRMS (ESI) m/z calcd for C16H14F3NO5 [M+H]+: 358.1, found: 358.1. 
dimethyl (1S,2S,2aS,8bR)-5-methyl-4-oxo-1,2,2a,3,4,8b-hexahydrocyclobuta[c]isoquinoline-1,2-
dicarboxylate 
1H NMR (400 MHz, CDCl3) δ 7.37 (t, J = 7.6 Hz, 1H), 7.17 (d, J = 7.5 Hz, 1H), 
7.13 (d, J = 7.6 Hz, 1H), 6.18 (s, NH), 4.64 – 4.51 (m, 1H), 4.08 (dd, J = 9.2, 
4.5 Hz, 1H), 3.76 (s, 3H), 3.71 (s, 3H), 3.52 (ddd, J = 9.6, 6.4, 1.1 Hz, 1H), 3.39 
(ddd, J = 9.7, 4.5, 1.0 Hz, 1H), 2.74 (s, 3H). 
13C NMR (101 MHz, cdcl3) δ 172.39, 171.20, 164.72, 142.17, 139.81, 132.28, 
131.80, 126.19, 124.56, 52.37, 52.15, 49.07, 48.86, 47.41, 37.24, 23.59. 













Off-white solid (30.5 mg, 99% yield) 
1H NMR (400 MHz, CDCl3) δ 7.98 (s, 1H), 7.33 (d, J = 9.7 Hz, 1H), 7.16 
(d, J = 8.0 Hz, 1H), 6.56 (s, NH), 4.74 – 4.60 (m, 1H), 4.02 (dd, J = 9.4, 
3.9 Hz, 1H), 3.76 (s, 3H), 3.69 (s, 3H), 3.54 (ddd, J = 9.8, 7.1, 1.2 Hz, 1H), 
3.36 (ddd, J = 9.7, 3.9, 1.1 Hz, 1H), 2.38 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 172.44, 171.17, 163.81, 137.61, 135.38, 
134.02, 128.63, 127.80, 126.35, 52.40, 52.14, 49.26, 49.21, 47.18, 36.37, 21.08.  
LRMS (ESI) m/z calcd for C16H17NO5 [M+H]+: 304.1, found: 304.1. 
dimethyl (1S,2S,2aS,8bR)-4-oxo-6-(trifluoromethyl)-1,2,2a,3,4,8b-
hexahydrocyclobuta[c]isoquinoline-1,2-dicarboxylate 
Off-white solid (31 mg, 87% yield) 
1H NMR (400 MHz, CDCl3) δ 8.46 (s, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.44 
(d, J = 8.1 Hz, 1H), 6.87 (s, NH), 4.72 (dddd, J = 9.2, 6.7, 4.0, 1.1 Hz, 
1H), 4.20 – 4.10 (m, 1H), 3.78 (s, 3H), 3.72 (s, 3H), 3.56 (ddd, J = 9.8, 
6.6, 1.1 Hz, 1H), 3.43 (ddd, J = 9.8, 4.5, 1.1 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 171.88, 170.79, 162.26, 141.96, 130.37 
(q, J = 33.3 Hz), 129.52 (q, J = 3.6 Hz), 128.67, 127.30, 125.70 (q, J = 4.0 Hz), 123.54 (q, J = 272.2 Hz), 
52.57, 52.31, 49.44, 49.06, 46.89, 36.33. 
19F NMR (376 MHz, CDCl3) δ -62.90. 
LRMS (ESI) m/z calcd for C16H14F3NO5 
[M+H]+: 358.1, found: 358.1 
Off-white solid (18.8 mg, 59% yield) ca. 
1.5:1 regioisomeric ratio 
1H NMR (400 MHz, CDCl3) see 1H NMR 
spectra 
13C NMR (101 MHz, CDCl3) δ 172.99, 172.45, 171.20, 171.18, 163.55, 163.49, 159.07, 156.56, 130.41, 
129.16, 128.35, 127.70, 127.66, 126.64, 121.20, 120.18, 114.05, 111.03, 55.69, 55.60, 52.40, 52.32, 
52.15, 52.07, 49.23, 49.21, 48.86, 47.21, 45.79, 36.18, 33.55. 







Off-white solid (34.5 mg, 91% yield) 
1H NMR (400 MHz, CDCl3) δ 7.48 (s, 1H), 6.42 (s, NH), 4.76 (dddt, J = 
9.1, 8.3, 4.6, 0.9 Hz, 1H), 3.99 – 3.85 (m, 10H), 3.77 (s, 3H), 3.67 (s, 
3H), 3.55 (ddd, J = 9.6, 8.3, 1.2 Hz, 1H), 3.26 (ddd, J = 10.1, 3.0, 1.0 Hz, 
1H). 
13C NMR (101 MHz, CDCl3) δ 172.88, 171.21, 163.24, 153.25, 150.50, 
145.66, 124.79, 122.09, 106.28, 60.82, 60.61, 56.15, 52.36, 52.06, 49.04, 48.96, 46.46, 33.59. 
LRMS (ESI) m/z calcd for C18H21NO8 [M+H]+: 380.1, found: 380.2 
dimethyl (5aS,6S,7S,7aS)-4-oxo-4,5,5a,6,7,7a-hexahydrocyclobuta[b]furo[2,3-d]pyridine-6,7-
dicarboxylate 
Off-white solid (22.0 mg, 79% yield) 
1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 2.0 Hz, 1H), 6.76 (d, J = 2.0 Hz, 1H), 
6.12 (s, NH), 4.87 (dddd, J = 9.6, 8.9, 4.8, 1.1 Hz, 1H), 4.04 – 3.95 (m, 1H), 3.76 
(s, 3H), 3.69 (m, 4H), 3.46 (ddd, J = 9.9, 2.3, 1.0 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 171.91, 170.73, 162.88, 156.74, 144.11, 115.51, 
108.03, 52.61, 52.20, 50.56, 49.34, 43.10, 34.80. 
LRMS (ESI) m/z calcd for C13H13NO6 [M+H]+: 280.1, found: 280.1. 
dimethyl (5aS,6S,7S,7aR)-2-bromo-4-oxo-4,5,5a,6,7,7a-hexahydrocyclobuta[b]furo[3,2-d]pyridine-
6,7-dicarboxylate 
Off-white solid (16.3 mg, 45% yield) 
1H NMR (400 MHz, CDCl3) δ 6.42 (s, 1H), 6.05 (s, NH), 4.78 (tdd, J = 8.9, 
4.8, 1.1 Hz, 1H), 3.89 (ddd, J = 9.1, 2.6, 1.3 Hz, 1H), 3.82 – 3.73 (m, 4H), 
3.70 (s, 3H), 3.32 (ddd, J = 9.9, 2.6, 1.1 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 172.00, 170.73, 155.69, 143.36, 131.58, 
129.69, 111.95, 52.60, 52.25, 51.09, 49.03, 45.13, 34.62. 










Off-white solid (25.6 mg, 87% yield) 
1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 5.0 Hz, 1H), 6.98 (d, J = 5.1 Hz, 
1H), 6.38 (s, NH), 4.82 (dddd, J = 9.3, 8.3, 4.5, 1.0 Hz, 1H), 3.97 (ddd, J = 9.3, 
2.8, 1.2 Hz, 1H), 3.76 (s, 3H), 3.73 – 3.65 (m, 4H), 3.32 (ddd, J = 9.9, 2.9, 1.0 
Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 172.30, 171.01, 160.67, 143.59, 132.97, 130.95, 
126.74, 52.50, 52.15, 51.09, 49.09, 45.84, 36.12. 
LRMS (ESI) m/z calcd for C13H13NO5S [M+H]+: 296.1 found: 296.1. 






15ea     
Computing details: Program(s) used to refine structure: SHELXL2014/7 (Sheldrick, 2014); molecular 
graphics: Olex2 (Dolomanov et al., 2009); software used to prepare material for publication: Olex2 
(Dolomanov et al., 2009). 
Crystal data 
 C16H14F3NO5 V = 1539.33 (7)  Å3 
Mr = 357.28 Z = 4 
Monoclinic, P21/c F(000) = 736 
a = 13.9171 (4) Å Dx = 1.542 Mg m-3 
b = 8.4431 (2) Å Mo Ka radiation, l = 0.71073 Å 
c = 13.1482 (4) Å m = 0.14 mm-1 
b = 94.892 (3)° T = 140 K 
Data collection 
 10791 measured reflections qmax = 26.4°, qmin = 3.3° 
3139 independent reflections h = -17ฎ15 
2717 reflections with I > 2s(I) k = -10ฎ10 
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Rint = 0.029 l = -16ฎ16 
Refinement 
 Refinement on F2 58 restraints 
Least-squares matrix: full Hydrogen site location: mixed 
R[F2 > 2s(F2)] = 0.044 H atoms treated by a mixture of 
independent and constrained refinement 
wR(F2) = 0.103  w = 1/[s2(Fo2) + (0.0376P)2 + 0.9964P]  
where P = (Fo2 + 2Fc2)/3 
S = 1.01 (D/s)max = 0.004 
3139 reflections Dρmax = 0.24 e Å-3 
263 parameters Dρmin = -0.34 e Å-3 
Special details  
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes)  are estimated using the 
full covariance matrix.  The cell esds are taken  into account individually in the estimation of esds in 
distances, angles  and torsion angles; correlations between esds in cell parameters are only  used when 
they are defined by crystal symmetry.  An approximate (isotropic)  treatment of cell esds is used for 
estimating esds involving l.s. planes. 
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2)  
 x y z Uiso*/Ueq Occ. (<1) 
N1 0.07832 (10) 0.84066 (17) 0.45335 (10) 0.0232 (3)  
H1 0.0543 (15) 0.938 (3) 0.4379 (15) 0.037 (6)*  
C2 0.04648 (11) 0.77335 (19) 0.53671 (12) 0.0214 (3)  
O3 -0.01448 (9) 0.83843 (14) 0.58590 (9) 0.0295 (3)  
C4 0.08745 (11) 0.61582 (19) 0.56979 (12) 0.0201 (3)  
C5 0.04998 (12) 0.53810 (19) 0.65090 (12) 0.0225 (3)  
H5 -0.0030 0.5829 0.6818 0.027*  
C6 0.08915 (12) 0.3958 (2) 0.68711 (12) 0.0238 (4)  
H6 0.0647 0.3446 0.7439 0.029*  
C7 0.16490 (12) 0.32893 (19) 0.63898 (13) 0.0240 (4)  
C8 0.20716 (14) 0.1751 (2) 0.67837 (14) 0.0321 (4)  
F9 0.14043 (12) 0.06734 (18) 0.69384 (19) 0.0584 (6) 0.876 (4) 
F10 0.2574 (2) 0.1918 (2) 0.76757 (17) 0.0881 (10) 0.876 (4) 
F11 0.26380 (17) 0.1061 (2) 0.61550 (16) 0.0681 (8) 0.876 (4) 
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F9B 0.1743 (10) 0.1237 (17) 0.7567 (10) 0.059 (4) 0.124 (4) 
F10B 0.3012 (6) 0.1870 (13) 0.6930 (11) 0.049 (3) 0.124 (4) 
F11B 0.1955 (13) 0.0674 (14) 0.6095 (11) 0.073 (4) 0.124 (4) 
C12 0.20147 (12) 0.40372 (19) 0.55634 (12) 0.0230 (4)  
H12 0.2519 0.3555 0.5230 0.028*  
C13 0.16424 (11) 0.54922 (19) 0.52237 (12) 0.0197 (3)  
C14 0.20753 (11) 0.64058 (19) 0.44055 (12) 0.0198 (3)  
H14 0.2318 0.5670 0.3889 0.024*  
C15 0.14648 (11) 0.77373 (19) 0.38716 (12) 0.0210 (3)  
H15 0.1174 0.7456 0.3173 0.025*  
C16 0.23835 (12) 0.87736 (19) 0.38790 (12) 0.0211 (3)  
H16 0.2289 0.9890 0.4104 0.025*  
C17 0.28992 (12) 0.86320 (19) 0.29211 (12) 0.0225 (3)  
O18 0.26835 (9) 0.77748 (15) 0.22116 (9) 0.0311 (3)  
O19 0.36832 (9) 0.95671 (15) 0.29989 (9) 0.0321 (3)  
C20 0.43194 (15) 0.9444 (3) 0.21848 (15) 0.0433 (5)  
H20A 0.4483 0.8330 0.2083 0.065*  
H20B 0.4910 1.0048 0.2368 0.065*  
H20C 0.3995 0.9871 0.1553 0.065*  
C21 0.28569 (11) 0.76587 (18) 0.47463 (12) 0.0198 (3)  
H21 0.2760 0.8086 0.5439 0.024*  
C22 0.38933 (12) 0.71896 (19) 0.46671 (12) 0.0216 (3)  
O23 0.41443 (9) 0.61002 (15) 0.41611 (10) 0.0315 (3)  
O24 0.45003 (8) 0.81568 (14) 0.52093 (9) 0.0274 (3)  
C25 0.55146 (12) 0.7847 (2) 0.51169 (16) 0.0362 (5)  
H25A 0.5670 0.6766 0.5346 0.054*  
H25B 0.5906 0.8602 0.5540 0.054*  
H25C 0.5652 0.7965 0.4402 0.054*  
Atomic displacement parameters (Å2)  
 U11 U22 U33 U12 U13 U23 
N1 0.0229 (7) 0.0234 (7) 0.0238 (7) 0.0065 (6) 0.0053 (6) 0.0039 (6) 
C2 0.0191 (8) 0.0243 (8) 0.0209 (8) 0.0001 (7) 0.0027 (6) -0.0010 (6) 
O3 0.0304 (7) 0.0282 (6) 0.0318 (6) 0.0077 (5) 0.0140 (5) 0.0033 (5) 
C4 0.0202 (8) 0.0209 (8) 0.0192 (7) -0.0022 (6) 0.0012 (6) -0.0021 (6) 
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C5 0.0216 (8) 0.0239 (8) 0.0227 (8) -0.0024 (7) 0.0055 (7) -0.0038 (7) 
C6 0.0262 (8) 0.0239 (8) 0.0219 (8) -0.0056 (7) 0.0056 (7) 0.0012 (7) 
C7 0.0250 (8) 0.0210 (8) 0.0262 (8) -0.0025 (7) 0.0026 (7) 0.0011 (7) 
C8 0.0344 (10) 0.0272 (9) 0.0363 (10) 0.0020 (8) 0.0113 (8) 0.0068 (8) 
F9 0.0483 (10) 0.0251 (8) 0.1048 (17) 0.0000 (7) 0.0247 (10) 0.0228 (9) 
F10 0.134 (2) 0.0387 (9) 0.0795 (15) 0.0130 (11) -0.0630 (16) 0.0088 (9) 
F11 0.0830 (16) 0.0425 (10) 0.0877 (14) 0.0354 (10) 0.0585 (13) 0.0312 (10) 
F9B 0.066 (8) 0.056 (8) 0.059 (6) 0.022 (6) 0.033 (6) 0.032 (6) 
F10B 0.036 (4) 0.039 (6) 0.071 (8) 0.012 (3) 0.007 (4) 0.037 (5) 
F11B 0.095 (9) 0.041 (6) 0.082 (6) 0.021 (6) -0.001 (6) -0.015 (5) 
C12 0.0226 (8) 0.0214 (8) 0.0258 (8) 0.0005 (7) 0.0067 (7) -0.0009 (7) 
C13 0.0200 (8) 0.0205 (8) 0.0189 (7) -0.0024 (6) 0.0024 (6) -0.0011 (6) 
C14 0.0209 (8) 0.0203 (8) 0.0186 (7) 0.0016 (6) 0.0043 (6) -0.0010 (6) 
C15 0.0225 (8) 0.0240 (8) 0.0170 (7) 0.0015 (7) 0.0037 (6) 0.0010 (6) 
C16 0.0245 (8) 0.0202 (8) 0.0188 (8) 0.0024 (7) 0.0042 (6) 0.0018 (6) 
C17 0.0251 (8) 0.0230 (8) 0.0196 (8) 0.0034 (7) 0.0033 (7) 0.0045 (7) 
O18 0.0338 (7) 0.0386 (7) 0.0211 (6) -0.0004 (6) 0.0042 (5) -0.0035 (5) 
O19 0.0342 (7) 0.0364 (7) 0.0276 (6) -0.0089 (6) 0.0127 (6) -0.0005 (5) 
C20 0.0405 (11) 0.0587 (14) 0.0335 (10) -0.0104 (10) 0.0199 (9) 0.0017 (10) 
C21 0.0236 (8) 0.0197 (8) 0.0163 (7) 0.0008 (6) 0.0035 (6) 0.0008 (6) 
C22 0.0241 (8) 0.0218 (8) 0.0190 (7) -0.0005 (7) 0.0028 (6) 0.0035 (6) 
O23 0.0259 (6) 0.0319 (7) 0.0370 (7) 0.0037 (5) 0.0055 (5) -0.0106 (6) 
O24 0.0213 (6) 0.0260 (6) 0.0350 (7) -0.0013 (5) 0.0020 (5) -0.0041 (5) 
C25 0.0194 (8) 0.0346 (10) 0.0545 (12) -0.0011 (8) 0.0020 (8) -0.0052 (9) 
Geometric parameters (Å, º)  
N1—H1 0.90 (2) C14—H14 1.0000 
N1—C2 1.343 (2) C14—C15 1.542 (2) 
N1—C15 1.455 (2) C14—C21 1.556 (2) 
C2—O3 1.2383 (19) C15—H15 1.0000 
C2—C4 1.497 (2) C15—C16 1.549 (2) 
C4—C5 1.391 (2) C16—H16 1.0000 
C4—C13 1.400 (2) C16—C17 1.507 (2) 
C5—H5 0.9500 C16—C21 1.579 (2) 
C5—C6 1.387 (2) C17—O18 1.199 (2) 
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C6—H6 0.9500 C17—O19 1.344 (2) 
C6—C7 1.395 (2) O19—C20 1.450 (2) 
C7—C8 1.500 (2) C20—H20A 0.9800 
C7—C12 1.390 (2) C20—H20B 0.9800 
C8—F9 1.328 (2) C20—H20C 0.9800 
C8—F10 1.321 (3) C21—H21 1.0000 
C8—F11 1.325 (2) C21—C22 1.508 (2) 
C8—F9B 1.241 (9) C22—O23 1.204 (2) 
C8—F10B 1.311 (9) C22—O24 1.336 (2) 
C8—F11B 1.283 (11) O24—C25 1.451 (2) 
C12—H12 0.9500 C25—H25A 0.9800 
C12—C13 1.392 (2) C25—H25B 0.9800 
C13—C14 1.492 (2) C25—H25C 0.9800 
    
C2—N1—H1 115.3 (13) C15—C14—C21 88.85 (12) 
C2—N1—C15 126.95 (14) C21—C14—H14 110.4 
C15—N1—H1 117.8 (13) N1—C15—C14 111.90 (12) 
N1—C2—C4 117.97 (14) N1—C15—H15 114.1 
O3—C2—N1 121.80 (15) N1—C15—C16 110.90 (13) 
O3—C2—C4 120.23 (14) C14—C15—H15 114.1 
C5—C4—C2 118.91 (14) C14—C15—C16 89.23 (12) 
C5—C4—C13 120.15 (15) C16—C15—H15 114.1 
C13—C4—C2 120.91 (14) C15—C16—H16 113.9 
C4—C5—H5 119.7 C15—C16—C21 87.77 (11) 
C6—C5—C4 120.65 (15) C17—C16—C15 113.70 (13) 
C6—C5—H5 119.7 C17—C16—H16 113.9 
C5—C6—H6 120.5 C17—C16—C21 110.93 (13) 
C5—C6—C7 119.04 (15) C21—C16—H16 113.9 
C7—C6—H6 120.5 O18—C17—C16 126.37 (15) 
C6—C7—C8 118.91 (15) O18—C17—O19 124.19 (15) 
C12—C7—C6 120.80 (15) O19—C17—C16 109.36 (14) 
C12—C7—C8 120.29 (15) C17—O19—C20 116.41 (14) 
F9—C8—C7 112.79 (16) O19—C20—H20A 109.5 
F10—C8—C7 112.12 (16) O19—C20—H20B 109.5 
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F10—C8—F9 105.14 (19) O19—C20—H20C 109.5 
F10—C8—F11 107.6 (2) H20A—C20—H20B 109.5 
F11—C8—C7 113.70 (15) H20A—C20—H20C 109.5 
F11—C8—F9 104.79 (18) H20B—C20—H20C 109.5 
F9B—C8—C7 115.4 (5) C14—C21—C16 87.65 (11) 
F9B—C8—F10B 109.8 (8) C14—C21—H21 111.2 
F9B—C8—F11B 107.7 (10) C16—C21—H21 111.2 
F10B—C8—C7 110.0 (4) C22—C21—C14 116.81 (13) 
F11B—C8—C7 110.4 (6) C22—C21—C16 116.71 (12) 
F11B—C8—F10B 102.8 (9) C22—C21—H21 111.2 
C7—C12—H12 120.0 O23—C22—C21 124.26 (15) 
C7—C12—C13 120.04 (15) O23—C22—O24 124.16 (15) 
C13—C12—H12 120.0 O24—C22—C21 111.56 (13) 
C4—C13—C14 118.94 (14) C22—O24—C25 114.86 (13) 
C12—C13—C4 119.27 (14) O24—C25—H25A 109.5 
C12—C13—C14 121.70 (14) O24—C25—H25B 109.5 
C13—C14—H14 110.4 O24—C25—H25C 109.5 
C13—C14—C15 117.68 (13) H25A—C25—H25B 109.5 
C13—C14—C21 117.35 (13) H25A—C25—H25C 109.5 
C15—C14—H14 110.4 H25B—C25—H25C 109.5 
    
N1—C2—C4—C5 -174.88 (15) C12—C7—C8—F11B -62.6 (10) 
N1—C2—C4—C13 7.1 (2) C12—C13—C14—C15 163.16 (15) 
N1—C15—C16—C17 -153.98 (13) C12—C13—C14—C21 -92.61 (19) 
N1—C15—C16—C21 94.09 (13) C13—C4—C5—C6 1.3 (2) 
C2—N1—C15—C14 -20.0 (2) C13—C14—C15—N1 27.7 (2) 
C2—N1—C15—C16 -117.89 (17) C13—C14—C15—C16 139.96 (14) 
C2—C4—C5—C6 -176.77 (15) C13—C14—C21—C16 -139.88 (14) 
C2—C4—C13—C12 178.95 (14) C13—C14—C21—C22 101.22 (16) 
C2—C4—C13—C14 2.3 (2) C14—C15—C16—C17 92.81 (14) 
O3—C2—C4—C5 5.5 (2) C14—C15—C16—C21 -19.12 (11) 
O3—C2—C4—C13 -172.51 (15) C14—C21—C22—O23 17.4 (2) 
C4—C5—C6—C7 -2.0 (2) C14—C21—C22—O24 -164.05 (13) 
C4—C13—C14—C15 -20.3 (2) C15—N1—C2—O3 -177.39 (16) 
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C4—C13—C14—C21 83.94 (19) C15—N1—C2—C4 3.0 (2) 
C5—C4—C13—C12 1.0 (2) C15—C14—C21—C16 -19.03 (11) 
C5—C4—C13—C14 -175.68 (14) C15—C14—C21—C22 -137.93 (13) 
C5—C6—C7—C8 179.95 (16) C15—C16—C17—O18 -3.1 (2) 
C5—C6—C7—C12 0.5 (2) C15—C16—C17—O19 -179.91 (13) 
C6—C7—C8—F9 47.5 (3) C15—C16—C21—C14 18.96 (11) 
C6—C7—C8—F10 -70.9 (3) C15—C16—C21—C22 137.94 (14) 
C6—C7—C8—F11 166.7 (2) C16—C17—O19—C20 173.68 (15) 
C6—C7—C8—F9B -4.5 (10) C16—C21—C22—O23 -84.3 (2) 
C6—C7—C8—F10B -129.3 (7) C16—C21—C22—O24 94.26 (16) 
C6—C7—C8—F11B 117.9 (10) C17—C16—C21—C14 -95.61 (14) 
C6—C7—C12—C13 1.7 (2) C17—C16—C21—C22 23.38 (19) 
C7—C12—C13—C4 -2.4 (2) O18—C17—O19—C20 -3.2 (2) 
C7—C12—C13—C14 174.10 (15) C21—C14—C15—N1 -92.88 (14) 
C8—C7—C12—C13 -177.73 (16) C21—C14—C15—C16 19.40 (11) 
C12—C7—C8—F9 -133.0 (2) C21—C16—C17—O18 93.9 (2) 
C12—C7—C8—F10 108.5 (2) C21—C16—C17—O19 -82.88 (16) 
C12—C7—C8—F11 -13.9 (3) C21—C22—O24—C25 -176.05 (14) 
C12—C7—C8—F9B 175.0 (10) O23—C22—O24—C25 2.5 (2) 
C12—C7—C8—F10B 50.1 (8)   
Hydrogen-bond geometry (Å, º)  
 D—H···A D—H H···A D···A D—H···A 
N1—H1···O3i 0.90 (2) 1.98 (2) 2.8842 (18) 173.4 (19) 
Symmetry code:  (i) -x, -y+2, -z+1. 
Document origin: publCIF [Westrip, S. P. (2010). J. Apply. Cryst., 43, 920-925. 
 





















































































Rh(III)-Catalyzed Coupling of N-Pivaloyloxy Acrylamides with Alkenes via C-H Activation:  
Direct Modular Assembly of Piperidones 
 
1. General methods 
 Unless otherwise noted, reactions were performed in flame-dried or oven-dried glassware and 
carried out under an atmosphere of nitrogen with magnetic stirring. Dichloromethane (DCM) were 
degassed with argon and passed through two columns of neutral alumina. Flash column chromatography 
was performed on SiliCycle Inc.® silica gel 60 (230-400 mesh). Thin Layer chromatography was 
performed on SiliCycle Inc.® 0.25 mm silica gel 60-F plates. Visualization was accomplished with UV 
light (254 nm) or KMnO4 staining. 
 1H-NMR and 13C-NMR spectra were recorded on Bruker 300, 400 or 500 MHz spectrometers at 
ambient temperature. 1H-NMR data are reported as the following: chemical shift in parts per million (δ, 
ppm) from chloroform (CDCl3) taken as 7.26 ppm, integration, multiplicity (s=singlet, d=doublet, 
t=triplet, q=quartet, m=multiplet, dd=doublet of doublets) and coupling constant (J in Hz unit). 13C-NMR 
is reported as the following: chemical shifts are reported in ppm from CDCl3 taken as 77.0 ppm. Low-
resolution mass spectra (LSMS) were obtained on ACQUITY Waters UPLC/mass spectrometer equipped 
with electrospray ionization. Infrared spectra (IR) were recored on a Perkin Elmer Paragon 1000 FT-IR 
spectrometer.  
2. Preparation of starting materials 
 2-substituted acrylic acids92 (for 9a and 9b), partial esterification of itaconic acid93 (for 9d), 2-aryl 
acrylic acids94 (9e-9j) and 2-ethoxy acrylic acid95 for (9k) were prepared according to the procedure. All 
alkenes in this study were purchased from commercial sources and used without further purification. 
N-pivaloyloxy -substituted acrylamides 
 
                                                          
92 Lai, Y; Sun, L; Sit, M. K.; Wang, Y.; Dai, W.-M. Tetrahedron 2016, 72, 664-673. 
93 Gowda, R. R.; Chen, E. Y.-X. Org. Chem. Front., 2014, 1, 230-234. 
94 Felpin, F. X.; Miqueu, K.; Sotiropoulos, J. M.; Fouquet, E.; Ibarguren, O.; Laudien, J. Chem. Eur. J. 2010, 16, 
5191-5204. 




 i. To a solution of 2-substituted acrylic acid (1 equiv) in dry CH2Cl2 (0.17 M) at 0C (ice bath) 
under N2 was added dropwise oxalyl chloride (1.1 equiv) and a few drops of DMF. The reaction was then 
stirred at 0 C to room temperature (typically 2-3 h). The volatile was removed under reduced pressure to 
give a crude acid chloride.  
 ii. To the solution of NH2OPivTfOH (1.1 equiv), K2CO3 (2.0 equiv) and EtOAc/H2O (2/1 by v/v, 
0.1M) at 0 C (ice bath), the crude acid chloride was added dropwise (while a small amount of EtOAc can 
be used as a solvent). The mixture was stirred at the same temperature for 1 h (prolong the reaction time 
led to the decomposition of the N-pivaloyloxy acrylamide). Upon the completion (monitored by TLC), a 
saturated NaHCO3 was added. The aqueous layer was extracted with EtOAc (3), washed with brine, 
dried with MgSO4, filtered. The solvent was removed under reduced pressure to give a crude N-
(pivaloyloxy) -substituted acrylamide, which was purified by a flash column chromatography (5% to 
25% EtOAc/hexane).  
2-benzyl-N-(pivaloyloxy)acrylamide  
1H NMR (500 MHz, CDCl3) δ 8.97 (s, NH), 7.35 (t, J = 7.4 Hz, 2H), 7.26 (m, 2H), 
5.96 (s, 1H), 5.39 (t, J = 1.3 Hz, 1H), 3.69 (s, 2H), 1.33 (s, 9H). 
 13C NMR (126 MHz, CDCl3) δ 176.73, 166.93, 141.07, 137.47, 129.00, 128.75, 
126.82, 122.52, 38.39, 38.10, 26.99. 
IR (neat, cm-1) 3217, 2981, 1780, 1668, 1080. 
LRMS (ESI) m/z calcd for C15H19NO3 [M+H]+: 262.1, found: 262.2. 
2-(4-bromobenzyl)-N-(pivaloyloxy)acrylamide  
1H NMR (500 MHz, CDCl3) δ 9.03 (s, NH), 7.45 (d, J = 8.4 Hz, 2H), 7.11 
(d, J = 8.4 Hz, 2H), 5.91 (s, 1H), 5.39 (t, J = 1.4 Hz, 1H), 3.63 (s, 2H), 
1.33 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 176.77, 166.75, 140.84, 136.60, 131.78, 
130.74, 122.28, 120.69, 38.39, 37.57, 26.98. 
IR (neat, cm-1) 3221, 29675, 1779, 1668, 1624, 1487, 1073, 1032, 1012. 
LRMS (ESI) m/z calcd for C15H18BrNO3 [M+H]+: 340.1, 342.1, found: 340.0, 342.0. 
N-(pivaloyloxy)methacrylamide  
1H NMR (500 MHz, CDCl3) δ 9.22 (s, NH), 5.84 (s, 1H), 5.50 – 5.47 (m, 1H), 1.99 
(t, J = 1.3 Hz, 3H), 1.34 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 176.90, 167.26, 136.91, 121.97, 38.39, 26.98, 18.29 
IR (neat, cm-1) 3225, 2977, 1782, 1671, 1629, 1481, 1055, 1033, 1015. 





methyl 3-((pivaloyloxy)carbamoyl)but-3-enoate  
1H NMR (500 MHz, CDCl3) δ 9.77 (s, NH), 6.07 (s, 1H), 5.63 (s, 1H), 3.74 
(s, 3H), 3.42 (s, 2H), 1.34 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 176.49, 171.40, 166.39, 134.56, 125.32, 
52.48, 38.39, 37.77, 27.02. 
IR (neat, cm-1) 2972, 1741, 1055, 1033, 1013. 
LRMS (ESI) m/z calcd for C11H17NO5 [M+H]+, [M+Na]+: 244.1, found: 244.1, 266.1. 
2-phenyl-N-(pivaloyloxy)acrylamide  
1H NMR (500 MHz, CDCl3) δ 9.18 (s, NH), 7.47 (m, 2H), 7.38 (m, 3H), 6.11 (s, 
1H), 5.75 (s, 1H), 1.33 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 176.61, 166.00, 141.59, 135.62, 128.87, 128.77, 
127.77, 123.06, 38.36, 27.00. 
IR (neat, cm-1) 3205, 2975, 1779, 1668, 1480, 1077, 1031, 701. 
LRMS (ESI) m/z calcd for C14H17NO3 [M+H]+: 248.1, found: 248.1. 
N-(pivaloyloxy)-2-(p-tolyl)acrylamide  
1H NMR (500 MHz, CDCl3) δ 9.32 (s, 1H), 7.33 (d, J = 7.9 Hz, 2H), 7.15 
(d, J = 7.6 Hz, 2H), 5.99 (s, 1H), 5.67 (s, 1H), 2.35 (s, 3H), 1.31 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 176.41, 166.31, 141.43, 138.71, 132.74, 
129.38, 127.59, 121.94, 38.30, 26.99, 21.20. 
IR (neat, cm-1) 3195, 2975, 1781, 1667, 1612, 1077, 826. 
LRMS (ESI) m/z calcd for C15H19NO3 [M+H]+: 262.1, found: 262.1. 
2-(4-methoxyphenyl)-N-(pivaloyloxy)acrylamide 
1H NMR (500 MHz, CDCl3) δ 9.23 (s, NH), 7.38 (d, J = 8.7 Hz, 2H), 6.88 
(d, J = 8.6 Hz, 2H), 5.97 (s, 1H), 5.66 (s, 1H), 3.79 (s, 3H), 1.32 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 176.60, 166.48, 160.04, 141.04, 129.00, 
127.96, 121.19, 114.11, 55.29, 38.34, 26.99. 
IR (neat, cm-1) 3229, 2973, 1780, 1670, 1608, 1513, 1252, 1181, 1076, 1033, 837. 
LRMS (ESI) m/z calcd for C15H19NO4 [M+H]+, [M+Na]+: 278.1, found: 278.1. 
2-(4-bromophenyl)-N-(pivaloyloxy)acrylamide  
1H NMR (500 MHz, CDCl3) δ 9.05 (s, NH), 7.51 (d, J = 8.4 Hz, 2H), 7.35 (d, 
J = 8.5 Hz, 2H), 6.09 (s, 1H), 5.78 (s, 1H), 1.34 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 176.65, 165.79, 140.66, 134.39, 131.93, 
129.33, 123.24, 123.10, 38.38, 26.99. 










LRMS (ESI) m/z calcd for C14H16BrNO3 [M+H]+: 326.0, found: 326.0, 328.0. 
2-(3-methoxyphenyl)-N-(pivaloyloxy)acrylamide  
1H NMR (500 MHz, CDCl3) δ 9.30 (s, NH), 7.25 (t, J = 7.9 Hz, 1H), 7.01 
(d, J = 7.6 Hz, 1H), 6.98 (s, 1H), 6.86 (d, J = 8.2 Hz, 1H), 6.06 (s, 1H), 
5.71 (s, 1H), 3.77 (s, 3H), 1.30 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 176.42, 171.28, 159.65, 141.45, 136.96, 
129.77, 120.10, 114.59, 113.14, 55.23, 38.30, 26.96. 
IR (neat, cm-1) 3203, 2974, 1779, 1670, 1600, 1579, 1484, 1462, 1247, 1034, 1075. 
LRMS (ESI) m/z calcd for C15H19NO4 [M+H]+: 278.1, found: 278.1. 
N-(pivaloyloxy)-2-(o-tolyl)acrylamide  
1H NMR (500 MHz, CDCl3) δ 8.91 (s, NH), 7.53 – 6.95 (m, 4H), 6.45 (s, 1H), 
5.52 (s, 1H), 2.29 (s, 3H), 1.26 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 176.23, 171.06, 140.80, 136.74, 135.57, 130.44, 
129.73, 128.89, 126.61, 126.13, 53.47, 38.22, 26.91. 
IR (neat, cm-1) 3207, 2974, 1780, 1671, 1480, 1459, 1074, 1033, 768, 729. 
LRMS (ESI) m/z calcd for C15H19NO3 [M+H]+: 262.1, found: 262.1. 
2-ethoxy-N-(pivaloyloxy)acrylamide  
1H NMR (500 MHz, CDCl3) δ 9.70 (s, 1H), 5.36 (s, 59H), 4.49 (s, 1H), 3.84 (q, J = 
6.8 Hz, 3H), 1.35 (t, J = 7.0 Hz, 5H), 1.31 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 176.18, 160.01, 151.78, 91.76, 64.25, 38.35, 26.95, 
14.18. 
IR (neat, cm-1) 3245, 2979, 2937, 1782, 1693, 1628, 1479, 1300, 1059, 1081. 
LRMS (ESI) m/z calcd for C10H17NO4 [M+H]+: 216.1, found: 216.2. 
3. General procedures for dihydropyridone synthesis 
 Without any precaution of air and moisture, substituted N-(pivaloyloxy) acrylamide (0.1 mmol, 1 
eq), [Cp*RhCl2]2 (0.0025 mmol, 2.5 mol%),  CsOAc (0.025 mmol, 0.25 equiv) and alkenes (0.11 mmol, 
1.1 equiv) were charged into a dram vial charged with a stir bar. Trifluoroethanol (TFE) (0.33 mL, 0.3 M) 
was added and the mixture was stirred at room temperature until the starting material was consumed 
(monitoring by TLC). The reaction was quenched with saturated NaHCO3 and extracted 3 times with 
EtOAc. The organic layer was washed with brine, dried over MgSO4, filtered, and solvent was evaporated 
to obtain crude product. The crude product was purified by column chromatography using gradient 10% 











4. Product characterizations 
3-benzyl-6-phenyl-5,6-dihydropyridin-2(1H)-one  
Off-white solid (22.2 mg, 85% yield).  
1H NMR (500 MHz, CDCl3) δ 7.40-7.23 (m, 10H), 6.16 (ddt, J = 5.1, 3.4, 1.6 Hz, 1H), 
5.71 (s, NH), 4.71 (dd, J = 10.4, 6.7 Hz, 1H), 3.69 (s, 2H), 2.53 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.96, 141.20, 139.29, 135.01, 134.99, 129.35, 
128.91, 128.42, 128.27, 126.45, 126.21, 55.91, 36.06, 33.41.  
IR (neat, cm-1) 3206, 3061, 3027, 2917, 1673, 1630, 1494, 1453, 1424, 1290, 698.  
LRMS (ESI) m/z calcd for C18H17NO [M+H]+: 265.1, found: 265.1.  
The regiochemistry based on COSY. 
3-(4-bromobenzyl)-6-phenyl-5,6-dihydropyridin-2(1H)-one  
Off-white solid (30.9 mg, 90% yield).  
1H NMR (500 MHz, CDCl3) δ 7.41 (d, J = 8.3 Hz, 2H), 7.37-7.30 (m, 5H), 
7.11 (d, J = 8.3 Hz, 2H), 6.18 (m, 1H), 5.76 (s, NH), 4.67 (dd, J = 10.8, 6.2 
Hz, 1H), 3.60 (s, 2H), 2.57-2.46 (m, 1H).  
13C NMR (CDCl3, 126 MHz) δ 166.69, 141.06, 138.40, 135.24, 134.54, 131.46, 131.03, 128.92, 128.30, 
126.42, 120.08, 55.81, 35.66, 33.35.  
IR (neat, cm-1) 3202, 3061, 2919, 1674, 1631, 1425, 1454, 1486, 1289, 1070, 1011, 699.  
LRMS (ESI) m/z calcd for C18H16BrNO [M+H]+: 342.0, 344.0, found: 342.0, 344.0. 
3-methyl-6-phenyl-5,6-dihydropyridin-2(1H)-one  
Off-white solid (13.1 mg, 70% yield).  
1H NMR (500 MHz, CDCl3) δ 7.39-7.26 (m, 5H), 6.34 (m, 1H), 5.66 (s, NH), 4.70 (dd, 
J = 10.5, 6.7 Hz, 1H), 2.50 (m, 2H), 1.93 (s, 3H).  
13C NMR (CDCl3, 126 MHz) δ 167.73, 141.35, 134.27, 130.92, 128.90, 128.23, 
126.39, 56.21, 33.37, 16.61. IR (neat, cm-1) 3214, 3063, 2923, 2886, 1676, 1633, 699.  
LRMS (ESI) m/z calcd for C12H13NO [M+H]+: 188.1, found: 188.2. 
methyl 2-(2-oxo-6-phenyl-1,2,5,6-tetrahydropyridin-3-yl)acetate  
Off-white solid (18.4 mg, 75% yield). 
1H NMR (500 MHz, CDCl3) δ 7.40-7.31 (m, 5H), 6.49 (m, 1H), 5.69 (s, NH), 
4.77 (dd, J = 10.8, 6.2 Hz, 1H), 3.71 (s, 3H), 3.41 (d, J = 16.5 Hz, 1H), 3.28 (d, 
J = 16.5 Hz, 1H), 2.65-2.53 (m, 2H).  
13C NMR (CDCl3, 126 MHz) δ 171.71, 166.16, 141.02, 137.39, 128.95, 128.71, 128.35, 126.46, 55.89, 
52.02, 35.61, 33.36.  














LRMS (ESI) m/z calcd for C14H15NO3 [M+H]+, [M+Na]+: 246.1, 268.1, found: 246.2, 268.1. 
3,6-diphenyl-5,6-dihydropyridin-2(1H)-one  
Off-white solid (13.3 mg, 55% yield).  
1H NMR (500 MHz, CDCl3) δ 7.49 (d, J = 6.9 Hz, 2H), 7.41-7.31 (m, 8H), 6.71 (dd, J 
= 5.5, 3.5 Hz, 1H), 5.86 (s, NH), 4.83 (dd, J = 11.4, 5.5 Hz, 1H), 2.78-2.66 (m, 2H).  
13C NMR (CDCl3, 126 MHz)  166.08, 141.00, 136.62, 136.27, 135.71, 129.00, 
128.59, 128.39, 128.06, 127.81, 126.47, 55.84, 33.72.  
IR (neat, cm-1) 3218, 3059, 2932, 1669, 1616, 697.  
LRMS (ESI) m/z calcd for C17H15NO [M+H]+, [M+Na]+: 250.1, found: 250.2, 272.1. 
6-phenyl-3-(p-tolyl)-5,6-dihydropyridin-2(1H)-one  
Off-white solid (21.1 mg, 80% yield).  
1H NMR (500 MHz, CDCl3) δ 7.41-7.35 (s, 7H), 7.18 (d, J = 7.9 Hz, 2H), 
6.67 (dd, J = 5.5, 3.5 Hz, 1H), 5.88 (s, NH), 4.81 (dd, J = 11.3, 5.5 Hz, 1H), 
2.78–2.58 (m, 2H), 2.36 (s, 3H).  
13C NMR (CDCl3, 126 MHz) δ 166.23, 141.10, 137.58, 135.90, 135.56, 
133.41, 128.98, 128.78, 128.46, 128.34, 126.48, 55.83, 33.70, 21.22. 
IR (neat, cm-1) 3182, 3056, 2921, 1665, 1511, 823, 699.  
LRMS (ESI) m/z calcd for C18H17NO [M+H]+, [M+Na]+: 264.1, 286.1, found: 264.2, 286.1. 
3-(4-methoxyphenyl)-6-phenyl-5,6-dihydropyridin-2(1H)-one  
Off-white solid (16.5 mg, 59% yield).  
1H NMR (500 MHz, CDCl3) δ 7.43 (d, J = 8.8 Hz, 2H), 7.41-7.34 (m, 5H), 
6.90 (d, J = 8.8 Hz, 2H), 6.64 (dd, J = 5.4, 3.6 Hz, 1H), 5.82 (s, NH), 4.81 
(dd, J = 10.3, 6.7 Hz,  1H), 3.82 (s, 3H), 2.98 – 2.54 (m, 2H).  
13C NMR (CDCl3, 126 MHz) δ 166.30, 159.36, 141.08, 135.30, 135.06, 
129.75, 128.98, 128.79, 128.36, 126.47, 113.54, 55.87, 55.31, 33.71.  
IR (neat, cm-1) 3198, 3059, 2933, 2836, 1665, 1607, 1510, 1244, 830.  
LRMS (ESI) m/z calcd for C18H17NO2 [M+H]+, [M+Na]+: 280.1, found: 280.2, 302.1. 
3-(4-bromophenyl)-6-phenyl-5,6-dihydropyridin-2(1H)-one  
Off-white solid (19.6 mg, 60% yield).  
1H NMR (500 MHz, CDCl3) δ 7.48 (d, J = 8.5 Hz, 2H), 7.40 (m, 4H), 7.35 (s, 
1H), 7.36 (d, J = 8.5 Hz, 2H), 6.71 (dd, J = 5.6, 3.4 Hz, 1H), 5.91 (s, NH), 4.82 
(dd, J = 11.1, 5.8 Hz, 1H), 2.98–2.46 (m,2H).  
13C NMR (CDCl3, 126 MHz) δ 165.70, 140.80, 137.00, 135.12, 134.68, 




IR (neat, cm-1) 3202, 3060, 2924, 1666, 1614, 1487, 824.  
LRMS (ESI) m/z calcd for C17H14BrNO [M+H]+: 327.0, 330.0, found: 328.0, 330.0. 
3-(3-methoxyphenyl)-6-phenyl-5,6-dihydropyridin-2(1H)-one  
Off-white solid (22.7 mg, 81% yield).  
1H NMR (500 MHz, CDCl3) 7.47 – 7.31 (m, 5H), 7.28 (d, J = 8.2 Hz, 1H), 
7.12 – 7.02 (m, 2H), 6.92 – 6.84 (m, 1H), 6.70 (dd, J = 5.5, 3.5 Hz, 1H), 5.89 
(s, NH), 4.84 – 4.78 (m, 1H), 3.82 (s, 3H), 2.77-2.65 (m, 2H).  
13C NMR (CDCl3, 126 MHz) δ 165.98, 159.25, 140.99, 137.65, 136.79, 
135.56, 129.03, 129.00, 128.38, 126.47, 121.08, 114.25, 113.60, 55.78, 55.27, 33.69.  
IR (neat, cm-1) 3211, 3061, 2938, 1669, 1270, 697.  
LRMS (ESI) m/z calcd for C18H17NO2 [M+H]+, [M+Na]+: 280.1, 302.1, found: 280.1, 302.1. 
6-phenyl-3-(o-tolyl)-5,6-dihydropyridin-2(1H)-one  
Off-white solid (26.3 mg, 77% yield).  
1H NMR (500 MHz, CDCl3) δ 7.56 – 7.07 (m, 9H), 6.56 (dd, J = 5.0, 3.7 Hz, 1H), 
5.90 (s, NH), 4.90 (dd, J = 10.1, 6.7 Hz, 1H), 2.79 – 2.69 (m, 2H), 2.31 (s, 3H). 
 13C NMR (CDCl3, 126 MHz) δ 165.89, 141.07, 137.73, 136.78, 136.61, 136.53, 
129.92, 129.78, 129.00, 128.37, 128.05, 126.46, 125.63, 56.01, 33.59, 20.21.  
IR (neat, cm-1) 3206, 3061, 2924, 1669, 1622, 727.  
LRMS (ESI) m/z calcd for C18H17NO [M+H]+, [M+Na]+: 264.1, 286.1, found: 264.2, 286.1. 
3-ethoxy-6-phenyl-5,6-dihydropyridin-2(1H)-one  
 (13.0 mg, 58% yield)  
1H NMR (500 MHz, CDCl3) δ 7.51 – 7.30 (m, 5H), 5.81 (s, NH), 5.42 – 5.38 (m, 1H), 
4.72 (dd, J = 10.2, 6.9 Hz, 1H), 3.84 (q, J = 7.1 Hz, 2H), 2.66 – 2.55 (m, 2H), 1.44 (t, 
J = 7.0 Hz, 3H).  
13C NMR (CDCl3, 126 MHz) δ 163.48, 146.86, 140.86, 128.92, 128.78, 128.32, 126.34, 104.53, 63.57, 
56.00, 31.92, 14.34.  
IR (neat, cm-1) 3228, 2979, 2932, 1682, 1633, 1224, 700.  
LRMS (ESI) m/z calcd for C13H15NO2 [M+H]+: 218.1, 240.1, found: 218.1, 240.1. 
3-benzyl-6-(p-tolyl)-5,6-dihydropyridin-2(1H)-one  
Off-white solid (25.4 mg, 92% yield). 
1H NMR (500 MHz, CDCl3) δ 7.34 (t, J = 5.0 Hz, 2H), 7.28 (m, 3H), 7.24 (d, 
J = 10.0 Hz, 2H), 7.19 (d, J = 10.0 Hz, 2H), 6.16 (t, J = 10.0 Hz, 1H), 5.76 (s, 
NH), 4.67 (t, J = 10.0 Hz, 1H), 3.69 (s, 2H), 2.49 (m, 2H), 2.38 (s, 3H).  




134.96, 129.55, 129.36, 128.42, 126.37, 126.20, 55.64, 36.05, 33.46, 21.11.  
IR (neat, cm-1) 3205, 3059, 3026, 2920, 1673, 1630, 699.  
LRMS (ESI) m/z calcd for C19H19NO [M+H]+, [M+Na]+: 278.1, 300.1, found: 278.2, 300.1. 
3-benzyl-6-(4-methoxyphenyl)-5,6-dihydropyridin-2(1H)-one  
Off-white solid (26.0 mg, 89% yield).  
1 mmol scale - 244.2, 83% yield 
1H NMR (500 MHz, CDCl3) δ 7.33 (t, J = 15.0 Hz, 2H), 7.27 (d, J = 15.0 
Hz, 2H), 7.28-7.23 (m, 3H), 6.90 (d, J = 15.0 Hz, 2H), 6.16 (t, J = 5.0 Hz, 
1H), 5.71 (s, NH), 4.65 (t, J = 10.0 Hz, 1H), 3.83 (s, 3H), 3.69 (s, 2H), 2.50-
2.47 (m, 1H).  
13C NMR (CDCl3, 126 MHz) δ 167.02, 159.50, 139.33, 135.16, 134.95, 133.18, 129.34, 128.41, 127.67, 
126.19, 114.22, 55.38, 55.34, 36.05, 33.50.  
IR (neat, cm-1) 3207, 3060, 3027, 2932, 2836, 1672, 1629, 1512, 1247, 1032, 826, 700.  
LRMS (ESI) m/z calcd for C19H19NO2 [M+H]+, [M+Na]+: 294.1, 316.1, found: 294.1, 316.1.  
3-benzyl-6-(4-(trifluoromethyl)phenyl)-5,6-dihydropyridin-2(1H)-one  
Off-white solid (15.3 mg, 46% yield). 
1H NMR (500 MHz, CDCl3) δ 7.63 (d, J = 8.1 Hz, 2H), 7.45 (d, J = 8.0 Hz, 
2H), 7.32 (m, 2H), 7.25 (m, 3H), 6.16 (m, 1H), 5.93 (s, NH), 4.78 (dd, J = 
10.7, 5.7 Hz, 1H), 3.68 (s, 2H), 2.84-2.56 (m, 1H), 2.55-2.38 (m, 1H).  
13C NMR (CDCl3, 126 MHz) δ 166.87, 145.23, 139.07, 135.23, 134.49, 
130.49, 129.28, 128.44, 126.79, 126.29, 125.88, 55.30, 36.07, 33.12. 
IR (neat, cm-1) 3212, 3064, 2922, 1675, 1630, 1324, 1164, 1121, 1068, 826, 700.  
LRMS (ESI) m/z calcd for C19H16F3NO [M+H]+: 332.1, found: 332.1. 
3-benzyl-6-(4-fluorophenyl)-5,6-dihydropyridin-2(1H)-one  
Yellow oil (18.9 mg, 67% yield). 
1H NMR (500 MHz, CDCl3) δ 7.32-7.27 (m, 4H), 7.23-7.20 (m, 3H), 7.03 (t, J 
= 8.6 Hz, 1H), 6.13 (m, 1H), 5.77 (s, NH), 4.67 (dd, J = 11.0, 5.9 Hz, 1H), 3.65 
(s, 2H), 2.54-2.41 (m, 2H).  
13C NMR (CDCl3, 126 MHz) δ 166.93, 162.71, 139.21, 136.98, 135.07, 134.82, 
129.31, 128.43, 128.15, 126.24, 115.88 115.69, 55.20, 36.05, 33.42.  
19F NMR (CDCl3, 282 MHz) δ 112.89.  
IR (neat, cm-1) 3207, 3062, 3028, 2922, 1673, 1630, 1510, 1427, 1225, 827, 699.  






Off-white solid (21.2 mg, 71% yield).  
1H NMR (500 MHz, CDCl3) δ 7.30-7.28 (m, 4H), 7.24-7.19 (m, 5H), 6.10 (m, 
1H), 5.88 (s, NH), 4.65 (dd, J = 5.0, 10.0 Hz, 1H), 3.62 (s, 2H), 2.53-2.49 (m, 
1H), 2.44-2.38 (m, 1H).  
13C NMR (CDCl3, 126 MHz) δ 166.94, 139.74, 139.17, 135.12, 134.68, 133.98, 
129.31, 129.04, 128.43, 127.82, 126.25, 55.15, 36.06, 33.25.  
IR (neat, cm-1) 3207, 3061, 3028, 2921, 1674, 1631, 1492, 1092, 1014, 822, 699.  
LRMS (ESI) m/z calcd for C18H16ClNO [M+H]+: 298.1, found: 298.1. 
methyl 4-(5-benzyl-6-oxo-1,2,3,6-tetrahydropyridin-2-yl)benzoate  
 (18.3 mg, 57% yield)  
1H NMR (500 MHz, CDCl3) δ 8.04 (d, J = 8.3 Hz, 2H), 7.40 (d, J = 8.3 
Hz, 2H), 7.37 – 7.29 (m, 2H), 7.24 (m, 3H), 6.15 (ddt, J = 5.1, 3.3, 1.6 Hz, 
1H), 5.87 (s, NH), 4.77 (dd, J = 10.8, 5.7 Hz, 1H) 3.94 (s, 3H), 3.67 (s, 
2H), 2.60 (dtd, J = 17.5, 5.5, 1.4 Hz, 1H), 2.49 (dddd, J = 16.3, 13.3, 5.2, 
2.4 Hz, 1H).  
13C NMR (CDCl3, 126 MHz) δ 166.84, 166.55, 146.24, 139.11, 135.17, 134.56, 130.19, 130.09, 129.30, 
128.43, 126.41, 126.26, 55.48, 52.22, 36.06, 33.10.  
IR (neat, cm-1) 3211, 3028, 2950, 1720, 1675, 1631, 1280, 1111, 701.  
LRMS (ESI) m/z calcd for C20H19NO3 [M+H]+: 322.1, found 322.1. 
3-benzyl-6-(m-tolyl)-5,6-dihydropyridin-2(1H)-one  
Off-white solid (23.3 mg, 84% yield). 
1H NMR (500 MHz, CDCl3) δ 7.33 (t, J =7.4 Hz, 2H), 7.28-7.23 (m, 4H), 
7.16-7.13 (m, 3H), 6.16 (m, 1H), 5.68 (s, NH), 4.67 (m, 1H), 3.70 (s, 2H), 2.52 
(m, 2H), 2.37 (s, 3H).  
13C NMR (CDCl3, 126 MHz) δ 166.93, 141.20, 139.33, 138.67, 135.05, 
134.94, 129.33, 128.97, 128.79, 128.42, 127.12, 126.20, 123.50, 55.85, 36.07, 
33.42, 21.44.  
IR (neat, cm-1) 3207,  3060, 3027, 1673, 1630, 1423, 1289, 780, 700.  









Off-white solid (25.8 mg, 88% yield).  
1H NMR (500 MHz, CDCl3) δ 7.34-7.23 (m, 6H), 6.93-6.87 (m, 3H), 6.16 
(m, 1H), 5.76 (m, NH), 4.68 (dd, J = 10.3, 7.0 Hz, 1H), 3.81 (s, 3H), 3.68 (s, 
2H), 2.52 (m, 2H).  
13C NMR (CDCl3, 126 MHz) δ 166.96, 159.98, 142.84, 139.29, 135.08, 
134.95, 129.98, 129.34, 128.43, 126.21, 118.67, 113.69, 111.96, 55.87, 
55.28, 36.05, 33.38.  
IR (neat, cm-1) 3209, 3027, 2935, 1674, 1630, 1454, 1262, 1048, 699.  
LRMS (ESI) m/z calcd for C19H19NO2 [M+H]+: 294.1, Found: 294.2. 
3-benzyl-6-(3-(trifluoromethyl)phenyl)-5,6-dihydropyridin-2(1H)-one  
Off-white solid (14.5 mg, 44% yield). 
 1H NMR (500 MHz, CDCl3) δ 7.62 (s, 1H), 7.61 (d, J = 10.0 Hz, 1H), 7.54-
7.48 (m, 2H), 7.36-7.31 (m, 2H), 7.26-7.23 (m, 3H), 6.17 (m, 1H), 5.90 (s, 
NH), 4.79 (dd, J = 5.0, 10.0 Hz, 1H), 3.69 (s, 2H), 2.64-2.59 (m, 1H), 2.54-
2.47 (m, 1H).  
13C NMR (CDCl3, 126 MHz) δ 166.90, 142.31, 139.07, 135.20, 134.58, 
131.46, 131.20, 130.94, 129.80, 129.46, 129.28, 128.46, 126.28, 125.11, 123.27, 55.43, 36.02, 33.21.  
19F NMR (CDCl3, 282 MHz) δ -61.82.  
IR (neat, cm-1) 2939, 1676, 1631, 1328, 700.  
LRMS (ESI) m/z calcd for C19H16F3NO [M+H]+: 332.1, found: 332.1. 
3-benzyl-6-(3-fluorophenyl)-5,6-dihydropyridin-2(1H)-one  
Yellow oil (19.9 mg, 71% yield).  
1H NMR (500 MHz, CDCl3) δ 7.34-7.29 (m, 3H), 7.23-7.20 (m, 3H), 7.09 (d, J 
= 7.8, Hz, 1H), 7.06-6.97 (m, 2H), 6.13 (m, 1H), 5.80 (s, NH), 4.68 (dd, J = 
11.0, 5.7 Hz, 1H), 3.65 (s, 2H), 2.58-2.52 (m, 1H), 2.49-2.42 (m, 1H).  
13C NMR (CDCl3, 126 MHz) δ 166.85, 163.94, 161.98, 143.87, 143.82, 139.14, 
135.09, 134.68, 130.54, 130.48, 129.31, 128.44, 126.25, 122.04, 122.01, 115.25, 
115.08, 113.58, 113.40, 55.33, 36.04, 33.18. 
IR (neat, cm-1) 3208, 3062, 3028, 2920, 1674, 1631, 784, 699.  








Off-white solid (17.4 mg, 58% yield).  
1H NMR (500 MHz, CDCl3) δ 7.33-7.28 (m, 5H), 7.23-7.18 (m, 4H), 6.13 (m, 
1H), 5.82 (s, NH), 4.67 (dd, J = 5.0, 10.0 Hz, 1H), 3.55 (s, 2H), 2.58-2.53 (m, 
1H), 2.49-2.43 (m, 1H).  
13C NMR (CDCl3, 126 MHz) δ 166.84, 143.33, 139.13, 135.11, 134.78, 134.64, 
130.20, 129.29, 128.45, 128.41, 126.69, 126.25, 124.57, 55.29, 36.04, 33.16.  
IR (neat, cm-1) 3204, 2897, 1674, 1630, 1422, 696.  
LRMS (ESI) m/z calcd for C18H16ClNO [M+H]+: 298.1, found: 298.1. 
3-(5-benzyl-6-oxo-1,2,3,6-tetrahydropyridin-2-yl)benzaldehyde  
Off-white solid (10.2 mg, 35% yield).  
1H NMR (500 MHz, CDCl3) δ 9.99 (s, CHO), 7.85 (d, J = 10.0 Hz, 1H), 
7.84 (s, 1H), 7.61 (d, J = 10.0 Hz, 1H), 7.55 (t, J = 5.0 Hz, 1H), 7.33-7.30 
(m, 2H), 7.25-7.23 (m, 3H), 6.17 (m, 1H), 5.91 (s, NH), 4.82 (dd, J = 5.0, 
10.0 Hz, 1H), 3.71 (d, J = 15.0 Hz, 1H), 3.66 (d, J = 15.0 Hz, 1H).  
13C NMR (CDCl3, 126 MHz) δ 191.79, 166.82, 142.55, 139.12, 136.89, 
135.26, 134.45, 132.33, 129.67, 129.58, 129.29, 128.45, 127.48, 126.28, 55.26, 36.09, 33.13.  
IR (neat, cm-1) 3211, 3060, 3027, 2918, 1696, 1673, 1629, 698.  
LRMS (ESI) m/z calcd for C19H17NO2 [M+H]+: 292.1, found: 292.1. 
3-benzyl-6-(naphthalen-2-yl)-5,6-dihydropyridin-2(1H)-one  
Off-white solid (16.8 mg, 60% yield).  
1H NMR (500 MHz, CDCl3) δ 7.88-7.77 (m, 4H), 7.55-7.47 (m, 3H), 7.35-
7.24 (m, 5H), 6.19 (m, 1H), 5.91 (s, NH), 4.58 (dd, J = 5.0, 10.0 Hz), 3.72 (s, 
2H), 2.63 (m, 2H).  
13C NMR (CDCl3, 126 MHz) δ 166.99, 139.30, 138.51, 135.03, 134.93, 
133.23, 133.11, 129.34, 128.84, 128.45, 127.96, 127.71, 126.55, 126.34, 
126.23, 125.40, 124.16, 55.87, 36.14, 33.26.  
IR (neat, cm-1) 3209, 3057, 3027, 2919, 1672, 1629, 1424, 747, 699.  










 (16.8 mg, 60% yield) 
 1H NMR (500 MHz, CDCl3) δ 7.40 – 7.27 (m, 4H), 7.25 (d, J = 7.5 Hz, 3H), 7.14 
(t, J = 7.6 Hz, 1H), 7.11 – 7.03 (m, 1H), 6.15 (ddt, J = 5.2, 3.4, 1.5 Hz, 1H), 5.66 (s, 
NH), 5.08 (ddd, J = 9.7, 5.9, 1.8 Hz, 1H), 3.71 (d, J = 16.6 Hz, 1H), 3.66 (d, J = 
15.7 Hz, 1H), 2.69 (dt, J = 17.7, 5.5 Hz, 1H), 2.51 (dddt, J = 17.6, 9.7, 3.9, 2.1 Hz, 
1H).  
13C NMR (CDCl3, 126 MHz) δ 167.00, 160.92, 158.95, 139.16, 134.96, 134.71, 129.60, 129.53, 129.34, 
128.41, 128.29, 128.19, 127.50, 127.47, 126.23, 124.53, 124.50, 115.77, 115.60, 48.69, 48.66, 36.07, 
31.35.  
19F NMR (CDCl3, 282 MHz) δ -118.24.  
IR (neat, cm-1) 3207, 3063, 2922, 1676, 1632, 1491, 757, 700.  
LRMS (ESI) m/z calcd for C18H16FNO [M+H]+, [M+Na]+: 281.1, found: 282.1, 304.1. 
3-benzyl-6-(6,6,6,6,6-pentafluoro-6λ8-hexa-1,3,5-triyn-1-yl)-5,6-dihydropyridin-2(1H)-one  
Yellow oil (17.7 mg, 50% yield).  
1H NMR (500 MHz, CDCl3) δ 7.32-7.29 (m, 2H), 7.24-7.20 (m, 3H), 6.42 (s, NH), 
6.15 (m, 1H), 5.14 (dd, J = 5.0, 10.0 Hz, 1H), 3.62 (q, J = 15.0 Hz), 2.76-2.71 (m, 
1H), 2.54-2.48 (m, 1H).  
13C NMR (CDCl3, 126 MHz) δ 166.53, 138.78, 135.29, 134.53, 129.35, 128.47, 
126.33, 46.12, 35.92, 29.54.  
19F NMR (CDCl3, 282 MHz) δ -138.86 – -140.68 (m), -151.01 – -153.96 (m), -159.97 (dd, J = 20.8, 14.0 
Hz). IR (neat, cm-1) 3207, 3065, 2926, 1679, 1633, 1522, 1502, 1000, 958, 700.  
LRMS (ESI) m/z calcd for C18H12F5NO [M+H]+: 353.1, found: 354.1. 
 (4aS,5S,8R,8aS)-3-benzyl-4a,5,6,7,8,8a-hexahydro-5,8-methanoquinolin-2(1H)-one  
Off-white solid (20 mg, 80% yield).  
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.25 (m, 3H), 7.21 (d, J = 7.8 Hz, 2H), 6.19 (dd, J 
= 5.7, 3.0 Hz, 1H), 6.03 (s, NH), 6.01 (dd, J = 5.7, 3.0 Hz, 1H), 5.96 (d, J = 4.3 Hz, 1H), 
3.63 (d, J = 15.7 Hz, 1H), 3.57 (d, J = 15.7 Hz, 1H), 3.49 (d, J = 9.4 Hz, 1H), 2.76 (s, 
1H), 2.67 (s, 1H), 2.42-2.40 (m, 1H), 1.71 (d, J = 9.2 Hz, 1H), 1.48 (d, J = 9.2 Hz, 1H).  
13C NMR (CDCl3, 126 MHz) 164.97, 139.63, 138.86, 137.67, 134.55, 131.71, 129.22, 
128.35, 126.07, 54.24, 52.35, 48.47, 42.83, 37.86, 36.18. 
 IR (neat, cm-1) 3204, 3059, 2970, 1681, 1634, 1477, 1453, 1279, 700.  






Off-white solid (23.2 mg, 92% yield).  
1H NMR (500 MHz, CDCl3) δ 7.30 (t, J = 7.5 Hz, 2H), 7.22 (d, J = 7.7 Hz, 3H), 5.87 (d, 
J = 4.3 Hz, 1H), 5.75 (s, NH), 3.72 – 3.50 (m, 3H), 2.64 – 2.39 (m, 1H), 2.12 (s, 1H), 
2.06 (s, 1H), 1.74 (m, 2H), 1.57 (m, 2H), 1.39 – 1.14 (m, 2H).  
13C NMR (CDCl3, 126 MHz) 164.62, 139.74, 137.51, 130.92, 129.21, 128.32, 126.01, 
58.25, 46.43, 43.19, 42.61, 35.93, 32.52, 29.60, 25.66.  
IR (neat, cm-1) 3204, 2952, 2872, 1683, 1635, 1453, 1477, 698.  
LRMS m/z (ESI+APCI) calcd for C17H19NO [M+H]+: 254.2, found: 254.2. 
3-benzyl-1,4a,5,6,7,7a-hexahydro-2H-cyclopenta[b]pyridin-2-one  
Off-white solid (20.2 mg, 93% yield).  
1 mmol scale - 213 mg, 94% yield 
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.29 (m, 2H), 7.28 – 7.15 (m, 3H), 6.10 (dt, J = 
5.1, 1.5 Hz, 1H), 5.61 (s, NH), 3.97 (dddd, J = 7.6, 5.6, 3.6, 1.6 Hz, 1H), 3.65 (d, J = 
15.8 Hz, 1H), 3.59 (d, J = 15.7 Hz, 1H), 2.64 (p, J = 7.4 Hz, 1H), 2.12 – 1.88 (m, 2H), 
1.88 – 1.45 (m, 4H).  
13C NMR (CDCl3, 126 MHz) δ 165.49, 139.61, 139.50, 132.06, 129.26, 128.34, 126.04, 55.34, 38.53, 
35.99, 34.93, 32.09, 23.13.  
IR (neat, cm-1) 3204, 3027, 2956, 1675, 1629, 1494, 1452, 699.  
LRMS (ESI) m/z calcd for C15H17NO [M+H]+: 228.1, found: 228.2. 
3-benzyl-1,4a,5,9b-tetrahydro-2H-indeno[1,2-b]pyridin-2-one  
Off-white solid (17.8 mg, 65% yield). 
1H NMR (500 MHz, CDCl3) δ 7.32-7.25 (m, 6H), 7.20 (t, J = 5.0 Hz, 1H), 7.20 (d, J 
= 5.0 Hz, 2H), 6.42 (s, NH), 6.07 (d, J = 5.0 Hz, 1H), 4.93 (dd, J = 5.0, 7.5 Hz, 1H), 
3.67 (d, J = 15.0 Hz, 1H), 3.56 (d, J = 15.0 Hz, 1H), 3.35 (m, 1H), 3.24 (dd, J = 5.0, 
15.0 Hz, 1H), 2.92 (dd, J = 5.0, 15.0 Hz, 1H). 
13C NMR (CDCl3, 126 MHz) δ 164.87, 142.60, 141.18, 139.32, 138.93, 133.63, 
129.14, 128.33, 127.21, 126.05, 124.77, 123.81, 58.20, 38.91, 38.13, 35.98.  
IR (neat, cm-1) 3210, 3026, 2915, 1676, 1629, 1478, 743, 699.  









Off-white solid (21 mg, 88% yield). 
 1H NMR (500 MHz, CDCl3) δ 7.32 – 7.25 (m, 2H), 7.20 (d, J = 7.1 Hz, 3H), 6.06 (d, J 
= 5.1 Hz, 1H), 5.93 (dt, J = 8.7, 4.1 Hz, 1H), 5.61 (ddt, J = 9.9, 4.3, 2.2 Hz, 2H), 5.58 (s, 
NH), 4.04 (m, 1H), 3.65 (d, J = 15.8 Hz, 1H), 3.57 (d, J = 15.8 Hz, 1H), 2.48 – 2.37 (m, 
1H), 2.15 – 1.95 (m, 2H), 1.76 – 1.53 (m, 2H).  
13C NMR (CDCl3, 126 MHz) δ 165.70, 139.96, 139.46, 133.96, 131.28, 129.25, 128.35, 
126.08, 124.98, 76.79, 48.13, 35.98, 34.01, 24.13, 22.69.  
IR (neat, cm-1) 3206, 3026, 2923, 1674, 1628, 1429, 1453, 738, 700.  
LRMS (ESI) m/z calcd for C16H17NO [M+H]+, [M+Na]+: 240.1, 262.1, found: 240.2, 262.2. 
(4aS,10bR)-3-benzyl-4a,5,6,10b-tetrahydrobenzo[h]quinolin-2(1H)-one  
Off-white solid (18.3 mg, 63% yield).  
1H NMR (500 MHz, CDCl3) δ 7.37 – 7.16 (m, 9H), 6.27 (d, J = 5.9 Hz, 1H), 5.45 
(s, NH), 4.72 (d, J = 5.0 Hz, 1H), 3.74 (d, J = 15.8 Hz, 1H), 3.62 (d, J = 15.8 Hz, 
1H), 2.90 (ddd, J = 17.0, 5.3, 2.9 Hz, 1H), 2.79 (ddd, J = 17.1, 11.8, 5.6 Hz, 1H), 
2.57 – 2.47 (m, 1H), 1.92 (dtd, J = 13.4, 11.8, 5.2 Hz, 1H), 1.79 (ddt, J = 13.3, 5.9, 
3.0 Hz, 1H).  
13C NMR (CDCl3, 126 MHz) δ 165.54, 139.87, 139.32, 136.54, 134.30, 134.25, 129.48, 129.29, 128.64, 
128.42, 128.27, 126.87, 126.17, 51.62, 35.98, 34.83, 28.71, 22.49.  
IR (neat, cm-1) 3060, 2925, 1674, 1631, 1494, 1427, 741, 700.  
LRMS (ESI) m/z calcd for C20H19NO [M+H]+, [M+Na]+: 290.2, 312.2, found: 290.1, 312.1. 
(4aS,10aS)-3-benzyl-4a,5,6,7,8,9,10,10a-octahydrocycloocta[b]pyridin-2(1H)-one  
Off-white solid (20.1 mg, 75% yield).  
1H NMR (500 MHz, CDCl3) δ 7.30-7.26 (m, 2H), 7.20-7.18 (m, 3H), 6.09 (d, J = 6.2 
Hz, 1H), 5.48 (s, NH), 3.67 (dt, J = 10.1, 4.5 Hz, 1H), 3.58 (dd, J = 42.5, 15.8 Hz, 2H), 
2.48-2.44 (m, 1H), 1.84 (m, 2H), 1.70-1.59 (m, 4H), 1.32-1.26 (m, 1H).  
13C NMR (CDCl3, 126 MHz) δ 167.01, 142.45, 139.60, 132.14, 129.24, 128.35, 
126.04, 54.03, 36.88, 35.72, 29.03, 28.27, 27.12, 25.29, 24.91, 23.50.  
IR (neat, cm-1) 3204, 2920, 2852, 1675, 1631, 1452, 1427, 698.  















Off-white solid (21.2 mg, 79% yield) was obtained from [Cp*RhCl2]2 precatalyst. 
1 mmol scale - 220 mg, 81% yield  
1H NMR (500 MHz, CDCl3) δ 7.35 – 7.28 (m, 2H), 7.23 (m, 3H), 6.13 (ddt, J = 5.0, 
3.3, 1.6 Hz, 1H), 5.64 (s, NH), 3.65 (d, J = 15.8 Hz, 1H), 3.60 (d, J = 15.8 Hz, 1H), 
3.34 (dt, J = 11.3, 6.0 Hz, 1H), 2.31 – 2.15 (m, 2H), 1.87 – 1.65 (m, 4H), 1.41 (tdt, J = 12.0, 6.4, 3.3 Hz, 
1H), 1.31 – 1.10 (m, 4H), 1.00 (qt, J = 12.5, 2.9 Hz, 2H).  
13C NMR (CDCl3, 126 MHz) δ 167.09, 139.48, 135.78, 134.66, 129.30, 128.35, 126.09, 55.81, 41.76, 
35.95, 28.81, 28.71, 27.30, 26.28, 26.04, 26.00.  
IR (neat, cm-1) 3205, 3062, 2923, 2852, 1674, 1631, 1450, 1428, 698.  
LRMS (ESI) m/z calcd for C18H23NO [M+H]+: 270.2, found: 270.1. 
The regiochemsitry based on COSY experiment. 
3-benzyl-5-cyclopentyl-5,6-dihydropyridin-2(1H)-one  
Off-white solid (16.8 mg, 76% yield) was obtained from [CptRhCl2]2 precatalyst. 
 1H NMR (500 MHz, CDCl3) δ 7.34 – 7.28 (m, 2H), 7.23 (dd, J = 7.8, 2.9 Hz, 3H), 6.17 
(m, 1H), 6.10 (s, NH), 3.66 (d, J = 15.7 Hz, 1H), 3.61 (d, J = 15.7 Hz, 1H), 3.42 (ddd, J = 
12.0, 5.8, 3.0 Hz, 1H), 3.21 (ddd, J = 11.7, 8.5, 2.3 Hz, 1H), 2.28 – 2.20 (m, 1H), 1.87 
(dtd, J = 16.5, 9.3, 7.4 Hz, 1H), 1.81 – 1.70 (m, 2H), 1.63 (m, 2H), 1.58 – 1.50 (m, 2H), 
1.22 – 1.09 (m, 2H).  
13C NMR (CDCl3, 126 MHz) δ 166.89, 140.72, 139.51, 134.09, 129.17, 128.35, 126.08, 44.26, 41.95, 
40.03, 36.24, 30.89, 30.20, 25.24, 25.08.  
IR (neat, cm-1) 2949, 2866, 1676, 1628, 1477, 1452, 1032, 699.  
LRMS m/z (ESI+APCI) calcd for C17H21NO [M+H]+, [M+Na]+: 256.2, found: 256.2, 278.2. 
The regiochemsitry based on COSY experiment. 
3,6-dibenzyl-5,6-dihydropyridin-2(1H)-one  
Off-white solid (7.2 mg, 32% yield)  
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.25 (m, 5H), 7.26 – 7.20 (m, 3H), 7.18 (m, 2H), 
6.13 (ddt, J = 5.9, 3.1, 1.6 Hz, 1H), 5.47 (s, NH), 3.84 – 3.76 (m, 1H), 3.64 (d, J = 16.8 
Hz, 1H), 3.60 (d, J = 15.9 Hz, 1H), 2.89 (dd, J = 13.5, 5.5 Hz, 1H), 2.74 (dd, J = 13.5, 
8.9 Hz, 1H), 2.39 (dtd, J = 17.4, 5.4, 1.4 Hz, 1H), 2.25 (ddq, J = 16.6, 11.1, 2.6 Hz, 
1H). 
13C NMR (CDCl3, 126 MHz) δ 166.86, 139.32, 136.55, 135.26, 135.05, 129.29, 129.12, 128.94, 128.39, 
127.11, 126.16, 52.21, 41.82, 35.97, 30.41. 









LRMS (ESI) m/z calcd for C19H19NO [M+H]+: 278.2, found: 278.2. 
3,5-dibenzyl-5,6-dihydropyridin-2(1H)-one  
 Off-white solid (13.4 mg, 48% yield) 
1H NMR (500 MHz, CDCl3) δ 7.31 (m, 4H), 7.28 – 7.20 (m, 4H), 7.16 – 7.10 (m, 2H), 
6.15 – 6.10 (m, 1H), 5.78 (s, NH), 3.66 (d, J = 15.8 Hz, 1H), 3.62 (d, J = 15.7 Hz, 1H), 
3.34 (ddd, J = 12.2, 5.2, 2.1 Hz, 1H), 3.15 (ddd, J = 12.2, 6.7, 2.3 Hz, 1H), 2.84 – 2.76 
(m, 1H), 2.75 – 2.60 (m, 2H). 
13C NMR (CDCl3, 126 MHz) δ 166.60, 140.57, 139.25, 138.67, 134.56, 129.27, 128.92, 128.60, 128.39, 
126.55, 126.17, 43.87, 38.03, 36.28, 36.13. 
IR (neat, cm-1) 3217, 3061, 3027, 2921, 2851, 1675, 1627, 1477, 1452, 735, 700.  
LRMS (ESI) m /z calcd for C19H19NO [M+H]+: 278.2, found: 278.2. 
3-benzyl-5-phenethyl-5,6-dihydropyridin-2(1H)-one  
Off-white solid (20 mg, 69% yield) was obtained from [CptRhCl2]2 precatalyst. 
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.27 (m, 4H), 7.26 – 7.18 (m, 4H), 7.17 – 7.11 (m, 
2H), 6.11 (m, 1H), 6.00 (s, NH), 3.64 (s, 2H), 3.47 (ddd, J = 12.1, 5.8, 2.9 Hz, 1H), 3.20 
(ddd, J = 12.1, 7.9, 2.7 Hz, 1H), 2.64 (ddd, J = 9.0, 7.1, 2.3 Hz, 2H), 2.45 (m, 1H), 1.96 – 
1.66 (m, 2H).  
13C NMR (CDCl3, 126 MHz) δ 166.70, 141.24, 140.83, 139.33, 134.37, 129.25, 128.52, 128.41, 128.27, 
126.16, 126.12, 44.47, 36.12, 33.80, 33.63, 33.08.  
IR (neat, cm-1) 3291, 2923, 2858, 1671, 1623, 1478, 1453, 1030, 747, 699.  
LRMS (ESI) m/z calcd for C20H21NO [M+H]+: 292.2, found: 292.1. 
3-benzyl-5-pentyl-5,6-dihydropyridin-2(1H)-one  
Off-white solid (14.2 mg, 55% yield) was obtained from [CptRhCl2]2 precatalyst 
1H NMR (500 MHz, CDCl3) δ 7.35 – 7.29 (m, 2H), 7.23 (d, J = 7.7 Hz, 3H), 6.10 – 6.08 
(m, 1H), 6.02 (s, NH), 3.63 (s, 2H), 3.42 (ddd, J = 11.9, 5.8, 2.4 Hz, 1H), 3.14 (ddd, J = 
12.0, 8.4, 2.0 Hz, 1H), 2.42 (m, 1H), 1.53 – 1.36 (m, 2H), 1.36 – 1.18 (m, 6H), 0.90 (t, J 
= 6.9 Hz, 3H).  
13C NMR (CDCl3, 126 MHz) δ 166.85, 141.54, 139.46, 133.89, 129.22, 128.36, 126.09, 44.60, 36.12, 
34.47, 31.99, 31.73, 26.56, 22.49, 14.00.  
IR (neat, cm-1) 3202, 3062, 2952, 2923, 2854, 1678, 1626, 1483, 744, 701.  







The regiochemsitry based on COSY experiment. 
3-benzyl-5-(4-bromobutyl)-5,6-dihydropyridin-2(1H)-one  
 (21.3 mg, 66% yield) was obtained from [CptRhCl2]2 precatalyst. 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.29 (m, 2H), 7.27 – 7.21 (m, 3H), 6.08 (m, 1H), 
6.08 (s, NH), 3.63 (s, 2H), 3.45 (ddd, J = 12.0, 5.8, 2.8 Hz, 1H), 3.41 (t, J = 6.6 Hz, 2H), 
3.16 (ddd, J = 12.0, 8.1, 2.4 Hz, 1H), 2.43 (ddt, J = 7.9, 4.0, 2.1 Hz, 1H), 1.86 (m, 4H), 
1.46 (m, 4H). 
13C NMR (CDCl3, 126 MHz) δ 166.72, 140.81, 139.30, 134.34, 129.24, 128.41, 126.16, 44.46, 36.11, 
34.29, 33.45, 32.48, 31.12, 25.43. 
IR (neat, cm-1) 3216, 2931, 2858, 1675, 1627, 1477, 1453, 701.  
LRMS m/z (ESI+APCI) calcd for C16H20BrNO [M+H]+: 322.1, 324.1, found: 322.0, 323.9. 
ethyl 5-(5-benzyl-6-oxo-1,2,3,6-tetrahydropyridin-3-yl)pentanoate  
 (17.2 mg, 55% yield) was obtained from [CptRhCl2]2 precatalyst. 
1H NMR (500 MHz, CDCl3) δ 7.35 – 7.27 (m, 2H), 7.22 (m, 3H), 6.08 (m, 1H), 5.91 (s, 
NH), 4.14 (q, J = 7.1 Hz, 2H), 3.62 (s, 2H), 3.43 (ddd, J = 12.1, 5.9, 2.8 Hz, 1H), 3.14 
(ddd, J = 12.0, 8.2, 2.3 Hz, 1H), 2.49 – 2.38 (m, 2H), 2.30 (t, J = 7.4 Hz, 2H), 1.74 – 1.36 
(m, 4H), 1.27 (t, J = 7.1 Hz, 3H). 13C NMR (CDCl3, 126 MHz) δ 173.46, 166.69, 141.06, 
139.35, 134.16, 129.22, 128.38, 126.13, 60.30, 44.51, 36.12, 34.28, 34.05, 31.68, 26.39, 
24.81, 14.27. 
IR (neat, cm-1) 3220, 2931, 2860, 1731, 1676, 1628, 1477, 1266, 1183, 733, 701.  














5. Control Experiments and Mechanistic Studies 
 
The reversibility of the C-H activation was determined by running the reaction in the absence of 
styrene in TFE-d1. After 1 h, 65% deuterium incorporation at the C-H bond cis to amide was observed, as 










cis to amide 
ca. 65% D 
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Additionally, an experiment with styrene was conducted using TFE-d1. After 1 h (ca. 60% 
conversion), 51% deuterium incorporation to 1a-d at the C-H bond cis to the amide was observed. These 




N-methoxy -benzyl acrylamide did not give any product, implies that the N-pivaloyloxy group 





cis to amide 
ca. 50% D 
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9a (13.1 mg, 0.05 mmol, 1 eq), 9a-d2 (13.2 mg, 0.05 mmol, 1 eq), [Cp*RhCl2]2 (1.5 mg, 0.0025 
mmol, 2.5 mol%),  CsOAc (4.8 mg, 0.025 mmol, 0.25 equiv) and styrene (12.6 L, 0.11 mmol, 1.1 equiv) 
were charged into a dram vial charged with a stir bar. Trifluoroethanol-d1 (TFE-d1) (0.33 mL, 0.3 M) was 
added and the mixture was stirred at room temperature for 1 h. The reaction was quenched with saturated 
NaHCO3 and extracted 3 times with EtOAc. The organic layer was washed with brine, dried over MgSO4, 
filtered, and solvent was evaporated to obtain crude product. The crude was analyzed by 1H-NMR 
spectrometer. The KIE value (PH/PD) of 2.3 was calculated by integrating the Ha of the product 11ab 
(0.70) and Hc of products 11ab (0.70) and 11ab-d (0.30). However the reversibility of C-H activation 






6. Product derivatizations 
 General procedure for the hydrogenation: Pd/C (10% wt) was weighed to the N2-filled round 
bottom flask containing the ,-unsaturated--lactams (0.1 mmol). This was evacuated and refilled with 
N2 (3), following by adding MeOH (0.1 M). Then, the suspension was stirred under H2 (balloon) until 
completion as indicated by TLC. The resulting solution was filtered through a plug of celite and washed 




Off-white solid (24.5 mg, 84% yield, 13:1 dr)  
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.29 (m, 2H), 7.27 – 7.21 (m, 3H), 7.05 (d, J = 8.6 Hz, 2H), 6.85 
(d, J = 8.7 Hz, 2H), 5.98 (s, NH), 4.62 – 4.50 (m, 1H), 3.82 (s, 3H), 3.32 (dd, J = 13.5, 4.0 Hz, 1H), 2.93 
11ab 
 
11ab + 11ab-d 
 





(dd, J = 13.5, 9.7 Hz, 1H), 2.78 – 2.63 (m, 1H), 1.99 (dddd, J = 13.4, 8.4, 5.1, 3.3 Hz, 1H), 1.80 – 1.70 
(m, 1H), 1.71 – 1.52 (m, 2H). 
13C NMR (CDCl3, 126 MHz) δ 174.35, 159.07, 139.45, 134.53, 129.52, 128.42, 127.18, 126.33, 114.02, 
56.46, 55.32, 42.34, 37.56, 29.39, 21.80. 
IR (neat, cm-1) 3204, 2934, 1622, 1511, 1454, 1247.  
LRMS (ESI) m/z calcd for C19H21NO2 [M+H]+, [M+Na]+: 295.2, found: 296.1, 318.1. 
 
(3S,4aS,7aS)-3-benzyloctahydro-2H-cyclopenta[b]pyridin-2-one 
Off-white solid (19.7 mg, 86% yield, >20:1 dr)  
1H NMR (500 MHz, CDCl3) δ 7.31 (m, 2H), 7.22 (m, 3H), 6.16 (s, NH), 3.70 (qd, J = 7.5, 1.9 Hz, 1H), 
3.52 (dd, J = 13.8, 3.8 Hz, 1H), 2.52 (dd, J = 13.8, 10.2 Hz, 1H), 2.39 (ddt, J = 14.2, 10.1, 4.2 Hz, 1H), 
2.21 (dtdd, J = 12.2, 8.0, 5.8, 4.3 Hz, 1H), 2.01 – 1.90 (m, 1H), 1.85 (dtd, J = 13.3, 7.9, 5.6 Hz, 1H), 1.75 
(tdd, J = 10.2, 7.6, 4.6 Hz, 2H), 1.53 (tdd, J = 10.6, 7.6, 5.2 Hz, 2H), 1.41 – 1.33 (m, 1H), 1.25 (q, J = 
12.6 Hz, 1H). 
13C NMR (CDCl3, 126 MHz) δ 175.18, 140.38, 129.24, 128.32, 126.03, 55.29, 42.28, 36.51, 36.26, 
34.32, 31.55, 30.80, 22.95. 
IR (neat, cm-1) 3203, 2943, 1662, 1453, 701.  
LRMS (ESI) m/z calcd for C15H19NO [M+H]+, [M+Na]+: 229.2, found: 230.2, 252.2. 
 
7. NMR Spectra 
 
 
 
 
 
 
 
 
170 
 
 
 
 
171 
 
 
 
172 
 
 
 
173 
 
 
 
174 
 
 
 
175 
 
 
 
176 
 
 
 
177 
 
 
 
178 
 
 
 
179 
 
 
 
 
180 
 
 
 
181 
 
 
 
182 
 
 
 
183 
 
 
 
184 
 
 
 
185 
 
 
 
186 
 
 
 
187 
 
 
 
188 
 
 
 
189 
 
 
 
190 
 
 
 
191 
 
 
192 
 
 
 
193 
 
 
NH
O
Bn
11ac
Me
 
194 
 
 
 
195 
 
NH
O
11ae
Bn
CF3
 
196 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
197 
 
 
 
198 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
199 
 
 
 
200 
 
 
 
201 
 
 
 
202 
 
 
 
203 
 
 
 
204 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
205 
 
 
 
206 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
207 
 
 
 
208 
 
 
 
209 
 
 
 
 
210 
 
 
 
211 
 
 
 
 
 
212 
 
 
 
 
213 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
214 
 
 
 
215 
 
 
 
216 
 
 
 
217 
 
 
 
218 
 
 
 
219 
 
 
NH
O
Bn
13ag
H
H
 
220 
 
 
 
221 
 
 
 
222 
 
 
 
 
223 
 
 
 
 
224 
 
 
 
 
225 
 
 
 
 
226 
 
 
 
227 
 
 
 
228 
 
 
 
229 
 
 
 
 
230 
 
 
 
231 
 
 
 
232 
 
 
 
NH
Bn
O
OMe
 
233 
 
 
NH
Bn
O
H
H
